SUBSTITUTED NUCLEOTIDE ANALOGS

[0001] This application claims the benefit of U.S. Provisional Application Nos. 61/385,363, filed Sep. 22, 2010; and 61/426,461, filed Dec. 22, 2010; both of which are incorporated herein by reference in their entirety; including any drawings.

[0002] 1. Field

[0003] The present application relates to the fields of chemistry, biochemistry and medicine. More particularly, disclosed herein are phosphorothioate nucleotide analogs, pharmaceutical compositions that include one or more nucleotide analogs and methods of synthesizing the same. Also disclosed herein are methods of treating diseases and/or conditions with a phosphorothioate nucleotide analog, alone or in combination therapy with other agents.

[0004] 2. Description

[0005] Nucleoside analogs are a class of compounds that have been shown to exert antiviral and anticancer activity both in vitro and in vivo, and thus, have been the subject of widespread research for the treatment of viral infections and cancer. Nucleoside analogs are usually therapeutically inactive compounds that are converted by host or viral enzymes to their respective active anti-metabolites, which, in turn, may inhibit polymerases involved in viral or cell proliferation. The activation occurs by a variety of mechanisms, such as the addition of one or more phosphate groups and, or in combination with, other metabolic processes.

[0006] Some embodiments disclosed herein relate to a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

[0007] Some embodiments disclosed herein relate to methods of ameliorating and/or treating a neoplastic disease that can include administering to a subject suffering from the neoplastic disease a therapeutically effective amount of one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof. Other embodiments described herein relate to using one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for ameliorating and/or treating a neoplastic disease. Still other embodiments described herein relate to one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof, that can be used for ameliorating and/or treating a neoplastic disease.

[0008] Some embodiments disclosed herein relate to methods of inhibiting the growth of a tumor that can include administering to a subject having a tumor a therapeutically effective amount of one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof. Other embodiments described herein relate to using one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting the growth of a tumor. Still other embodiments described herein relate to one or more compounds of Formula (I), or a pharmaceutically acceptable salt of thereof, that can be used for inhibiting the growth of a tumor.

[0009] Some embodiments disclosed herein relate to methods of ameliorating and/or treating a viral infection that can include administering to a subject suffering from the viral infection a therapeutically effective amount of one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof. Other embodiments described herein relate to using one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for ameliorating and/or treating a viral infection. Still other embodiments described herein relate to one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof, that can be used for ameliorating and/or treating a viral infection.

[0010] Some embodiments disclosed herein relate to methods of ameliorating and/or treating a viral infection that can include contacting a cell infected with the virus with an effective amount of one or more compounds described herein, or a pharmaceutically acceptable salt of one or more compounds described herein, or a pharmaceutical composition that includes one or more compounds described herein, or a pharmaceutically acceptable salt thereof. Other embodiments described herein relate to using one or more compounds described herein, or a pharmaceutically acceptable salt of one or more compounds described herein, in the manufacture of a medicament for ameliorating and/or treating a viral infection that can include contacting a cell infected with the virus with an effective amount of said compound(s). Still other embodiments described herein relate to one or more compounds described herein, or a pharmaceutically acceptable salt of one or more compounds described herein, that can be used for ameliorating and/or treating a viral infection by contacting a cell infected with the virus with an effective amount of said compound(s).

[0011] Some embodiments disclosed herein relate to methods of inhibiting replication of a virus that can include contacting a cell infected with the virus with an effective amount of one or more compounds described herein, or a pharmaceutically acceptable salt of one or more compounds described herein, or a pharmaceutical composition that includes one or more compounds described herein, or a pharmaceutically acceptable salt thereof. Other embodiments described herein relate to using one or more compounds described herein, or a pharmaceutically acceptable salt of one or more compounds described herein, in the manufacture of a medicament for inhibiting replication of a virus that can include contacting a cell infected with the virus with an effective amount of said compound(s). Still other embodiments described herein relate to one or more compounds described herein, or a pharmaceutically acceptable salt of one or more compounds described herein, that can be used for inhibiting replication of a virus by contacting a cell infected with the virus with an effective amount of said compound(s).

[0012] Some embodiments disclosed herein relate to methods of ameliorating and/or treating a parasitic disease that can include administering to a subject suffering from the parasitic disease a therapeutically effective amount of one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof. Other embodiments described herein relate to using one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for ameliorating and/or treating a parasitic disease. Still other embodiments described herein relate to one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof, that can be used for ameliorating and/or treating a parasitic disease.

[0013] Some embodiments disclosed herein relate to methods of ameliorating and/or treating a viral infection that can include administering to a subject suffering from the viral infection a therapeutically effective amount of a compound described herein or a pharmaceutically acceptable salt thereof (for example, one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof), or a pharmaceutical composition that includes a compound described herein, in combination with an agent selected from an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an other antiviral compound, a compound of Formula (AA), a mono-, di- and/or tri-phosphate thereof, or a pharmaceutically acceptable salt of the foregoing, a compound of Formula (BB), or a pharmaceutically acceptable salt thereof, and a compound of Formula (DD), or a pharmaceutically acceptable salt thereof. Some embodiments disclosed herein relate to methods of ameliorating and/or treating a viral infection that can include contacting a cell infected with the viral infection with a therapeutically effective amount of a compound described herein or a pharmaceutically acceptable salt thereof (for example, one or more compounds of Formula (I), or a pharmaceutically acceptable salt thereof), or a pharmaceutical composition that includes a compound described herein, in combination with an agent selected from an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an other antiviral compound, a compound of Formula (AA), a mono-, di- and/or tri-phosphate thereof, or a pharmaceutically acceptable salt of the foregoing, a compound of Formula (BB), or a pharmaceutically acceptable salt thereof, and a compound of Formula (DD), or a pharmaceutically acceptable salt thereof. Some embodiments disclosed herein relate to methods of inhibiting replication of a virus that can include administering to a subject a therapeutically effective amount of a compound described herein or a pharmaceutically acceptable salt thereof (for example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof), or a pharmaceutical composition that includes a compound described herein, or a pharmaceutically acceptable salt thereof, in combination with an agent selected from an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an other antiviral compound, a compound of Formula (AA), a mono-, di- and/or tri-phosphate thereof, or a pharmaceutically acceptable salt of the foregoing, a compound of Formula (BB), or a pharmaceutically acceptable salt thereof, and a compound of Formula (DD), or a pharmaceutically acceptable salt thereof. In some embodiments, the agent can be a compound, or a pharmaceutically acceptable salt thereof, selected from Compound 1001-1014, 2001-2010, 3001-3008, 4001-4005, 5001-5002, 7000-7077, 8000-8012 or 9000, or a pharmaceutical composition that includes one or more of the aforementioned compounds, or pharmaceutically acceptable salt thereof. In some embodiments, the method can include administering a second agent selected from an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an other antiviral compound, a compound of Formula (AA), a mono-, di- and/or tri-phosphate thereof, or a pharmaceutically acceptable salt of the foregoing, a compound of Formula (BB), or a pharmaceutically acceptable salt thereof and a compound of Formula (DD), or a pharmaceutically acceptable salt thereof. In some embodiments, the viral infection is HCV.

[0024] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art. All patents, applications, published applications and other publications referenced herein are incorporated by reference in their entirety unless stated otherwise. In the event that there are a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.

[0025] As used herein, any “R” group(s) such as, without limitation, R, R¹, R², R^3a, R^3b, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, R²¹, R^1A, R^2A, R^3A, R^3B, R^4A, R^5A, R^6A, R^7A, R^8A, R^9A and R″ represent substituents that can be attached to the indicated atom. An R group may be substituted or unsubstituted. If two “R” groups are described as being “taken together” the R groups and the atoms they are attached to can form a cycloalkyl, aryl, heteroaryl or heterocycle. For example, without limitation, if R^1a and R^1b of an NR^1aR^1b group are indicated to be “taken together,” it means that they are covalently bonded to one another to form a ring:

[0026] Whenever a group is described as being “optionally substituted” that group may be unsubstituted or substituted with one or more of the indicated substituents. Likewise, when a group is described as being “unsubstituted or substituted” if substituted, the substituent(s) may be selected from one or more the indicated substituents. If no substituents are indicated, it is meant that the indicated “optionally substituted” or “substituted” group may be substituted with one or more group(s) individually and independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl, (heteroalicyclyl)alkyl, hydroxy, protected hydroxyl, alkoxy, aryloxy, acyl, mercapto, alkylthio, arylthio, cyano, halogen, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, protected C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, an amino, a mono-substituted amino group and a di-substituted amino group, and protected derivatives thereof.

[0027] As used herein, “C_a to C_b” in which “a” and “b” are integers refer to the number of carbon atoms in an alkyl, alkenyl or alkynyl group, or the number of carbon atoms in the ring of a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl or heteroalicyclyl group. That is, the alkyl, alkenyl, alkynyl, ring of the cycloalkyl, ring of the cycloalkenyl, ring of the cycloalkynyl, ring of the aryl, ring of the heteroaryl or ring of the heteroalicyclyl can contain from “a” to “b”, inclusive, carbon atoms. Thus, for example, a “C₁ to C₄ alkyl” group refers to all alkyl groups having from 1 to 4 carbons, that is, CH₃—, CH₃CH₂—, CH₃CH₂CH₂—, (CH₃)₂CH—, CH₃CH₂CH₂CH₂—, CH₃CH₂CH(CH₃)— and (CH₃)₃C—. If no “a” and “b” are designated with regard to an alkyl, alkenyl, alkynyl, cycloalkyl cycloalkenyl, cycloalkynyl, aryl, heteroaryl or heteroalicyclyl group, the broadest range described in these definitions is to be assumed.

[0028] As used herein, “alkyl” refers to a straight or branched hydrocarbon chain that comprises a fully saturated (no double or triple bonds) hydrocarbon group. The alkyl group may have 1 to 20 carbon atoms (whenever it appears herein, a numerical range such as “1 to 20” refers to each integer in the given range; e.g., “1 to 20 carbon atoms” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated). The alkyl group may also be a medium size alkyl having 1 to 10 carbon atoms. The alkyl group could also be a lower alkyl having 1 to 6 carbon atoms. The alkyl group of the compounds may be designated as “C₁-C₄ alkyl” or similar designations. By way of example only, “C₁-C₄ alkyl” indicates that there are one to four carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and t-butyl. Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl and hexyl. The alkyl group may be substituted or unsubstituted.

[0029] As used herein, “alkenyl” refers to an alkyl group that contains in the straight or branched hydrocarbon chain one or more double bonds. An alkenyl group may be unsubstituted or substituted.

[0030] As used herein, “alkynyl” refers to an alkyl group that contains in the straight or branched hydrocarbon chain one or more triple bonds. An alkynyl group may be unsubstituted or substituted.

[0031] As used herein, “cycloalkyl” refers to a completely saturated (no double or triple bonds) mono- or multi-cyclic hydrocarbon ring system. When composed of two or more rings, the rings may be joined together in a fused fashion. Cycloalkyl groups can contain 3 to 10 atoms in the ring(s) or 3 to 8 atoms in the ring(s). A cycloalkyl group may be unsubstituted or substituted. Typical cycloalkyl groups include, but are in no way limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

[0032] As used herein, “cycloalkenyl” refers to a mono- or multi-cyclic hydrocarbon ring system that contains one or more double bonds in at least one ring; although, if there is more than one, the double bonds cannot form a fully delocalized pi-electron system throughout all the rings (otherwise the group would be “aryl,” as defined herein). When composed of two or more rings, the rings may be connected together in a fused fashion. A cycloalkenyl group may be unsubstituted or substituted.

[0033] As used herein, “cycloalkynyl” refers to a mono- or multi-cyclic hydrocarbon ring system that contains one or more triple bonds in at least one ring. If there is more than one triple bond, the triple bonds cannot form a fully delocalized pi-electron system throughout all the rings. When composed of two or more rings, the rings may be joined together in a fused fashion. A cycloalkynyl group may be unsubstituted or substituted.

[0034] As used herein, “aryl” refers to a carbocyclic (all carbon) monocyclic or multicyclic aromatic ring system (including fused ring systems where two carbocyclic rings share a chemical bond) that has a fully delocalized pi-electron system throughout all the rings. The number of carbon atoms in an aryl group can vary. For example, the aryl group can be a C₆-C₁₄ aryl group, a C₆-C₁₀ aryl group, or a C₆ aryl group. Examples of aryl groups include, but are not limited to, benzene, naphthalene and azulene. An aryl group may be substituted or unsubstituted.

[0035] As used herein, “heteroaryl” refers to a monocyclic or multicyclic aromatic ring system (a ring system with fully delocalized pi-electron system) that contain(s) one or more heteroatoms, that is, an element other than carbon, including but not limited to, nitrogen, oxygen and sulfur. The number of atoms in the ring(s) of a heteroaryl group can vary. For example, the heteroaryl group can contain 4 to 14 atoms in the ring(s), 5 to 10 atoms in the ring(s) or 5 to 6 atoms in the ring(s). Furthermore, the term “heteroaryl” includes fused ring systems where two rings, such as at least one aryl ring and at least one heteroaryl ring, or at least two heteroaryl rings, share at least one chemical bond. Examples of heteroaryl rings include, but are not limited to, furan, furazan, thiophene, benzothiophene, phthalazine, pyrrole, oxazole, benzoxazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, thiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, benzothiazole, imidazole, benzimidazole, indole, indazole, pyrazole, benzopyrazole, isoxazole, benzoisoxazole, isothiazole, triazole, benzotriazole, thiadiazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine, purine, pteridine, quinoline, isoquinoline, quinazoline, quinoxaline, cinnoline, and triazine. A heteroaryl group may be substituted or unsubstituted.

[0036] As used herein, “heterocyclyl” or “heteroalicyclyl” refers to three-, four-, five-, six-, seven-, eight-, nine-, ten-, up to 18-membered monocyclic, bicyclic, and tricyclic ring system wherein carbon atoms together with from 1 to 5 heteroatoms constitute said ring system. A heterocycle may optionally contain one or more unsaturated bonds situated in such a way, however, that a fully delocalized pi-electron system does not occur throughout all the rings. The heteroatom(s) is an element other than carbon including, but not limited to, oxygen, sulfur, and nitrogen. A heterocycle may further contain one or more carbonyl or thiocarbonyl functionalities, so as to make the definition include oxo-systems and thio-systems such as lactams, lactones, cyclic imides, cyclic thioimides and cyclic carbamates. When composed of two or more rings, the rings may be joined together in a fused fashion. Additionally, any nitrogens in a heteroalicyclic may be quaternized. Heterocyclyl or heteroalicyclic groups may be unsubstituted or substituted. Examples of such “heterocyclyl” or “heteroalicyclyl” groups include but are not limited to, 1,3-dioxin, 1,3-dioxane, 1,4-dioxane, 1,2-dioxolane, 1,3-dioxolane, 1,4-dioxolane, 1,3-oxathiane, 1,4-oxathiin, 1,3-oxathiolane, 1,3-dithiole, 1,3-dithiolane, 1,4-oxathiane, tetrahydro-1,4-thiazine, 2H-1,2-oxazine, maleimide, succinimide, barbituric acid, thiobarbituric acid, dioxopiperazine, hydantoin, dihydrouracil, trioxane, hexahydro-1,3,5-triazine, imidazoline, imidazolidine, isoxazoline, isoxazolidine, oxazoline, oxazolidine, oxazolidinone, thiazoline, thiazolidine, morpholine, oxirane, piperidine N-Oxide, piperidine, piperazine, pyrrolidine, pyrrolidone, pyrrolidione, 4-piperidone, pyrazoline, pyrazolidine, 2-oxopyrrolidine, tetrahydropyran, 4H-pyran, tetrahydrothiopyran, thiamorpholine, thiamorpholine sulfoxide, thiamorpholine sulfone, and their benzo-fused analogs (e.g., benzimidazolidinone, tetrahydroquinoline, 3,4-methylenedioxyphenyl)

[0037] As used herein, “aralkyl” and “aryl(alkyl)” refer to an aryl group connected, as a substituent, via a lower alkylene group. The lower alkylene and aryl group of an aralkyl may be substituted or unsubstituted. Examples include but are not limited to benzyl, 2-phenylalkyl, 3-phenylalkyl, and naphthylalkyl.

[0038] As used herein, “heteroaralkyl” and “heteroaryl(alkyl)” refer to a heteroaryl group connected, as a substituent, via a lower alkylene group. The lower alkylene and heteroaryl group of heteroaralkyl may be substituted or unsubstituted. Examples include but are not limited to 2-thienylalkyl, 3-thienylalkyl, furylalkyl, thienylalkyl, pyrrolylalkyl, pyridylalkyl, isoxazolylalkyl, and imidazolylalkyl, and their benzo-fused analogs.

[0039] A “(heteroalicyclyl)alkyl” and “(heterocyclyl)alkyl” refer to a heterocyclic or a heteroalicyclylic group connected, as a substituent, via a lower alkylene group. The lower alkylene and heterocyclyl of a (heteroalicyclyl)alkyl may be substituted or unsubstituted. Examples include but are not limited tetrahydro-2H-pyran-4-yl)methyl, (piperidin-4-yl)ethyl, (piperidin-4-yl)propyl, (tetrahydro-2H-thiopyran-4-yl)methyl, and (1,3-thiazinan-4-yl)methyl.

[0040] “Lower alkylene groups” are straight-chained —CH₂— tethering groups, forming bonds to connect molecular fragments via their terminal carbon atoms. Examples include but are not limited to methylene (—CH₂—), ethylene (—CH₂CH₂—), propylene (—CH₂CH₂CH₂—), and butylene (—CH₂CH₂CH₂CH₂—). A lower alkylene group can be substituted by replacing one or more hydrogen of the lower alkylene group with a substituent(s) listed under the definition of “substituted.”

[0041] As used herein, “alkoxy” refers to the formula —OR wherein R is an alkyl, an alkenyl, an alkynyl, a cycloalkyl, a cycloalkenyl or a cycloalkynyl is defined as above. A non-limiting list of alkoxys are methoxy, ethoxy, n-propoxy, 1-methylethoxy(isopropoxy), n-butoxy, iso-butoxy, sec-butoxy and tert-butoxy. An alkoxy may be substituted or unsubstituted.

[0042] As used herein, “acyl” refers to a hydrogen, alkyl, alkenyl, alkynyl, or aryl connected, as substituents, via a carbonyl group. Examples include formyl, acetyl, propanoyl, benzoyl, and acryl. An acyl may be substituted or unsubstituted.

[0043] As used herein, “hydroxyalkyl” refers to an alkyl group in which one or more of the hydrogen atoms are replaced by a hydroxy group. Exemplary hydroxyalkyl groups include but are not limited to, 2-hydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, and 2,2-dihydroxyethyl. A hydroxyalkyl may be substituted or unsubstituted.

[0044] As used herein, “haloalkyl” refers to an alkyl group in which one or more of the hydrogen atoms are replaced by a halogen (e.g., mono-haloalkyl, di-haloalkyl and tri-haloalkyl). Such groups include but are not limited to, chloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl and 1-chloro-2-fluoromethyl, 2-fluoroisobutyl. A haloalkyl may be substituted or unsubstituted.

[0045] As used herein, “haloalkoxy” refers to an alkoxy group in which one or more of the hydrogen atoms are replaced by a halogen (e.g., mono-haloalkoxy, di-haloalkoxy and tri-haloalkoxy). Such groups include but are not limited to, chloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy and 1-chloro-2-fluoromethoxy, 2-fluoroisobutoxy. A haloalkoxy may be substituted or unsubstituted.

[0046] As used herein, “aryloxy” and “arylthio” refers to RO— and RS—, in which R is an aryl, such as but not limited to phenyl. Both an aryloxy and arylthio may be substituted or unsubstituted.

[0047] A “sulfenyl” group refers to an “—SR” group in which R can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl. A sulfenyl may be substituted or unsubstituted.

[0048] A “sulfinyl” group refers to an “—S(═O)—R” group in which R can be the same as defined with respect to sulfenyl. A sulfinyl may be substituted or unsubstituted.

[0049] A “sulfonyl” group refers to an “SO₂R” group in which R can be the same as defined with respect to sulfenyl. A sulfonyl may be substituted or unsubstituted.

[0050] An “O-carboxy” group refers to a “RC(═O)O—” group in which R can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl, as defined herein. An O-carboxy may be substituted or unsubstituted.

[0051] The terms “ester” and “C-carboxy” refer to a “—C(═O)OR” group in which R can be the same as defined with respect to O-carboxy. An ester and C-carboxy may be substituted or unsubstituted.

[0052] A “thiocarbonyl” group refers to a “—C(═S)R” group in which R can be the same as defined with respect to O-carboxy. A thiocarbonyl may be substituted or unsubstituted.

[0053] A “trihalomethanesulfonyl” group refers to an “X₃CSO₂-” group wherein X is a halogen.

[0054] A “trihalomethanesulfonamido” group refers to an “X₃CS(O)₂N(R_A)-” group wherein X is a halogen and R_A hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl.

[0055] The term “amino” as used herein refers to a —NH₂ group.

[0056] As used herein, the term “hydroxy” refers to a —OH group.

[0057] A “cyano” group refers to a “—CN” group.

[0058] The term “azido” as used herein refers to a —N₃ group.

[0059] An “isocyanato” group refers to a “—NCO” group.

[0060] A “thiocyanato” group refers to a “—CNS” group.

[0061] An “isothiocyanato” group refers to an “—NCS” group.

[0062] A “mercapto” group refers to an “—SH” group.

[0063] A “carbonyl” group refers to a C═O group.

[0064] An “S-sulfonamido” group refers to a “—SO₂N(R_AR_B)” group in which R_A and R_B can be independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl. An S-sulfonamido may be substituted or unsubstituted.

[0065] An “N-sulfonamido” group refers to a “RSO₂N(R_A)-” group in which R and R_A can be independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl. An N-sulfonamido may be substituted or unsubstituted.

[0066] An “O-carbamyl” group refers to a “—OC(═O)N(R_AR_B)” group in which R_A and R_B can be independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl. An O-carbamyl may be substituted or unsubstituted.

[0067] An “N-carbamyl” group refers to an “ROC(═O)N(R_A)-” group in which R and R_A can be independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl. An N-carbamyl may be substituted or unsubstituted.

[0068] An “O-thiocarbamyl” group refers to a “—OC(═S)—N(R_AR_B)” group in which R_A and R_B can be independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl. An O-thiocarbamyl may be substituted or unsubstituted.

[0069] An “N-thiocarbamyl” group refers to an “ROC(═S)N(R_A)-” group in which R and R_A can be independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl. An N-thiocarbamyl may be substituted or unsubstituted.

[0070] A “C-amido” group refers to a “—C(═O)N(R_AR_B)” group in which R_A and R_B can be independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl. A C-amido may be substituted or unsubstituted.

[0071] An “N-amido” group refers to a “RC(═O)N(R_A)-” group in which R and R_A can be independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl. An N-amido may be substituted or unsubstituted.

[0072] The term “halogen atom” or “halogen” as used herein, means any one of the radio-stable atoms of column 7 of the Periodic Table of the Elements, such as, fluorine, chlorine, bromine and iodine.

[0073] Where the numbers of substituents is not specified (e.g. haloalkyl), there may be one or more substituents present. For example “haloalkyl” may include one or more of the same or different halogens. As another example, “C₁-C₃ alkoxyphenyl” may include one or more of the same or different alkoxy groups containing one, two or three atoms.

[0074] As used herein, the abbreviations for any protective groups, amino acids and other compounds, are, unless indicated otherwise, in accord with their common usage, recognized abbreviations, or the IUPAC-IUB Commission on Biochemical Nomenclature (See, Biochem. 11:942-944 (1972)).

[0075] The term “nucleoside” is used herein in its ordinary sense as understood by those skilled in the art, and refers to a compound composed of an optionally substituted pentose moiety or modified pentose moiety attached to a heterocyclic base or tautomer thereof via a N-glycosidic bond, such as attached via the 9-position of a purine-base or the 1-position of a pyrimidine-base. Examples include, but are not limited to, a ribonucleoside comprising a ribose moiety and a deoxyribonucleoside comprising a deoxyribose moiety. A modified pentose moiety is a pentose moiety in which an oxygen atom has been replaced with a carbon and/or a carbon has been replaced with a sulfur or an oxygen atom. A “nucleoside” is a monomer that can have a substituted base and/or sugar moiety. Additionally, a nucleoside can be incorporated into larger DNA and/or RNA polymers and oligomers. In some instances, the nucleoside can be a nucleoside analog drug.

[0076] As used herein, the term “heterocyclic base” refers to an optionally substituted nitrogen-containing heterocyclyl that can be attached to an optionally substituted pentose moiety or modified pentose moiety. In some embodiments, the heterocyclic base can be selected from an optionally substituted purine-base, an optionally substituted pyrimidine-base and an optionally substituted triazole-base (for example, a 1,2,4-triazole). The term “purine-base” is used herein in its ordinary sense as understood by those skilled in the art, and includes its tautomers. Similarly, the term “pyrimidine-base” is used herein in its ordinary sense as understood by those skilled in the art, and includes its tautomers. A non-limiting list of optionally substituted purine-bases includes purine, adenine, guanine, hypoxanthine, xanthine, alloxanthine, 7-alkylguanine (e.g. 7-methylguanine), theobromine, caffeine, uric acid and isoguanine. Examples of pyrimidine-bases include, but are not limited to, cytosine, thymine, uracil, 5,6-dihydrouracil and 5-alkylcytosine (e.g., 5-methylcytosine). An example of an optionally substituted triazole-base is 1,2,4-triazole-3-carboxamide. Other non-limiting examples of heterocyclic bases include diaminopurine, 8-oxo-N⁶-alkyladenine (e.g., 8-oxo-N⁶-methyladenine), 7-deazaxanthine, 7-deazaguanine, 7-deazaadenine, N⁴,N⁴-ethanocytosin, N⁶,N⁶-ethano-2,6-diaminopurine, 5-halouracil (e.g., 5-fluorouracil and 5-bromouracil), pseudoisocytosine, isocytosine, isoguanine, and other heterocyclic bases described in U.S. Pat. Nos. 5,432,272 and 7,125,855, which are incorporated herein by reference for the limited purpose of disclosing additional heterocyclic bases. In some embodiments, a heterocyclic base can be optionally substituted with an amine or an enol protecting group(s).

[0077] The term “—N-linked amino acid” refers to an amino acid that is attached to the indicated moiety via a main-chain amino or mono-substituted amino group. When the amino acid is attached in an —N-linked amino acid, one of the hydrogens that is part of the main-chain amino or mono-substituted amino group is not present and the amino acid is attached via the nitrogen. As used herein, the term “amino acid” refers to any amino acid (both standard and non-standard amino acids), including, but not limited to, α-amino acids, β-amino acids, γ-amino acids and δ-amino acids. Examples of suitable amino acids include, but are not limited to, alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine. Additional examples of suitable amino acids include, but are not limited to, ornithine, hypusine, 2-aminoisobutyric acid, dehydroalanine, gamma-aminobutyric acid, citrulline, beta-alanine, alpha-ethyl-glycine, alpha-propyl-glycine and norleucine. N-linked amino acids can be substituted or unsubstituted.

[0078] The term “—N-linked amino acid ester derivative” refers to an amino acid in which a main-chain carboxylic acid group has been converted to an ester group. In some embodiments, the ester group has a formula selected from alkyl-O—C(═O)—, cycloalkyl-O—C(═O)—, aryl-O—C(═O)— and aryl(alkyl)-O—C(═O)—. A non-limiting list of ester groups include, methyl-O—C(═O)—, ethyl-O—C(═O)—, n-propyl-O—C(═O)—, isopropyl-O—C(═O)—, n-butyl-β—C(═O)—, isobutyl-O—C(═O)—, tert-butyl-O—C(═O)—, neopentyl-O—C(═O)—, cyclopropyl-β—C(═O)—, cyclobutyl-O—C(═O)—, cyclopentyl-O—C(═O)—, cyclohexyl-O—C(═O)—, phenyl-O—C(═O)—, and benzyl-O—C(═O)—. N-linked amino acid ester derivatives can be substituted or unsubstituted.

[0079] The terms “protecting group” and “protecting groups” as used herein refer to any atom or group of atoms that is added to a molecule in order to prevent existing groups in the molecule from undergoing unwanted chemical reactions. Examples of protecting group moieties are described in T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3. Ed. John Wiley & Sons, 1999, and in J. F. W. McOmie, Protective Groups in Organic Chemistry Plenum Press, 1973, both of which are hereby incorporated by reference for the limited purpose of disclosing suitable protecting groups. The protecting group moiety may be chosen in such a way, that they are stable to certain reaction conditions and readily removed at a convenient stage using methodology known from the art. A non-limiting list of protecting groups include benzyl; substituted benzyl; alkylcarbonyls and alkoxycarbonyls (e.g., t-butoxycarbonyl (BOC), acetyl, or isobutyryl); arylalkylcarbonyls and arylalkoxycarbonyls (e.g., benzyloxycarbonyl); substituted methyl ether (e.g. methoxymethyl ether); substituted ethyl ether; a substituted benzyl ether; tetrahydropyranyl ether; silyls (e.g., trimethylsilyl, triethylsilyl, triisopropylsilyl, t-butyldimethylsilyl, tri-iso-propylsilyloxymethyl, [2-(trimethylsilyl)ethoxy]methyl or t-butyldiphenylsilyl); esters (e.g. benzoate ester); carbonates (e.g. methoxymethylcarbonate); sulfonates (e.g. tosylate or mesylate); acyclic ketal (e.g. dimethyl acetal); cyclic ketals (e.g., 1,3-dioxane, 1,3-dioxolanes, and those described herein); acyclic acetal; cyclic acetal (e.g., those described herein); acyclic hemiacetal; cyclic hemiacetal; cyclic dithioketals (e.g., 1,3-dithiane or 1,3-dithiolane); orthoesters (e.g., those described herein) and triarylmethyl groups (e.g., trityl; monomethoxytrityl (MMTr); 4,4′-dimethoxytrityl (DMTr); 4,4′,4″-trimethoxytrityl (TMTr); and those described herein).

[0080] “Leaving group” as used herein refers to any atom or moiety that is capable of being displaced by another atom or moiety in a chemical reaction. More specifically, in some embodiments, “leaving group” refers to the atom or moiety that is displaced in a nucleophilic substitution reaction. In some embodiments, “leaving groups” are any atoms or moieties that are conjugate bases of strong acids. Examples of suitable leaving groups include, but are not limited to, tosylates and halogens. Non-limiting characteristics and examples of leaving groups can be found, for example in Organic Chemistry, 2d ed., Francis Carey (1992), pages 328-331; Introduction to Organic Chemistry, 2d ed., Andrew John McMurry (2000), pages 398 and 408; all of which are incorporated herein by reference for the limited purpose of disclosing characteristics and examples of leaving groups.

[0081] The term “pharmaceutically acceptable salt” refers to a salt of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compound. In some embodiments, the salt is an acid addition salt of the compound. Pharmaceutical salts can be obtained by reacting a compound with inorganic acids such as hydrohalic acid (e.g., hydrochloric acid or hydrobromic acid), sulfuric acid, nitric acid and phosphoric acid. Pharmaceutical salts can also be obtained by reacting a compound with an organic acid such as aliphatic or aromatic carboxylic or sulfonic acids, for example formic, acetic, succinic, lactic, malic, tartaric, citric, ascorbic, nicotinic, methanesulfonic, ethanesulfonic, p-toluensulfonic, salicylic or naphthalenesulfonic acid. Pharmaceutical salts can also be obtained by reacting a compound with a base to form a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, C₁-C₇ alkylamine, cyclohexylamine, triethanolamine, ethylenediamine, and salts with amino acids such as arginine and lysine.

[0082] Terms and phrases used in this application, and variations thereof, especially in the appended claims, unless otherwise expressly stated, should be construed as open ended as opposed to limiting. As examples of the foregoing, the term ‘including’ should be read to mean ‘including, without limitation,’ ‘including but not limited to,’ or the like; the term ‘comprising’ as used herein is synonymous with ‘including,’ ‘containing,’ or ‘characterized by,’ and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps; the term ‘having’ should be interpreted as ‘having at least;’ the term ‘includes’ should be interpreted as ‘includes but is not limited to;’ the term ‘example’ is used to provide exemplary instances of the item in discussion, not an exhaustive or limiting list thereof; and use of terms like ‘preferably,’ preferred, ‘desired,’ or ‘desirable,’ and words of similar meaning should not be understood as implying that certain features are critical, essential, or even important to the structure or function of the invention, but instead as merely intended to highlight alternative or additional features that may or may not be utilized in a particular embodiment of the invention. In addition, the term “comprising” is to be interpreted synonymously with the phrases “having at least” or “including at least”. When used in the context of a process, the term “comprising” means that the process includes at least the recited steps, but may include additional steps. When used in the context of a compound, composition or device, the term “comprising” means that the compound, composition or device includes at least the recited features or components, but may also include additional features or components. Likewise, a group of items linked with the conjunction ‘and’ should not be read as requiring that each and every one of those items be present in the grouping, but rather should be read as ‘and/or’ unless expressly stated otherwise. Similarly, a group of items linked with the conjunction ‘or’ should not be read as requiring mutual exclusivity among that group, but rather should be read as ‘and/or’ unless expressly stated otherwise.

[0083] With respect to the use of substantially any plural and/or singular terms herein, those having skill in the art can translate from the plural to the singular and/or from the singular to the plural as is appropriate to the context and/or application. The various singular/plural permutations may be expressly set forth herein for sake of clarity. The indefinite article “a” or “an” does not exclude a plurality. A single processor or other unit may fulfill the functions of several items recited in the claims. The mere fact that certain measures are recited in mutually different dependent claims does not indicate that a combination of these measures cannot be used to advantage. Any reference signs in the claims should not be construed as limiting the scope.

[0084] It is understood that, in any compound described herein having one or more chiral centers, if an absolute stereochemistry is not expressly indicated, then each center may independently be of R-configuration or S-configuration or a mixture thereof. Thus, the compounds provided herein may be enantiomerically pure, enantiomerically enriched, racemic mixture, diastereomerically pure, diastereomerically enriched, or a stereoisomeric mixture. In addition it is understood that, in any compound described herein having one or more double bond(s) generating geometrical isomers that can be defined as E or Z, each double bond may independently be E or Z a mixture thereof.

[0085] Likewise, it is understood that, in any compound described, all tautomeric forms are also intended to be included. For example all tautomers of a phosphate and a phosphorothioate groups are intended to be included. Examples of tautomers of a phosphorothioate include the following:

Furthermore, all tautomers of heterocyclic bases known in the art are intended to be included, including tautomers of natural and non-natural purine-bases and pyrimidine-bases.

[0086] It is to be understood that where compounds disclosed herein have unfilled valencies, then the valencies are to be filled with hydrogens or isotopes thereof, e.g., hydrogen-1 (protium) and hydrogen-2 (deuterium).

[0087] It is understood that the compounds described herein can be labeled isotopically. Substitution with isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, such as, for example, increased in vivo half-life or reduced dosage requirements. Each chemical element as represented in a compound structure may include any isotope of said element. For example, in a compound structure a hydrogen atom may be explicitly disclosed or understood to be present in the compound. At any position of the compound that a hydrogen atom may be present, the hydrogen atom can be any isotope of hydrogen, including but not limited to hydrogen-1 (protium) and hydrogen-2 (deuterium). Thus, reference herein to a compound encompasses all potential isotopic forms unless the context clearly dictates otherwise.

[0088] It is understood that the methods and combinations described herein include crystalline forms (also known as polymorphs, which include the different crystal packing arrangements of the same elemental composition of a compound), amorphous phases, salts, solvates, and hydrates. In some embodiments, the compounds described herein exist in solvated forms with pharmaceutically acceptable solvents such as water, ethanol, or the like. In other embodiments, the compounds described herein exist in unsolvated form. Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and may be formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, or the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. In addition, the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.

[0089] Where a range of values is provided, it is understood that the upper and lower limit, and each intervening value between the upper and lower limit of the range is encompassed within the embodiments.

[0090] Some embodiments disclosed herein relate to a compound of Formula (I) or a pharmaceutically acceptable salt thereof:

wherein: B¹ can be an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group; R¹ can be selected from O⁻, OH, an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative; R² can be selected from an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl and

wherein R¹⁹, R²⁰ and R²¹ can be independently absent or hydrogen, and n can be 0 or 1; provided that when R¹ is O⁻ or OH, then R² is

R^3a and R^3b can be independently selected from hydrogen, deuterium, an optionally substituted C_1-6 alkyl, an optionally substituted C_2-6 alkenyl, an optionally substituted C_2-6 alkynyl, an optionally substituted C_1-6 haloalkyl and aryl(C_1-6 alkyl); or R^3a and R^3b can be taken together to form an optionally substituted C_3-6 cycloalkyl; R⁴ can be selected from hydrogen, azido, an optionally substituted C_1-6 alkyl, an optionally substituted C_2-6 alkenyl and an optionally substituted C_2-6 alkynyl; R⁵ can be selected from hydrogen, halogen, azido, cyano, an optionally substituted C_1-6 alkyl, —OR¹⁰ and —OC(═O)R¹¹; R⁶ can be selected from hydrogen, halogen, azido, cyano, an optionally substituted C_1-6 alkyl, —OR¹² and —OC(═O)R¹³; R⁷ can be selected from hydrogen, halogen, azido, cyano, an optionally substituted C_1-6 alkyl, —OR¹⁴ and —OC(═O)R¹⁵; or R⁶ and R⁷ can be both oxygen atoms and linked together by a carbonyl group; R⁸ can be selected from hydrogen, halogen, azido, cyano, an optionally substituted C_1-6 alkyl, —OR¹⁶ and —OC(═O)R¹⁷; R⁹ can be selected from hydrogen, azido, cyano, an optionally substituted C_1-6 alkyl and —OR¹⁸; R¹⁰, R¹², R¹⁴, R¹⁶ and R¹⁸ can be independently selected from hydrogen and an optionally substituted C_1-6 alkyl; and R¹¹, R¹³, R¹⁵ and R¹⁷ can be independently selected from an optionally substituted C_1-6 alkyl and an optionally substituted C_3-6 cycloalkyl; with the proviso that when R^3a, R^3b), R⁴, R⁵, R⁷, R⁸ and R⁹ are all hydrogen, then R⁶ cannot be azido.

[0091] With respect to R², in some embodiments, R² can be an optionally substituted heteroaryl. In other embodiments, R² can be an optionally substituted heterocyclyl. In still other embodiments, R² can be an optionally substituted aryl. For example, R² can be an optionally substituted phenyl or an optionally substituted naphthyl. If R² is a substituted phenyl or a substituted naphthyl, the phenyl ring and the naphthyl ring(s) can be substituted one or more times. Suitable substituents that can be present on optionally substituted phenyl and an optionally substituted naphthyl include electron-donating groups and electron-withdrawing groups. In some embodiments, R² can be a para-substituted phenyl. In other embodiment, R² can be an unsubstituted phenyl or an unsubstituted naphthyl. In yet still other embodiments, R² can be

wherein R¹⁹, R²⁰ and R²¹ can be independently absent or hydrogen, and n can be 0 or 1. In some embodiments, n can be 0. In other embodiments, n can be 1. Those skilled in the art understand when n is 0, R² can be an α-thiodiphosphate. Similarly, those skilled in the art understand when n is 1, R² can be an α-thiotriphosphate. In some embodiments, at least one of R¹⁹, R²⁰ and R²¹ can be absent. In other embodiments, at least one of R¹⁹, R²⁰ and R²¹ can be hydrogen. In some embodiments, R²⁰ and R²¹ can be absent. In other embodiments, R²⁰ and R²¹ can be hydrogen. In some embodiments, R¹⁹, R²⁰ and R²¹ can be absent. In some embodiments, R¹⁹, R²⁰ and R²¹ can be hydrogen. Those skilled in the art understand that when any of R¹⁹, R²⁰ and R²¹ are absent the oxygen atom to which R¹⁹, R²⁰ and R²¹ are associated with can have a negative charge. For example, when R²⁰ is absent, the oxygen atom to which R²⁰ is associated with can be Depending upon the substituents attached to each phosphorus atoms, one or more the phosphorus atoms can be a chiral center. For example, when n is 1, the alpha-phosphorus (the phosphorus nearest to the pentose ring) can be a chiral center. In some embodiments, the alpha-phosphorus can be a (R)-stereocenter. In other embodiments, the alpha-phosphorus can be a (S)-stereocenter.

[0092] In some embodiments, R¹ can be absent. In other embodiments, R¹ can be hydrogen. In still other embodiments, R¹ can be an optionally substituted N-linked α-amino acid. In yet still other embodiments, R¹ can be an optionally substituted N-linked α-amino acid ester derivative. Various amino acids and amino acid ester derivatives can be used, including those described herein. Suitable amino acids include, but are not limited to, alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine. Additional suitable amino acids include, but are not limited to, alpha-ethyl-glycine, alpha-propyl-glycine and beta-alanine. Examples of an N-linked amino acid ester derivatives include, but are not limited to, an ester derivatives of any of the following amino acids: alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine. Additional examples of N-linked amino acid ester derivatives include, but are not limited to, an ester derivative of any of the following amino acids: alpha-ethyl-glycine, alpha-propyl-glycine and beta-alanine.

[0093] In an embodiment, R¹ can be an ester derivative of alanine. In an embodiment, R¹ can be selected from alanine methyl ester, alanine ethyl ester, alanine isopropyl ester, alanine cyclohexyl ester, alanine neopentyl ester, valine isopropyl ester and leucine isopropyl ester. In some embodiments, the optionally substituted N-linked amino acid or the optionally substituted N-linked amino acid ester derivative can be in the L-configuration. In other embodiments, the optionally substituted N-linked amino acid or the optionally substituted N-linked amino acid ester derivative can be in the D-configuration.

[0094] In some embodiments, when R¹ is an optionally substituted N-linked α-amino acid or an optionally substituted N-linked α-amino acid ester derivative, then R² can be selected from optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl. In some embodiments, when R¹ is an optionally substituted N-linked α-amino acid ester derivative, then R² can be an optionally substituted aryl. In other embodiments, when R¹ is an optionally substituted N-linked α-amino acid ester derivative, then R² can be an optionally substituted heteroaryl. In still other embodiments, when R¹ is an optionally substituted N-linked α-amino acid ester derivative, then R² can be an optionally substituted heterocyclyl.

[0095] In some embodiments, R¹ can have the structure

wherein R²² can be selected from hydrogen, an optionally substituted C_1-6-alkyl, an optionally substituted C_3-6 cycloalkyl, an optionally substituted aryl, an optionally substituted aryl(C_1-6 alkyl) and an optionally substituted C_1-6 haloalkyl; and R²³ can be selected from hydrogen, an optionally substituted C_1-6 alkyl, an optionally substituted C_1-6 haloalkyl, an optionally substituted C_3-6 cycloalkyl, an optionally substituted C₆ aryl, an optionally substituted C₁₀ aryl and an optionally substituted aryl(C_1-6 alkyl); and R²⁴ can be hydrogen or an optionally substituted C_1-4-alkyl; or R²³ and R²⁴ can be taken together to form an optionally substituted C_3-6 cycloalkyl.

[0096] When R¹ has the structure shown above, R²³ can be an optionally substituted C_1-6-alkyl. Examples of suitable optionally substituted C_1-6-alkyls include optionally substituted variants of the following: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl (branched and straight-chained), and hexyl (branched and straight-chained). When R²³ is substituted, R²³ can be substituted with one or more substituents selected from N-amido, mercapto, alkylthio, an optionally substituted aryl, hydroxy, an optionally substituted heteroaryl, O-carboxy, and amino. In some embodiment, R²³ can be an unsubstituted C_1-6-alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl (branched and straight-chained), and hexyl (branched and straight-chained). In an embodiment, R²³ can be methyl.

[0097] As to R²², in some embodiments, R²² can be an optionally substituted C_1-6 alkyl. Examples of optionally substituted C_1-6-alkyls include optionally substituted variants of the following: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl (branched and straight-chained), and hexyl (branched and straight-chained). In some embodiments, R²² can be methyl or isopropyl. In some embodiments, R²² can be ethyl or neopentyl. In other embodiments, R²² can be an optionally substituted C_3-6 cycloalkyl. Examples of optionally substituted C_3-6 cycloalkyl include optionally substituted variants of the following: cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In an embodiment, R²² can be an optionally substituted cyclohexyl. In still other embodiments, R²² can be an optionally substituted aryl, such as phenyl and naphthyl. In yet still other embodiments, R²² can be an optionally substituted aryl(C_1-6 alkyl). In some embodiments, R²² can be an optionally substituted benzyl. In some embodiments, R²² can be an optionally substituted C_1-6 haloalkyl, for example, CF₃.

[0098] In some embodiments, R²⁴ can be hydrogen. In other embodiments, R²⁴ can be an optionally substituted C_1-4-alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl. In an embodiment, R²⁴ can be methyl. In some embodiments, R²³ and R²⁴ can be taken together to form an optionally substituted C_3-6 cycloalkyl. Examples of optionally substituted C_3-6 cycloalkyl include optionally substituted variants of the following: cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Depending on the groups that are selected for R²³ and R²⁴, the carbon to which R²³ and R²⁴ are attached may be a chiral center. In some embodiment, the carbon to which R²³ and R²⁴ are attached may be a (R)-chiral center. In other embodiments, the carbon to which R²³ and R²⁴ are attached may be a (S)-chiral center.

[0099] As example of a suitable

groups include the following:

[0100] The substituents attached to the 5′-position of a compound of Formula (I) can vary. In some embodiments, R^3a and R^3b can be the same. In other embodiments, R^3a and R^3b can be different. In some embodiments, R^3a and R^3b can be both hydrogen. In some embodiments, at least one of R^3a and R^3b can be an optionally substituted C_1-6-alkyl; and the other of R^3a and R^3b can be hydrogen. Examples of suitable optionally substituted C_1-6 alkyls include optionally substituted variants of the following: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl (branched and straight-chained), and hexyl (branched and straight-chained). In an embodiment, at least one of R^3a and R^3b can be methyl, and the other of R^3a and R^3b can be hydrogen. In other embodiments, at least one of R^3a and R^3b can be an optionally substituted C_1-6-haloalkyl, and the other of R^3a and R^3b can be hydrogen. One example of a suitable optionally substituted C_1-6-haloalkyl is CF₃. In other still embodiments, R^3a and R^3b can be taken together to form an optionally substituted C_3-6 cycloalkyl. When the substituents attached to the 5′-carbon make the 5′-carbon chiral, in some embodiments, the 5′-carbon can be a (R)-stereocenter. In other embodiments, the 5′-carbon can be an (S)-stereocenter.

[0101] The substituents attached to the 4′-carbon can vary. In some embodiments, R⁴ can be hydrogen. In other embodiments, R⁴ can be azido. In still other embodiments, R⁴ can be an optionally substituted C_1-6 alkyl, such as optionally substituted variants of the following: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl (branched and straight-chained), and hexyl (branched and straight-chained). In some embodiments, R⁴ can be an optionally substituted C_2-6 alkenyl. In some embodiments, R⁴ can be an optionally substituted C_2-6 alkynyl.

[0102] The substituents attached to the 2′-carbon and the 3′-carbon can also vary. In some embodiments, R⁵ can be hydrogen. In other embodiments, R⁵ can be halogen. In still other embodiments, R⁵ can be azido. In yet still other embodiments, R⁵ can be cyano. In some embodiments, R⁵ can be an optionally substituted C_1-6 alkyl, such as optionally substituted variants of the following: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl (branched and straight-chained), and hexyl (branched and straight-chained). In other embodiments, R⁵ can be —OR¹⁰, wherein R¹⁰ can be hydrogen. In still other embodiments, R⁵ can be —OR¹⁰, wherein R¹⁰ can be an optionally substituted C_1-6 alkyl. In yet still other embodiments, R⁵ can be —OC(═O)R¹¹, wherein R^H can be an optionally substituted C_1-6 alkyl or an optionally substituted C_3-6 cycloalkyl. Examples of suitable C_1-6 alkyls and C_3-6 cycloalkyls are described herein.

[0103] In some embodiments, R⁶ can be hydrogen. In other embodiments, R⁶ can be halogen. In still other embodiments, R⁶ can be azido. In yet still other embodiments, R⁶ can be cyano. In some embodiments, R⁶ can be an optionally substituted C_1-6 alkyl. In other embodiments, R⁶ can be —OR¹², wherein R¹² can be hydrogen. In still other embodiments, R⁶ can be —OR¹², wherein R¹² can be an optionally substituted C_1-6 alkyl. A non-limiting list of examples of R⁶ being —OR¹², wherein R¹² can be an optionally substituted C_1-6 alkyl are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy and tert-butoxy, pentoxy (straight-chained or branched) and hexoxy (straight-chained or branched). In yet still other embodiments, R⁶ can be —OC(═O)R¹³, wherein R¹³ can be an optionally substituted C_1-6 alkyl or an optionally substituted C_3-6 cycloalkyl. Examples of suitable optionally substituted C_1-6 alkyls include optionally substituted variants of the following: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl pentyl (branched and straight-chained), and hexyl (branched and straight-chained). Examples of suitable optionally substituted C_3-6 cycloalkyls include optionally substituted variants of the following: cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

[0104] In some embodiments, R⁷ can be hydrogen. In other embodiments, R⁷ can be halogen. In still other embodiments, R⁷ can be azido. In yet still other embodiments, R⁷ can be cyano. In some embodiments, R⁷ can be an optionally substituted C_1-6 alkyl. In other embodiments, R⁷ can be —OR¹⁴. In an embodiment, when R¹⁴ is hydrogen, R⁷ can be a hydroxy group. In still other embodiments, when R¹⁴ is an optionally substituted C_1-6 alkyl, R⁷ can be an optionally substituted C_1-6 alkoxy. Examples, of R⁷ being —OR¹⁴, wherein R¹⁴ can be an optionally substituted C_1-6 alkyl include, but are not limited to, are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, pentoxy (straight-chained or branched) and hexoxy (straight-chained or branched). In yet still other embodiments, R⁷ can be —OC(═O)R¹⁵, wherein R¹⁵ can be an optionally substituted C_1-6 alkyl, such as optionally substituted variants of the following: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl (branched and straight-chained), and hexyl (branched and straight-chained). In some embodiments, R⁷ can be —OC(═O)R¹⁵, wherein R¹⁵ can be an optionally substituted C_3-6 cycloalkyl

[0105] In some embodiments, R⁸ can be hydrogen. In other embodiments, R⁸ can be halogen. In still other embodiments, R⁸ can be azido. In yet still other embodiments, R⁸ can be cyano. In some embodiments, R⁸ can be −OR¹⁶. When R¹⁶ is hydrogen, R⁸ can be hydroxy. Alternatively, when R¹⁶ is an optionally substituted C_1-6 alkyl, R⁸ can be an optionally substituted C_1-6 alkoxy. Suitable alkoxy groups are described herein. In other embodiments, R⁸ can be an optionally substituted C_1-6 alkyl. In still other embodiments, R⁸ can be —OC(═O)R¹⁷ in which R¹⁷ is an optionally substituted C_1-6 alkyl. In yet still other embodiments, R⁸ can be —OC(═O)R¹⁷ in which R¹⁷ is an optionally substituted C_3-6 cycloalkyl. Examples of suitable C_1-6 alkyl and C_3-6 cycloalkyl groups are described herein.

[0106] In some embodiments, R⁶ and R⁷ can both be hydroxy. In still other embodiments, R⁶ and R⁷ can both be both oxygen atoms and linked together by a carbonyl group, for example, —O—C(═O)—O—. In some embodiments, at least one of R⁷ and R⁸ can be a halogen. In some embodiments, R⁷ and R⁸ can both be a halogen. In other embodiments, R⁷ can be a halogen and R⁸ can be an optionally substituted C_1-6 alkyl, such as those described herein. In other embodiments, R⁷ can be hydrogen and R⁸ can be a halogen. In still other embodiments, at least one of R⁶ and R⁷ can be a hydroxy and R⁸ can be an optionally substituted C_1-6 alkyl. In yet still other embodiments, R⁶ can be hydroxy, R⁷ can be hydroxy, H or halogen, and R⁸ can be an optionally substituted C_1-6 alkyl. In some embodiments, R^3a, R³″, R⁴, R⁵ and R⁹ can be hydrogen in any of the embodiments described in this paragraph. In some embodiments, B¹ can be an optionally substituted adenine, an optionally substituted guanine, and optionally substituted thymine, optionally substituted cytosine, or an optionally substituted uracil in any of the embodiments described in this paragraph.

[0107] In some embodiments, R⁹ can be hydrogen. In other embodiments, R⁹ can be azido. In still other embodiments, R⁹ can be cyano. In yet still other embodiments, R⁹ can be an optionally substituted C_1-6 alkyl, such as those described herein. In some embodiments, R⁹ can be —OR¹⁸. In some embodiments, when R⁹ is —OR¹⁸, R⁹ can be a hydroxy group. In other embodiments, when R⁹ is —OR¹⁸, R⁹ can be an optionally substituted C_1-6 alkoxy. Examples of optionally substituted C_1-6 alkoxy include the following: methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, pentoxy (branched and straight-chained), and hexoxy (branched and straight-chained).

[0108] Various optionally substituted heterocyclic bases can be attached to the pentose ring. In some embodiments, one or more of the amine and/or amino groups may be protected with a suitable protecting group. For example, an amino group may be protected by transforming the amine and/or amino group to an amide or a carbamate. In some embodiments, an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with one or more protected amino groups can have one of the following structures.

wherein: R^A2 can be selected from hydrogen, halogen and NHR^J2, wherein R^J2 can be selected from hydrogen, —C(═O)R^K2 and —C(═O)OR^L2; R^B2 can be halogen or NHR^W2, wherein R^W2 is selected from hydrogen, an optionally substituted C_1-6 alkyl, an optionally substituted C_2-6 alkenyl, an optionally substituted C_3-8 cycloalkyl, —C(═O)R^M2 and —C(═O)OR^N2; R^C2 can be hydrogen or NHR^O2, wherein R^O2 can be selected from hydrogen, —C(═O)R^P2 and —C(═O)OR^Q2; R^D2 can be selected from hydrogen, halogen, an optionally substituted C_1-6 alkyl, an optionally substituted C_2-6 alkenyl and an optionally substituted C_2-6 alkynyl; R^E2 can be selected from hydrogen, an optionally substituted C_1-6 alkyl, an optionally substituted C_3-8 cycloalkyl, —C(═O)R^R2 and —C(═O)OR^S2; R^F2 can be selected from hydrogen, halogen, an optionally substituted C_1-6 alkyl, an optionally substituted C_2-6 alkenyl and an optionally substituted C_2-6 alkynyl; Y² can be N (nitrogen) or CR^I2, wherein R^I2 can be selected from hydrogen, halogen, an optionally substituted C_1-6-alkyl, an optionally substituted C_2-6-alkenyl and an optionally substituted C_2-6-alkynyl; R^G2 can be an optionally substituted C_1-6 alkyl; R^H2 can be hydrogen or NHR^T2, wherein R^T2 can be independently selected from hydrogen, —C(═O)R^U2 and —C(═O)OR^v2, and R^K2, R^L2, R^M2, R^N2, R^P2, R^Q2, R^R2, R^S2, R^U2 and R^V2 can be independently selected from C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_3-6 cycloalkyl, C_3-6 cycloalkenyl, C_3-6 cycloalkynyl, C_6-10 aryl, heteroaryl, heteroalicyclyl, aryl(C_1-6 alkyl), heteroaryl(C_1-6 alkyl) and heteroalicyclyl(C_1-6 alkyl). In some embodiments, the structures shown above can be modified by replacing one or more hydrogens with substituents selected from the list of substituents provided for the definition of “substituted.” Suitable optionally substituted C_1-6 alkyl groups that can be present on an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with one or more protected amino groups are described herein, and include, optionally substituted variants of the following: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl (branched and straight-chained), and hexyl (branched and straight-chained).

[0109] In some embodiments, B¹ can be selected from adenine, guanine, thymine, cytosine and uracil. In some embodiments, R^B2 can be NH₂. In other embodiments, R^E2 can be hydrogen. In some embodiments, B¹ can be

In other embodiments, B¹ can be

In some embodiments, B¹ can be

In some embodiments, B¹ can be

In still other embodiments, B¹ can be

[0110] In yet still other embodiments, B¹ can be

In some embodiments, B¹ can be

In some embodiments, when R² is a substituted or unsubstituted phenyl, then R¹ cannot be

In other embodiments, when R² is a substituted or unsubstituted phenyl, then R¹ cannot be

In still other embodiments, when R² is a substituted or unsubstituted phenyl and R¹ is

then at least one of R⁵ and R⁶ cannot be hydroxy.

[0111] In some embodiments, when R¹ is O⁻ or OH, then R² cannot be

In some embodiments, at least one of R^3a and R^3b cannot be hydrogen. In some embodiments, R⁴ is not azido. In some embodiments, when R⁴ is not azido, then R⁷ and R⁸ are not both halogen. In some embodiments, when R⁴ is azido, then B¹ is not an optionally substituted uracil, optionally substituted uracil with one or more protected amino groups, an optionally substituted cytosine or optionally substituted cytosine with one or more protected amino groups. In some embodiments, R⁶ cannot be azido. In some embodiments, when R¹ is a methyl ester of glycine, alanine, valine, or phenylalanine; R² is p-chlorophenyl or p-nitrophenyl; B¹ is thymine; and R^3a, R^3b, R⁴, R⁵, R⁷, R⁸, and R⁹ are all hydrogen; then R⁶ cannot be azido. In some embodiments, at least one of R⁶ and R⁷ cannot be hydroxy. For example, R⁶ cannot be hydroxy, R⁷ cannot be hydroxy, or both of R⁶ and R⁷ cannot be hydroxy.

[0112] Some embodiments disclosed herein relate to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: B¹ can be an optionally substituted heterocyclic base as described in paragraph [0106]; R¹ can be selected from O⁻, OH, an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative; R² can be selected from an optionally substituted aryl and

wherein R¹⁹, R²⁰ and R²¹ can be independently absent or hydrogen, and n can be 0 or 1; provided that when R¹ is O⁻ or OH, then R² is

R^3a and R^3b can be hydrogen; R⁴ can be hydrogen; R⁵ can be selected from hydrogen, halogen, an optionally substituted C_1-6 alkyl and —OR¹⁰; R⁶ can be selected from hydrogen, halogen, optionally substituted C_1-6 alkyl, —OR¹² and —OC(═O)R¹³; R⁷ can be selected from hydrogen, halogen, azido, cyano, an optionally substituted C_1-6 alkyl, —OR¹⁴ and —OC(═O)R¹⁵; or R⁶ and R⁷ can be both oxygen atoms and linked together by a carbonyl group; R⁸ can be selected from hydrogen, halogen, an optionally substituted C_1-6 alkyl and —OR¹⁶; R⁹ can be hydrogen; R¹⁰, R¹²_{, R}¹⁴ and R¹⁶ can be independently selected from hydrogen and an optionally substituted C_1-6 alkyl; and R¹³ and R¹⁵ can be independently selected from an optionally substituted C_1-6 alkyl and an optionally substituted C_3-6 cycloalkyl.

[0113] Some embodiments disclosed herein relate to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: B¹ can be an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group selected from

R¹ can be selected from O⁻, OH, an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative; R² can be selected from an optionally substituted aryl and

wherein R¹⁹, R²⁰ and R²¹ can be independently absent or hydrogen, and n can be 0 or 1; provided that when R¹ is O⁻ or OH, then R² is

R^3a and R^3b can be hydrogen; R⁴ can be hydrogen; R⁵ can be selected from hydrogen, halogen, an optionally substituted C_1-6 alkyl and —OR¹⁰; R⁶ can be selected from hydrogen, halogen, optionally substituted C_1-6 alkyl, —OR¹² and —OC(═O)R¹³; R⁷ can be selected from hydrogen, halogen, azido, cyano, an optionally substituted C_1-6 alkyl, —OR¹⁴ and —OC(═O)R¹⁵; or R⁶ and R⁷ can be both oxygen atoms and linked together by a carbonyl group; R⁸ can be selected from hydrogen, halogen, an optionally substituted C_1-6 alkyl and —OR¹⁶; R⁹ can be hydrogen; R¹⁰, R¹², R¹⁴ and R¹⁶ can be independently selected from hydrogen and an optionally substituted C_1-6 alkyl; and R¹³ and R¹⁵ can be independently selected from an optionally substituted C_1-6 alkyl and an optionally substituted C_3-6 cycloalkyl.

[0114] In some embodiments, Formula (I) can be a compound of Formula (Iα), wherein: B¹ can be an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group selected from cytosine, uridine, thymidine, guanine and adenine; R¹ can be selected from O⁻, OH, and an optionally substituted N-linked amino acid ester derivative of alanine, valine, or leucine; R² can be selected from an optionally substituted phenyl, an optionally substituted naphthyl, an optionally substituted pyridyl, an optionally substituted quinolyl, and

wherein R¹⁹, R²⁰ and R²¹ independently can be hydrogen or absent, and n can be 0 or 1; provided that when R¹ is O⁻ or OH, then R² is

R^3a and R^3b can be hydrogen; R⁴ can be hydrogen; R⁵ can be hydrogen; R⁶ can be −OR¹² or —OC(═O)R¹³; R⁷ can be selected from halogen, —OR¹⁴ and —OC(═O)R¹⁵; R⁸ can be an optionally substituted C_1-6 alkyl; R⁹ can be hydrogen; R¹² and R¹⁴ can be independently hydrogen or an optionally substituted C_1-6 alkyl; and R¹³ and R¹⁵ can be independently an optionally substituted C_1-6 alkyl.

[0115] Some embodiments relate to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: B¹ can be an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group; R¹ can be selected from O⁻, OH, an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative; R² can be selected from an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl and

wherein R¹⁹, R²⁰ and R²¹ can be independently absent or hydrogen, and n can be 0 or 1; provided that when R¹ is O⁻ or OH, then R² is

R^3a and R^3b can be independently selected from hydrogen, an optionally substituted C_1-6 alkyl, an optionally substituted C_2-6 alkenyl, an optionally substituted C_2-6 alkynyl, an optionally substituted C_1-6 haloalkyl and aryl(C_1-6 alkyl); or R^3a and R^3b can be taken together to form an optionally substituted C_3-6 cycloalkyl; R⁴ can be selected from hydrogen, azido, an optionally substituted C_1-6 alkyl, an optionally substituted C_2-6 alkenyl and an optionally substituted C_2-6 alkynyl; R⁵ can be selected from hydrogen, halogen, azido, cyano, an optionally substituted C_1-6 alkyl, —OR¹⁹ and —OC(═O)R¹¹; R⁶ can be selected from hydrogen, halogen, azido, cyano, an optionally substituted C_1-6 alkyl, —OR¹² and —OC(═O)R¹³; R⁷ can be selected from hydrogen, halogen, azido, cyano, an optionally substituted C_1-6 alkyl, —OR¹⁴ and —OC(═O)R¹⁵; or R⁶ and R⁷ can be both oxygen atoms and linked together by a carbonyl group; R⁸ can be selected from hydrogen, halogen, azido, cyano, an optionally substituted C_1-6 alkyl, —OR¹⁶ and —OC(═O)R¹⁷; R⁹ can be selected from hydrogen, azido, cyano, an optionally substituted C_1-6 alkyl and —OR¹⁸; R¹⁰; R¹²; R¹⁴; R¹⁶ and R¹⁸ can be independently selected from hydrogen and an optionally substituted C_1-6 alkyl; and R¹¹, R¹³, R¹⁵ and R¹⁷ can be independently an optionally substituted C_1-6 alkyl and an optionally substituted C_3-6 cycloalkyl.

[0116] In some embodiments, a compound of Formula (I) can be a single diastereomer. In other embodiments, a compound of Formula (I) can be a mixture of diastereomers. In some embodiments, a compound of Formula (I) can be a 1:1 mixture of two diastereomers. In some embodiments, a compound of Formula (I) can be diasteriometrically enriched (for example, one diastereomer can be present at a concentration of >55%, ≧75%, ≧80%, ≧90%, ≧95%, ≧98%, or ≧99% as compared to the total concentration of the other diastereomers).

[0117] Some embodiments of R¹ and R² of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, are provided in Table 1. Tables 2-4 provide the structures of the variables bb01-bb12, aa01-aa11 and es01-es14, respectively. For example, the first entry in Table 1 is “bb01, aa01, es01,” corresponds to a compound of Formula (I), wherein R²

[0118]

TABLE 1
R2, R1, Rα	R2, R1, Rα	R2, R1, Rα	R2, R1, Rα	R2, R1, Rα
bb01, aa01, es01	bb03, aa01, es01	bb05, aa01, es01	bb07, aa01, es01	bb09, aa01, es01
bb01, aa01, es02	bb03, aa01, es02	bb05, aa01, es02	bb07, aa01, es02	bb09, aa01, es02
bb01, aa01, es03	bb03, aa01, es03	bb05, aa01, es03	bb07, aa01, es03	bb09, aa01, es03
bb01, aa01, es04	bb03, aa01, es04	bb05, aa01, es04	bb07, aa01, es04	bb09, aa01, es04
bb01, aa01, es05	bb03, aa01, es05	bb05, aa01, es05	bb07, aa01, es05	bb09, aa01, es05
bb01, aa01, es06	bb03, aa01, es06	bb05, aa01, es06	bb07, aa01, es06	bb09, aa01, es06
bb01, aa01, es07	bb03, aa01, es07	bb05, aa01, es07	bb07, aa01, es07	bb09, aa01, es07
bb01, aa01, es08	bb03, aa01, es08	bb05, aa01, es08	bb07, aa01, es08	bb09, aa01, es08
bb01, aa01, es09	bb03, aa01, es09	bb05, aa01, es09	bb07, aa01, es09	bb09, aa01, es09
bb01, aa01, es10	bb03, aa01, es10	bb05, aa01, es10	bb07, aa01, es10	bb09, aa01, es10
bb01, aa01, es11	bb03, aa01, es11	bb05, aa01, es11	bb07, aa01, es11	bb09, aa01, es11
bb01, aa01, es12	bb03, aa01, es12	bb05, aa01, es12	bb07, aa01, es12	bb09, aa01, es12
bb01, aa02, es01	bb03, aa02, es01	bb05, aa02, es01	bb07, aa02, es01	bb09, aa02, es01
bb01, aa02, es02	bb03, aa02, es02	bb05, aa02, es02	bb07, aa02, es02	bb09, aa02, es02
bb01, aa02, es03	bb03, aa02, es03	bb05, aa02, es03	bb07, aa02, es03	bb09, aa02, es03
bb01, aa02, es04	bb03, aa02, es04	bb05, aa02, es04	bb07, aa02, es04	bb09, aa02, es04
bb01, aa02, es05	bb03, aa02, es05	bb05, aa02, es05	bb07, aa02, es05	bb09, aa02, es05
bb01, aa02, es06	bb03, aa02, es06	bb05, aa02, es06	bb07, aa02, es06	bb09, aa02, es06
bb01, aa02, es07	bb03, aa02, es07	bb05, aa02, es07	bb07, aa02, es07	bb09, aa02, es07
bb01, aa02, es08	bb03, aa02, es08	bb05, aa02, es08	bb07, aa02, es08	bb09, aa02, es08
bb01, aa02, es09	bb03, aa02, es09	bb05, aa02, es09	bb07, aa02, es09	bb09, aa02, es09
bb01, aa02, es10	bb03, aa02, es10	bb05, aa02, es10	bb07, aa02, es10	bb09, aa02, es10
bb01, aa02, es11	bb03, aa02, es11	bb05, aa02, es11	bb07, aa02, es11	bb09, aa02, es11
bb01, aa02, es12	bb03, aa02, es12	bb05, aa02, es12	bb07, aa02, es12	bb09, aa02, es12
bb01, aa03, es01	bb03, aa03, es01	bb05, aa03, es01	bb07, aa03, es01	bb09, aa03, es01
bb01, aa03, es02	bb03, aa03, es02	bb05, aa03, es02	bb07, aa03, es02	bb09, aa03, es02
bb01, aa03, es03	bb03, aa03, es03	bb05, aa03, es03	bb07, aa03, es03	bb09, aa03, es03
bb01, aa03, es04	bb03, aa03, es04	bb05, aa03, es04	bb07, aa03, es04	bb09, aa03, es04
bb01, aa03, es05	bb03, aa03, es05	bb05, aa03, es05	bb07, aa03, es05	bb09, aa03, es05
bb01, aa03, es06	bb03, aa03, es06	bb05, aa03, es06	bb07, aa03, es06	bb09, aa03, es06
bb01, aa03, es07	bb03, aa03, es07	bb05, aa03, es07	bb07, aa03, es07	bb09, aa03, es07
bb01, aa03, es08	bb03, aa03, es08	bb05, aa03, es08	bb07, aa03, es08	bb09, aa03, es08
bb01, aa03, es09	bb03, aa03, es09	bb05, aa03, es09	bb07, aa03, es09	bb09, aa03, es09
bb01, aa03, es10	bb03, aa03, es10	bb05, aa03, es10	bb07, aa03, es10	bb09, aa03, es10
bb01, aa03, es11	bb03, aa03, es11	bb05, aa03, es11	bb07, aa03, es11	bb09, aa03, es11
bb01, aa03, es12	bb03, aa03, es12	bb05, aa03, es12	bb07, aa03, es12	bb09, aa03, es12
bb01, aa04, es01	bb03, aa04, es01	bb05, aa04, es01	bb07, aa04, es01	bb09, aa04, es01
bb01, aa04, es02	bb03, aa04, es02	bb05, aa04, es02	bb07, aa04, es02	bb09, aa04, es02
bb01, aa04, es03	bb03, aa04, es03	bb05, aa04, es03	bb07, aa04, es03	bb09, aa04, es03
bb01, aa04, es04	bb03, aa04, es04	bb05, aa04, es04	bb07, aa04, es04	bb09, aa04, es04
bb01, aa04, es05	bb03, aa04, es05	bb05, aa04, es05	bb07, aa04, es05	bb09, aa04, es05
bb01, aa04, es06	bb03, aa04, es06	bb05, aa04, es06	bb07, aa04, es06	bb09, aa04, es06
bb01, aa04, es07	bb03, aa04, es07	bb05, aa04, es07	bb07, aa04, es07	bb09, aa04, es07
bb01, aa04, es08	bb03, aa04, es08	bb05, aa04, es08	bb07, aa04, es08	bb09, aa04, es08
bb01, aa04, es09	bb03, aa04, es09	bb05, aa04, es09	bb07, aa04, es09	bb09, aa04, es09
bb01, aa04, es10	bb03, aa04, es10	bb05, aa04, es10	bb07, aa04, es10	bb09, aa04, es10
bb01, aa04, es11	bb03, aa04, es11	bb05, aa04, es11	bb07, aa04, es11	bb09, aa04, es11
bb01, aa04, es12	bb03, aa04, es12	bb05, aa04, es12	bb07, aa04, es12	bb09, aa04, es12
bb01, aa05, es01	bb03, aa05, es01	bb05, aa05, es01	bb07, aa05, es01	bb09, aa05, es01
bb01, aa05, es02	bb03, aa05, es02	bb05, aa05, es02	bb07, aa05, es02	bb09, aa05, es02
bb01, aa05, es03	bb03, aa05, es03	bb05, aa05, es03	bb07, aa05, es03	bb09, aa05, es03
bb01, aa05, es04	bb03, aa05, es04	bb05, aa05, es04	bb07, aa05, es04	bb09, aa05, es04
bb01, aa05, es05	bb03, aa05, es05	bb05, aa05, es05	bb07, aa05, es05	bb09, aa05, es05
bb01, aa05, es06	bb03, aa05, es06	bb05, aa05, es06	bb07, aa05, es06	bb09, aa05, es06
bb01, aa05, es07	bb03, aa05, es07	bb05, aa05, es07	bb07, aa05, es07	bb09, aa05, es07
bb01, aa05, es08	bb03, aa05, es08	bb05, aa05, es08	bb07, aa05, es08	bb09, aa05, es08
bb01, aa05, es09	bb03, aa05, es09	bb05, aa05, es09	bb07, aa05, es09	bb09, aa05, es09
bb01, aa05, es10	bb03, aa05, es10	bb05, aa05, es10	bb07, aa05, es10	bb09, aa05, es10
bb01, aa05, es11	bb03, aa05, es11	bb05, aa05, es11	bb07, aa05, es11	bb09, aa05, es11
bb01, aa05, es12	bb03, aa05, es12	bb05, aa05, es12	bb07, aa05, es12	bb09, aa05, es12
bb01, aa06, es01	bb03, aa06, es01	bb05, aa06, es01	bb07, aa06, es01	bb09, aa06, es01
bb01, aa06, es02	bb03, aa06, es02	bb05, aa06, es02	bb07, aa06, es02	bb09, aa06, es02
bb01, aa06, es03	bb03, aa06, es03	bb05, aa06, es03	bb07, aa06, es03	bb09, aa06, es03
bb01, aa06, es04	bb03, aa06, es04	bb05, aa06, es04	bb07, aa06, es04	bb09, aa06, es04
bb01, aa06, es05	bb03, aa06, es05	bb05, aa06, es05	bb07, aa06, es05	bb09, aa06, es05
bb01, aa06, es06	bb03, aa06, es06	bb05, aa06, es06	bb07, aa06, es06	bb09, aa06, es06
bb01, aa06, es07	bb03, aa06, es07	bb05, aa06, es07	bb07, aa06, es07	bb09, aa06, es07
bb01, aa06, es08	bb03, aa06, es08	bb05, aa06, es08	bb07, aa06, es08	bb09, aa06, es08
bb01, aa06, es09	bb03, aa06, es09	bb05, aa06, es09	bb07, aa06, es09	bb09, aa06, es09
bb01, aa06, es10	bb03, aa06, es10	bb05, aa06, es10	bb07, aa06, es10	bb09, aa06, es10
bb01, aa06, es11	bb03, aa06, es11	bb05, aa06, es11	bb07, aa06, es11	bb09, aa06, es11
bb01, aa06, es12	bb03, aa06, es12	bb05, aa06, es12	bb07, aa06, es12	bb09, aa06, es12
bb01, aa07, es01	bb03, aa07, es01	bb05, aa07, es01	bb07, aa07, es01	bb09, aa07, es01
bb01, aa07, es02	bb03, aa07, es02	bb05, aa07, es02	bb07, aa07, es02	bb09, aa07, es02
bb01, aa07, es03	bb03, aa07, es03	bb05, aa07, es03	bb07, aa07, es03	bb09, aa07, es03
bb01, aa07, es04	bb03, aa07, es04	bb05, aa07, es04	bb07, aa07, es04	bb09, aa07, es04
bb01, aa07, es05	bb03, aa07, es05	bb05, aa07, es05	bb07, aa07, es05	bb09, aa07, es05
bb01, aa07, es06	bb03, aa07, es06	bb05, aa07, es06	bb07, aa07, es06	bb09, aa07, es06
bb01, aa07, es07	bb03, aa07, es07	bb05, aa07, es07	bb07, aa07, es07	bb09, aa07, es07
bb01, aa07, es08	bb03, aa07, es08	bb05, aa07, es08	bb07, aa07, es08	bb09, aa07, es08
bb01, aa07, es09	bb03, aa07, es09	bb05, aa07, es09	bb07, aa07, es09	bb09, aa07, es09
bb01, aa07, es10	bb03, aa07, es10	bb05, aa07, es10	bb07, aa07, es10	bb09, aa07, es10
bb01, aa07, es11	bb03, aa07, es11	bb05, aa07, es11	bb07, aa07, es11	bb09, aa07, es11
bb01, aa07, es12	bb03, aa07, es12	bb05, aa07, es12	bb07, aa07, es12	bb09, aa07, es12
bb01, aa08, es01	bb03, aa08, es01	bb05, aa08, es01	bb07, aa08, es01	bb09, aa08, es01
bb01, aa08, es02	bb03, aa08, es02	bb05, aa08, es02	bb07, aa08, es02	bb09, aa08, es02
bb01, aa08, es03	bb03, aa08, es03	bb05, aa08, es03	bb07, aa08, es03	bb09, aa08, es03
bb01, aa08, es04	bb03, aa08, es04	bb05, aa08, es04	bb07, aa08, es04	bb09, aa08, es04
bb01, aa08, es05	bb03, aa08, es05	bb05, aa08, es05	bb07, aa08, es05	bb09, aa08, es05
bb01, aa08, es06	bb03, aa08, es06	bb05, aa08, es06	bb07, aa08, es06	bb09, aa08, es06
bb01, aa08, es07	bb03, aa08, es07	bb05, aa08, es07	bb07, aa08, es07	bb09, aa08, es07
bb01, aa08, es08	bb03, aa08, es08	bb05, aa08, es08	bb07, aa08, es08	bb09, aa08, es08
bb01, aa08, es09	bb03, aa08, es09	bb05, aa08, es09	bb07, aa08, es09	bb09, aa08, es09
bb01, aa08, es10	bb03, aa08, es10	bb05, aa08, es10	bb07, aa08, es10	bb09, aa08, es10
bb01, aa08, es11	bb03, aa08, es11	bb05, aa08, es11	bb07, aa08, es11	bb09, aa08, es11
bb01, aa08, es12	bb03, aa08, es12	bb05, aa08, es12	bb07, aa08, es12	bb09, aa08, es12
bb01, aa09, es01	bb03, aa09, es01	bb05, aa09, es01	bb07, aa09, es01	bb09, aa09, es01
bb01, aa09, es02	bb03, aa09, es02	bb05, aa09, es02	bb07, aa09, es02	bb09, aa09, es02
bb01, aa09, es03	bb03, aa09, es03	bb05, aa09, es03	bb07, aa09, es03	bb09, aa09, es03
bb01, aa09, es04	bb03, aa09, es04	bb05, aa09, es04	bb07, aa09, es04	bb09, aa09, es04
bb01, aa09, es05	bb03, aa09, es05	bb05, aa09, es05	bb07, aa09, es05	bb09, aa09, es05
bb01, aa09, es06	bb03, aa09, es06	bb05, aa09, es06	bb07, aa09, es06	bb09, aa09, es06
bb01, aa09, es07	bb03, aa09, es07	bb05, aa09, es07	bb07, aa09, es07	bb09, aa09, es07
bb01, aa09, es08	bb03, aa09, es08	bb05, aa09, es08	bb07, aa09, es08	bb09, aa09, es08
bb01, aa09, es09	bb03, aa09, es09	bb05, aa09, es09	bb07, aa09, es09	bb09, aa09, es09
bb01, aa09, es10	bb03, aa09, es10	bb05, aa09, es10	bb07, aa09, es10	bb09, aa09, es10
bb01, aa09, es11	bb03, aa09, es11	bb05, aa09, es11	bb07, aa09, es11	bb09, aa09, es11
bb01, aa09, es12	bb03, aa09, es12	bb05, aa09, es12	bb07, aa09, es12	bb09, aa09, es12
bb01, aa10, es01	bb03, aa10, es01	bb05, aa10, es01	bb07, aa10, es01	bb09, aa10, es01
bb01, aa10, es02	bb03, aa10, es02	bb05, aa10, es02	bb07, aa10, es02	bb09, aa10, es02
bb01, aa10, es03	bb03, aa10, es03	bb05, aa10, es03	bb07, aa10, es03	bb09, aa10, es03
bb01, aa10, es04	bb03, aa10, es04	bb05, aa10, es04	bb07, aa10, es04	bb09, aa10, es04
bb01, aa10, es05	bb03, aa10, es05	bb05, aa10, es05	bb07, aa10, es05	bb09, aa10, es05
bb01, aa10, es06	bb03, aa10, es06	bb05, aa10, es06	bb07, aa10, es06	bb09, aa10, es06
bb01, aa10, es07	bb03, aa10, es07	bb05, aa10, es07	bb07, aa10, es07	bb09, aa10, es07
bb01, aa10, es08	bb03, aa10, es08	bb05, aa10, es08	bb07, aa10, es08	bb09, aa10, es08
bb01, aa10, es09	bb03, aa10, es09	bb05, aa10, es09	bb07, aa10, es09	bb09, aa10, es09
bb01, aa10, es10	bb03, aa10, es10	bb05, aa10, es10	bb07, aa10, es10	bb09, aa10, es10
bb01, aa10, es11	bb03, aa10, es11	bb05, aa10, es11	bb07, aa10, es11	bb09, aa10, es11
bb01, aa10, es12	bb03, aa10, es12	bb05, aa10, es12	bb07, aa10, es12	bb09, aa10, es12
bb02, aa01, es01	bb04, aa01, es01	bb06, aa01, es01	bb08, aa01, es01	bb10, aa01, es01
bb02, aa01, es02	bb04, aa01, es02	bb06, aa01, es02	bb08, aa01, es02	bb10, aa01, es02
bb02, aa01, es03	bb04, aa01, es03	bb06, aa01, es03	bb08, aa01, es03	bb10, aa01, es03
bb02, aa01, es04	bb04, aa01, es04	bb06, aa01, es04	bb08, aa01, es04	bb10, aa01, es04
bb02, aa01, es05	bb04, aa01, es05	bb06, aa01, es05	bb08, aa01, es05	bb10, aa01, es05
bb02, aa01, es06	bb04, aa01, es06	bb06, aa01, es06	bb08, aa01, es06	bb10, aa01, es06
bb02, aa01, es07	bb04, aa01, es07	bb06, aa01, es07	bb08, aa01, es07	bb10, aa01, es07
bb02, aa01, es08	bb04, aa01, es08	bb06, aa01, es08	bb08, aa01, es08	bb10, aa01, es08
bb02, aa01, es09	bb04, aa01, es09	bb06, aa01, es09	bb08, aa01, es09	bb10, aa01, es09
bb02, aa01, es10	bb04, aa01, es10	bb06, aa01, es10	bb08, aa01, es10	bb10, aa01, es10
bb02, aa01, es11	bb04, aa01, es11	bb06, aa01, es11	bb08, aa01, es11	bb10, aa01, es11
bb02, aa01, es12	bb04, aa01, es12	bb06, aa01, es12	bb08, aa01, es12	bb10, aa01, es12
bb02, aa02, es01	bb04, aa02, es01	bb06, aa02, es01	bb08, aa02, es01	bb10, aa02, es01
bb02, aa02, es02	bb04, aa02, es02	bb06, aa02, es02	bb08, aa02, es02	bb10, aa02, es02
bb02, aa02, es03	bb04, aa02, es03	bb06, aa02, es03	bb08, aa02, es03	bb10, aa02, es03
bb02, aa02, es04	bb04, aa02, es04	bb06, aa02, es04	bb08, aa02, es04	bb10, aa02, es04
bb02, aa02, es05	bb04, aa02, es05	bb06, aa02, es05	bb08, aa02, es05	bb10, aa02, es05
bb02, aa02, es06	bb04, aa02, es06	bb06, aa02, es06	bb08, aa02, es06	bb10, aa02, es06
bb02, aa02, es07	bb04, aa02, es07	bb06, aa02, es07	bb08, aa02, es07	bb10, aa02, es07
bb02, aa02, es08	bb04, aa02, es08	bb06, aa02, es08	bb08, aa02, es08	bb10, aa02, es08
bb02, aa02, es09	bb04, aa02, es09	bb06, aa02, es09	bb08, aa02, es09	bb10, aa02, es09
bb02, aa02, es10	bb04, aa02, es10	bb06, aa02, es10	bb08, aa02, es10	bb10, aa02, es10
bb02, aa02, es11	bb04, aa02, es11	bb06, aa02, es11	bb08, aa02, es11	bb10, aa02, es11
bb02, aa02, es12	bb04, aa02, es12	bb06, aa02, es12	bb08, aa02, es12	bb10, aa02, es12
bb02, aa03, es01	bb04, aa03, es01	bb06, aa03, es01	bb08, aa03, es01	bb10, aa03, es01
bb02, aa03, es02	bb04, aa03, es02	bb06, aa03, es02	bb08, aa03, es02	bb10, aa03, es02
bb02, aa03, es03	bb04, aa03, es03	bb06, aa03, es03	bb08, aa03, es03	bb10, aa03, es03
bb02, aa03, es04	bb04, aa03, es04	bb06, aa03, es04	bb08, aa03, es04	bb10, aa03, es04
bb02, aa03, es05	bb04, aa03, es05	bb06, aa03, es05	bb08, aa03, es05	bb10, aa03, es05
bb02, aa03, es06	bb04, aa03, es06	bb06, aa03, es06	bb08, aa03, es06	bb10, aa03, es06
bb02, aa03, es07	bb04, aa03, es07	bb06, aa03, es07	bb08, aa03, es07	bb10, aa03, es07
bb02, aa03, es08	bb04, aa03, es08	bb06, aa03, es08	bb08, aa03, es08	bb10, aa03, es08
bb02, aa03, es09	bb04, aa03, es09	bb06, aa03, es09	bb08, aa03, es09	bb10, aa03, es09
bb02, aa03, es10	bb04, aa03, es10	bb06, aa03, es10	bb08, aa03, es10	bb10, aa03, es10
bb02, aa03, es11	bb04, aa03, es11	bb06, aa03, es11	bb08, aa03, es11	bb10, aa03, es11
bb02, aa03, es12	bb04, aa03, es12	bb06, aa03, es12	bb08, aa03, es12	bb10, aa03, es12
bb02, aa04, es01	bb04, aa04, es01	bb06, aa04, es01	bb08, aa04, es01	bb10, aa04, es01
bb02, aa04, es02	bb04, aa04, es02	bb06, aa04, es02	bb08, aa04, es02	bb10, aa04, es02
bb02, aa04, es03	bb04, aa04, es03	bb06, aa04, es03	bb08, aa04, es03	bb10, aa04, es03
bb02, aa04, es04	bb04, aa04, es04	bb06, aa04, es04	bb08, aa04, es04	bb10, aa04, es04
bb02, aa04, es05	bb04, aa04, es05	bb06, aa04, es05	bb08, aa04, es05	bb10, aa04, es05
bb02, aa04, es06	bb04, aa04, es06	bb06, aa04, es06	bb08, aa04, es06	bb10, aa04, es06
bb02, aa04, es07	bb04, aa04, es07	bb06, aa04, es07	bb08, aa04, es07	bb10, aa04, es07
bb02, aa04, es08	bb04, aa04, es08	bb06, aa04, es08	bb08, aa04, es08	bb10, aa04, es08
bb02, aa04, es09	bb04, aa04, es09	bb06, aa04, es09	bb08, aa04, es09	bb10, aa04, es09
bb02, aa04, es10	bb04, aa04, es10	bb06, aa04, es10	bb08, aa04, es10	bb10, aa04, es10
bb02, aa04, es11	bb04, aa04, es11	bb06, aa04, es11	bb08, aa04, es11	bb10, aa04, es11
bb02, aa04, es12	bb04, aa04, es12	bb06, aa04, es12	bb08, aa04, es12	bb10, aa04, es12
bb02, aa05, es01	bb04, aa05, es01	bb06, aa05, es01	bb08, aa05, es01	bb10, aa05, es01
bb02, aa05, es02	bb04, aa05, es02	bb06, aa05, es02	bb08, aa05, es02	bb10, aa05, es02
bb02, aa05, es03	bb04, aa05, es03	bb06, aa05, es03	bb08, aa05, es03	bb10, aa05, es03
bb02, aa05, es04	bb04, aa05, es04	bb06, aa05, es04	bb08, aa05, es04	bb10, aa05, es04
bb02, aa05, es05	bb04, aa05, es05	bb06, aa05, es05	bb08, aa05, es05	bb10, aa05, es05
bb02, aa05, es06	bb04, aa05, es06	bb06, aa05, es06	bb08, aa05, es06	bb10, aa05, es06
bb02, aa05, es07	bb04, aa05, es07	bb06, aa05, es07	bb08, aa05, es07	bb10, aa05, es07
bb02, aa05, es08	bb04, aa05, es08	bb06, aa05, es08	bb08, aa05, es08	bb10, aa05, es08
bb02, aa05, es09	bb04, aa05, es09	bb06, aa05, es09	bb08, aa05, es09	bb10, aa05, es09
bb02, aa05, es10	bb04, aa05, es10	bb06, aa05, es10	bb08, aa05, es10	bb10, aa05, es10
bb02, aa05, es11	bb04, aa05, es11	bb06, aa05, es11	bb08, aa05, es11	bb10, aa05, es11
bb02, aa05, es12	bb04, aa05, es12	bb06, aa05, es12	bb08, aa05, es12	bb10, aa05, es12
bb02, aa06, es01	bb04, aa06, es01	bb06, aa06, es01	bb08, aa06, es01	bb10, aa06, es01
bb02, aa06, es02	bb04, aa06, es02	bb06, aa06, es02	bb08, aa06, es02	bb10, aa06, es02
bb02, aa06, es03	bb04, aa06, es03	bb06, aa06, es03	bb08, aa06, es03	bb10, aa06, es03
bb02, aa06, es04	bb04, aa06, es04	bb06, aa06, es04	bb08, aa06, es04	bb10, aa06, es04
bb02, aa06, es05	bb04, aa06, es05	bb06, aa06, es05	bb08, aa06, es05	bb10, aa06, es05
bb02, aa06, es06	bb04, aa06, es06	bb06, aa06, es06	bb08, aa06, es06	bb10, aa06, es06
bb02, aa06, es07	bb04, aa06, es07	bb06, aa06, es07	bb08, aa06, es07	bb10, aa06, es07
bb02, aa06, es08	bb04, aa06, es08	bb06, aa06, es08	bb08, aa06, es08	bb10, aa06, es08
bb02, aa06, es09	bb04, aa06, es09	bb06, aa06, es09	bb08, aa06, es09	bb10, aa06, es09
bb02, aa06, es10	bb04, aa06, es10	bb06, aa06, es10	bb08, aa06, es10	bb10, aa06, es10
bb02, aa06, es11	bb04, aa06, es11	bb06, aa06, es11	bb08, aa06, es11	bb10, aa06, es11
bb02, aa06, es12	bb04, aa06, es12	bb06, aa06, es12	bb08, aa06, es12	bb10, aa06, es12
bb02, aa07, es01	bb04, aa07, es01	bb06, aa07, es01	bb08, aa07, es01	bb10, aa07, es01
bb02, aa07, es02	bb04, aa07, es02	bb06, aa07, es02	bb08, aa07, es02	bb10, aa07, es02
bb02, aa07, es03	bb04, aa07, es03	bb06, aa07, es03	bb08, aa07, es03	bb10, aa07, es03
bb02, aa07, es04	bb04, aa07, es04	bb06, aa07, es04	bb08, aa07, es04	bb10, aa07, es04
bb02, aa07, es05	bb04, aa07, es05	bb06, aa07, es05	bb08, aa07, es05	bb10, aa07, es05
bb02, aa07, es06	bb04, aa07, es06	bb06, aa07, es06	bb08, aa07, es06	bb10, aa07, es06
bb02, aa07, es07	bb04, aa07, es07	bb06, aa07, es07	bb08, aa07, es07	bb10, aa07, es07
bb02, aa07, es08	bb04, aa07, es08	bb06, aa07, es08	bb08, aa07, es08	bb10, aa07, es08
bb02, aa07, es09	bb04, aa07, es09	bb06, aa07, es09	bb08, aa07, es09	bb10, aa07, es09
bb02, aa07, es10	bb04, aa07, es10	bb06, aa07, es10	bb08, aa07, es10	bb10, aa07, es10
bb02, aa07, es11	bb04, aa07, es11	bb06, aa07, es11	bb08, aa07, es11	bb10, aa07, es11
bb02, aa07, es12	bb04, aa07, es12	bb06, aa07, es12	bb08, aa07, es12	bb10, aa07, es12
bb02, aa08, es01	bb04, aa08, es01	bb06, aa08, es01	bb08, aa08, es01	bb10, aa08, es01
bb02, aa08, es02	bb04, aa08, es02	bb06, aa08, es02	bb08, aa08, es02	bb10, aa08, es02
bb02, aa08, es03	bb04, aa08, es03	bb06, aa08, es03	bb08, aa08, es03	bb10, aa08, es03
bb02, aa08, es04	bb04, aa08, es04	bb06, aa08, es04	bb08, aa08, es04	bb10, aa08, es04
bb02, aa08, es05	bb04, aa08, es05	bb06, aa08, es05	bb08, aa08, es05	bb10, aa08, es05
bb02, aa08, es06	bb04, aa08, es06	bb06, aa08, es06	bb08, aa08, es06	bb10, aa08, es06
bb02, aa08, es07	bb04, aa08, es07	bb06, aa08, es07	bb08, aa08, es07	bb10, aa08, es07
bb02, aa08, es08	bb04, aa08, es08	bb06, aa08, es08	bb08, aa08, es08	bb10, aa08, es08
bb02, aa08, es09	bb04, aa08, es09	bb06, aa08, es09	bb08, aa08, es09	bb10, aa08, es09
bb02, aa08, es10	bb04, aa08, es10	bb06, aa08, es10	bb08, aa08, es10	bb10, aa08, es10
bb02, aa08, es11	bb04, aa08, es11	bb06, aa08, es11	bb08, aa08, es11	bb10, aa08, es11
bb02, aa08, es12	bb04, aa08, es12	bb06, aa08, es12	bb08, aa08, es12	bb10, aa08, es12
bb02, aa09, es01	bb04, aa09, es01	bb06, aa09, es01	bb08, aa09, es01	bb10, aa09, es01
bb02, aa09, es02	bb04, aa09, es02	bb06, aa09, es02	bb08, aa09, es02	bb10, aa09, es02
bb02, aa09, es03	bb04, aa09, es03	bb06, aa09, es03	bb08, aa09, es03	bb10, aa09, es03
bb02, aa09, es04	bb04, aa09, es04	bb06, aa09, es04	bb08, aa09, es04	bb10, aa09, es04
bb02, aa09, es05	bb04, aa09, es05	bb06, aa09, es05	bb08, aa09, es05	bb10, aa09, es05
bb02, aa09, es06	bb04, aa09, es06	bb06, aa09, es06	bb08, aa09, es06	bb10, aa09, es06
bb02, aa09, es07	bb04, aa09, es07	bb06, aa09, es07	bb08, aa09, es07	bb10, aa09, es07
bb02, aa09, es08	bb04, aa09, es08	bb06, aa09, es08	bb08, aa09, es08	bb10, aa09, es08
bb02, aa09, es09	bb04, aa09, es09	bb06, aa09, es09	bb08, aa09, es09	bb10, aa09, es09
bb02, aa09, es10	bb04, aa09, es10	bb06, aa09, es10	bb08, aa09, es10	bb10, aa09, es10
bb02, aa09, es11	bb04, aa09, es11	bb06, aa09, es11	bb08, aa09, es11	bb10, aa09, es11
bb02, aa09, es12	bb04, aa09, es12	bb06, aa09, es12	bb08, aa09, es12	bb10, aa09, es12
bb02, aa10, es01	bb04, aa10, es01	bb06, aa10, es01	bb08, aa10, es01	bb10, aa10, es01
bb02, aa10, es02	bb04, aa10, es02	bb06, aa10, es02	bb08, aa10, es02	bb10, aa10, es02
bb02, aa10, es03	bb04, aa10, es03	bb06, aa10, es03	bb08, aa10, es03	bb10, aa10, es03
bb02, aa10, es04	bb04, aa10, es04	bb06, aa10, es04	bb08, aa10, es04	bb10, aa10, es04
bb02, aa10, es05	bb04, aa10, es05	bb06, aa10, es05	bb08, aa10, es05	bb10, aa10, es05
bb02, aa10, es06	bb04, aa10, es06	bb06, aa10, es06	bb08, aa10, es06	bb10, aa10, es06
bb02, aa10, es07	bb04, aa10, es07	bb06, aa10, es07	bb08, aa10, es07	bb10, aa10, es07
bb02, aa10, es08	bb04, aa10, es08	bb06, aa10, es08	bb08, aa10, es08	bb10, aa10, es08
bb02, aa10, es09	bb04, aa10, es09	bb06, aa10, es09	bb08, aa10, es09	bb10, aa10, es09
bb02, aa10, es10	bb04, aa10, es10	bb06, aa10, es10	bb08, aa10, es10	bb10, aa10, es10
bb02, aa10, es11	bb04, aa10, es11	bb06, aa10, es11	bb08, aa10, es11	bb10, aa10, es11
bb02, aa10, es12	bb04, aa10, es12	bb06, aa10, es12	bb08, aa10, es12	bb10, aa10, es12

	TABLE 2
		bb01
		bb02
		bb03
		bb04
		bb05
		bb06
		bb07
		bb08
		bb09
		bb10

	TABLE 3
		aa01
		aa02
		aa03
		aa04
		aa05
		aa06
		aa07
		aa08
		aa09
		aa10

TABLE 4
es01 Rα = methyl	es02 Rα = ethyl	es03 Rα = isopropyl
es04 Rα = propyl	es05 Rα = cyclohexyl	es06 Rα = cyclopentyl
es07 Rα = cyclobutyl	es08 Rα = cyclopropyl	es09 Rα = benzyl
es11 Rα = neopentyl	es10 Rα = t-butyl	es12 Rα = hydrogen

[0119] In some embodiments, R^3a, R^3b, R⁴, R⁵ and R⁹ can be all hydrogens in any of the embodiments described in Table 1. In some embodiments, at least one of R⁶ and R⁷ can be OH in any of the embodiments described in Table 1. In some embodiments, R⁸ can be a C_1-6 alkyl in any of the embodiments described in Table 1. In some embodiments, B¹ can be adenine, guanine, uracil, thymine or cystine in any of the embodiments described in Table 1. In some embodiments, R^3a, R^3b, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹ and B¹ can be the groups provided with respect to Formula (Iα) in any of the embodiments described in Table 1.

[0120] Examples of compounds of Formula (I) include, but are not limited to the following:

[0121] Additional examples of compounds of Formula (I) include, but are not limited to the following:

[0122] In some embodiments, the compound of Formula (I) can be the following:

[0123] Additional examples of compounds of Formula (I) include the following:

[0124] In some embodiments, neutralizing the charge on the thiophosphate group may facilitate the penetration of the cell membrane by a compound of Formula (I) (including a compound of Formula (Iα)) by making the compound more lipophilic compared to a thionucleotide having a comparable structure with one or more charges present on the phosphate. Once absorbed and taken inside the cell, the groups attached to the thiophosphate can be easily removed by esterases, proteases, or other enzymes. In some embodiments, the groups attached to the thiophosphate can be removed by simple hydrolysis. Inside the cell, the thio-monophosphate thus released may then be metabolized by cellular enzymes to the thio-diphosphate or the active thio-triphosphate. In some embodiments, the phosphorylation of a thio-monophosphate of a compound of Formula (I), or pharmaceutically acceptable salt thereof, can be stereoselective. For example, a thio-monophosphate of a compound of Formula (I) (including a compound of Formula (Iα)) can be phosphorylated to give an alpha-thiodiphosphate and/or an alpha-thiotriphosphate compound that can be enriched in the (R) or (S) diastereomer with respect to the 5′-O-phosphorous atom. For example, one of the (R) and (S) configuration with respect to the 5′-O-phosphorous atom of the alpha-thiodiphosphate and/or the alpha-thiotriphosphate compound can be present in an amount >50%, ≧75%, ≧90%, ≧95% or ≧99% compared to the amount of the other of the (R) or (9 configuration with respect to the 5′-O-phosphorous atom. In some embodiments, phosphorylation of a compound of Formula (I), or pharmaceutically acceptable salt thereof, can result in the formation of a compound that has the (R)-configuration at the 5′-β-phosphorous atom. In some embodiments, phosphorylation of a compound of Formula (I), or pharmaceutically acceptable salt thereof, can result in formation of a compound that has the (9-configuration at the 5′-O-phosphorous atom.

[0125] In some embodiments, a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, can act as a chain terminator of HCV replication. For example, incorporation of a compound of Formula (I) containing a moiety at the 2′-carbon position can terminate further elongation of the RNA chain of HCV. For example, a compound of Formula (I) can contain a 2′-carbon modification when R⁸ is a non-hydrogen group selected from halogen, azido, cyano, an optionally substituted C_1-6 alkyl, —OR¹⁶ and —OC(═O)R¹⁷.

[0126] In some embodiments, a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, can have increased metabolic and/or plasma stability. In some embodiments, a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, can be more resistant to hydrolysis and/or more resistant to enzymatic transformations. For example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can have increased metabolic stability, increased plasma stability, can be more resistant to hydrolysis and/or can be more resistant to enzymatic transformations compared to a compound that is identical in structure but for having a phosphate attached to the 5′-carbon of the ribose ring. In some embodiments, a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, can have improved properties. In previous studies, replacing a sulfur with an oxygen on the alpha-phosphate of a nucleotide phosphoramidate has resulted in more than a 1000-fold decrease in potency. See Venkatachalam et al. European Journal of Medicinal Chemistry (2004) 39:665-683. A non-limiting list of example properties include, but are not limited to, increased biological half life, increased bioavailability, increase potency, a sustained in vivo response, increased dosing intervals, decreased dosing amounts, decreased cytotoxicity, reduction in required amounts for treating disease conditions, reduction in viral load, reduction in time to seroconversion (i.e., the virus becomes undetectable in patient serum), increased sustained viral response, a reduction of morbidity or mortality in clinical outcomes, increased subject compliance, decreased liver conditions (such as liver fibrosis, liver cirrohis and/or liver cancer), and compatibility with other medications. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can have a biological half life of greater than 24 hours. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can have a biological half life in the range of about 40 hours to about 46 hours. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can have a biological half life greater than a compound that has a phosphate attached to the 5′-carbon of the ribose ring (for example, a compound that is identical in structure but for having a phosphate attached to the 5′-carbon of the ribose ring). In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can have more potent antiviral activity (for example, a lower IC₅₀ in an HCV replicon assay) as compared to the current standard of care.

[0127] Compounds of Formula (I) (including compounds of Formula (Iα)), and those described herein may be prepared in various ways. General synthetic routes to the compound of Formula (I), and some examples of starting materials used to synthesize the compounds of Formula (I) are shown in Scheme 1, and described herein. The routes shown and described herein are illustrative only and are not intended, nor are they to be construed, to limit the scope of the claims in any manner whatsoever. Those skilled in the art will be able to recognize modifications of the disclosed syntheses and to devise alternate routes based on the disclosures herein; all such modifications and alternate routes are within the scope of the claims.

[0128] One method for forming a compound of Formula (I) is shown in Scheme 1. In Scheme 1, R^3A, R^3B, R^4A, R^5A, R^6A, R^7A, R^8A, R^9A and B^1A can be the same as R^3a, R^3b, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹ and B¹ as described herein for Formula (I); and R¹ and R² can be the same as described herein for Formula (I). As shown in Scheme 1, a compound of Formula (A) can be reacted with a compound having the formula R²⁰—P(═S)(R¹)—Cl to form a compound of Formula (I).

[0129] To reduce the formation of side products, one or more the groups attached to the pentose ring can be protected with one or more suitable protecting groups. As an example, if R^6A and/or R^7A is/are hydroxy group(s), the hydroxy group(s) can be protected with suitable protecting groups, such as triarylmethyl and/or silyl groups. Examples of triarylmethyl groups include but are not limited to, trityl, monomethoxytrityl (MMTr), 4,4′-dimethoxytrityl (DMTr), 4,4′,4″-trimethoxytrityl (TMTr), 4,4′,4″-tris-(benzoyloxy)trityl (TBTr), 4,4′,4″-tris (4,5-dichlorophthalimido)trityl (CPTr), 4,4′,4″-tris(levulinyloxy)trityl (TLTr), p-anisyl-1-naphthylphenylmethyl, di-o-anisyl-1-naphthylmethyl, p-tolyldipheylmethyl, 3-(imidazolylmethyl)-4,4′-dimethoxytrityl, 9-phenylxanthen-9-yl (Pixyl), 9-(p-methoxyphenyl)xanthen-9-yl (Mox), 4-decyloxytrityl, 4-hexadecyloxytrityl, 4,4′-dioctadecyltrityl, 9-(4-octadecyloxyphenyl)xanthen-9-yl, 1,1′-bis-(4-methoxyphenyl)-1′-pyrenylmethyl, 4,4′,4″-tris-(tert-butylphenyl)methyl (TTTr) and 4,4′-di-3,5-hexadienoxytrityl. Examples of suitable silyl groups are described herein. Alternatively, R^6A and/or R^7A can be protected by a single achiral or chiral protecting group, for example, by forming an orthoester, a cyclic acetal or a cyclic ketal. Suitable orthoesters include methoxymethylene acetal, ethoxymethylene acetal, 2-oxacyclopentylidene orthoester, dimethoxymethylene orthoester, 1-methoxyethylidene orthoester, 1-ethoxyethylidene orthoester, methylidene orthoester, phthalide orthoester 1,2-dimethoxyethylidene orthoester, and alpha-methoxybenzylidene orthoester; suitable cyclic acetals include methylene acetal, ethylidene acetal, t-butylmethylidene acetal, 3-(benzyloxy)propyl acetal, benzylidene acetal, 3,4-dimethoxybenzylidene acetal and p-acetoxybenzylidene acetal; and suitable cyclic ketals include 1-t-butylethylidene ketal, 1-phenylethylidene ketal, isopropylidene ketal, cyclopentylidene ketal, cyclohexylidene ketal, cycloheptylidene ketal and 1-(4-methoxyphenyl)ethylidene ketal.

[0130] If desired, any —NH and/or NH₂ groups present on the B^1A can also be protected with one or more suitable protecting groups. Examples of suitable protecting groups include triarylmethyl groups and silyl groups. Examples of silyl groups include, but are not limited to, trimethylsilyl (TMS), tert-butyldimethylsilyl (TBDMS), triisopropylsilyl (TIPS), tert-butyldiphenylsilyl (TBDPS), tri-iso-propylsilyloxymethyl and [2-(trimethylsilyl)ethoxy]methyl.

[0131] Suitable thiophosphorochloridates can be commercially obtained or prepared by a synthetic method described herein. An example of a general structure of a thiophosphorochloridate is shown in Scheme 1. In some embodiments, the thiophosphorochloridate can be coupled to a compound of Formula (A). In some embodiments, to facilitate the coupling, a Grignard reagent can be used. Suitable Grignard reagents are known to those skilled in the art and include, but are not limited to, alkylmagnesium chlorides and alkylmagnesium bromides. In other embodiments, the thiophosphorochloridate can be added to a compound of Formula (A) using a base. Suitable bases are known to those skilled in the art. Examples of bases include, but are not limited to, an amine base, such as an alkylamine (including mono-, di- and tri-alkylamines (e.g., triethylamine)), optionally substituted pyridines (e.g. collidine) and optionally substituted imidzoles (e.g., N-methylimidazole)).

[0132] When at least one of R^3a and R^3b is an optionally substituted C_1-6 alkyl or an optionally substituted C_1-6 haloalkyl, the optionally substituted C_1-6 alkyl or the optionally substituted C_1-6 haloalkyl can be added to the 5′-position using methods known to those skilled in the art. In some embodiments, the hydroxy attached to the 5′-carbon can be oxidized to an aldehyde. Suitable oxidation conditions include, but are not limited to, DMSO in combination with an activating agent (usually an acylating agent or an acid) and an amine base, Moffatt oxidation, Swern oxidation and Corey-Kim oxidation, and suitable oxidizing agents include, but are not limited to, Dess-Martin periodinane, TPAP/NMO (tetrapropylammonium perruthenate/N-methylmorpholine N-oxide), Swern oxidation reagent, PCC (pyridinium chlorochromate), and/or PDC (pyridinium dichromate), sodium periodate, Collin's reagent, ceric ammonium nitrate CAN, Na₂Cr₂O₇ in water, Ag₂CO₃ on celite, hot HNO₃ in aqueous glyme, O₂-pyridine CuCl, Pb(OAc)-4-pyridine and benzoyl peroxide-NiBr₂. The resulting aldehyde compound can be reacted with a Grignard reagent, an organolithium reagent or trialkylaluminum (e.g., trimethylaluminum) to form a compound of Formula (A) where at least one of R^3A and R^3B is an optionally substituted C_1-6 alkyl or an optionally substituted C_1-6 haloalkyl. Optionally, the alkylating reagents can be in the presence of a Lewis acid. Suitable Lewis acids are known to those skilled in the art.

[0133] The chirality of the 5′-carbon of compounds of Formulae (A) and/or (I) can be inverted using methods known to the skilled in the art. For example, the oxygen attached to the 5′-carbon can be oxidized, for example to an aldehyde, for a compound of Formula (A), or ketone, for a compound of Formula (I), using a suitable oxidizing agent. The aldehyde and/or ketone can then be reduced using a suitable reducing agent. Examples of suitable reducing agents include, but are not limited to, NaH, LiH, NaBH₄, LiAlH₄ and CaH₂. Suitable oxidizing and reducing agents are known to those skilled in the art. Examples of suitable oxidizing agents and conditions are described herein.

[0134] As described herein, in some embodiments, R⁶ and R⁷ can be both oxygen atoms linked together by a carbonyl groups. The —O—C(═O)—O— group can be formed using methods known to those skilled in the art. For example, a compound of Formula (I), wherein R⁶ and R⁷ are both hydroxy groups, can be treated with 1,1′-carbonyldiimidazole (CDI).

[0135] In some embodiments, R⁶ and/or R⁷ can be —OC(═O)R¹³ and —OC(═O)R¹⁵, respectively. The —OC(═O)R¹³ and —OC(═O)R¹⁵ groups can be formed at the 2′- and 3′-positions using various methods known to those skilled in the art. As an example, a compound of Formula (I), wherein R⁶ and R⁷ are both hydroxy groups, can be treated with an alkyl anhydride (e.g., acetic anhydride and propionic anhydride) or an alkyl acid chloride (e.g., acetylchloride). If desired, a catalyst can be used to facilitate the reaction. An example of suitable catalyst is 4-dimethylaminopyridine (DMAP). Alternatively, the —OC(═O)R¹³ and —OC(═O)R¹⁵ groups can be formed at the 2′- and 3′-positions by reacting an alkyl acid (e.g. acetic acid and propionic acid) in the presence of a carbodiimide or a coupling reagent. Examples of carbodiimides include, but are not limited to, N,N′-dicyclohexylcarbodiimide (DCC), N,N′-diisopropylcarbodiimide (DIC) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC).

[0136] As described herein, B^1A can include a carbamate and/or an amide. Those skilled in the art know methods for forming a carbamate and/or an amide on B^1A. In some embodiments, the carbamate can be formed using 1,1′-carbonyldiimidazole and an alcohol.

[0137] B^1A can be added to the pentose ring using various methods known to those skilled in the art. In some embodiments, a compound of Formula (B) can be reacted with a nitrogenous base. In some embodiments, R^3A, R^3B, R^4A, R^5A, R^6A, R^7A, R^8A, R^9A and B^1A of a compound of Formula (B) can be the same as disclosed herein, with respect to R^3a, R^3b, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹ and B¹; and PG¹ can be an appropriate protecting group. In some embodiments, PG¹ can be p-nitrobenzyl group. In some embodiments, any hydroxy groups attached to the pentose ring can be protected with one or more suitable protecting groups. In some embodiments, any hydroxy groups attached to the pentose ring can be protected with benzoyl groups. Examples of nitrogenous bases include an optionally substituted heterocyclic bases described herein, wherein the nitrogen atom (—N) connected to the pentose ring is —NH. If desired, any —NH and/or NH₂ groups present on the nitrogenous base can be protected with one or more suitable protecting groups. Suitable protecting groups are described herein. In some embodiments, the nitrogenous base can be added via a coupling reaction in the presence of a Lewis acid or TMSOTf. Suitable Lewis acids are known to those skilled in the art.

[0138] Various methods can be used to make a compound of Formula (I), wherein R¹ is

For example, a thiophosphorochloridate having the general formula of (P(═S)Cl₃) can be transformed into a phosphorus reagent having the general formula, P(═S)LG₃, wherein each LG can be amine-based leaving group. In some embodiments, each LG can be a triazole. The phosphorus reagent having the general formula, P(═S)LG₃, can be reacted with a compound of Formula (I). Using a suitable pyrophosphorylation reagent, the β and γ phosphates can be added. An example of a suitable pyrophosphorylation reagent is tris(tetrabutylammonium)hydrogen pyrophosphate.

[0139] During the synthesis of any of the compounds described herein, if desired, any hydroxy groups attached to the pentose ring, and any —NH and/or NH₂ groups present on the B^1A can be protected with one or more suitable protecting groups. Suitable protecting groups are described herein. Those skilled in the art will appreciate that groups attached to the pentose ring and any —NH and/or NH₂ groups present on the B^1A can be protected with various protecting groups, and any protecting groups present can be exchanged for other protecting groups. The selection and exchange of the protecting groups is within the skill of those of ordinary skill in the art. Any protecting group(s) can also be removed by methods known in the art, for example, with an acid (e.g., a mineral or an organic acid), a base or a fluoride source.

[0140] Some embodiments described herein relates to a pharmaceutical composition, that can include a therapeutically effective amount of one or more compounds described herein (e.g., a compound of Formulae (I) or (Iα)), or a pharmaceutically acceptable salt thereof) and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof. In some embodiments, the pharmaceutical composition can include a single diastereomer of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, (for example, a single diastereomer is present in the pharmaceutical composition at a concentration of greater than 99% compared to the total concentration of the other diastereomers). In other embodiments, the pharmaceutical composition can include a mixture of diastereomers of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. For example, the pharmaceutical composition can include a concentration of one diastereomer of >50%, ≧60%, ≧70%, ≧80%, ≧90%, ≧95%, or ≧98%, as compared to the total concentration of the other diastereomers. In some embodiments, the pharmaceutical composition includes a 1:1 mixture of two diastereomers of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0141] The term “pharmaceutical composition” refers to a mixture of one or more compounds disclosed herein with other chemical components, such as diluents or carriers. The pharmaceutical composition facilitates administration of the compound to an organism. Pharmaceutical compositions can also be obtained by reacting compounds with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid and salicylic acid. Pharmaceutical compositions will generally be tailored to the specific intended route of administration.

[0142] The term “physiologically acceptable” defines a carrier, diluent or excipient that does not abrogate the biological activity and properties of the compound.

[0143] As used herein, a “carrier” refers to a compound that facilitates the incorporation of a compound into cells or tissues. For example, without limitation, dimethyl sulfoxide (DMSO) is a commonly utilized carrier that facilitates the uptake of many organic compounds into cells or tissues of a subject.

[0144] As used herein, a “diluent” refers to an ingredient in a pharmaceutical composition that lacks pharmacological activity but may be pharmaceutically necessary or desirable. For example, a diluent may be used to increase the bulk of a potent drug whose mass is too small for manufacture and/or administration. It may also be a liquid for the dissolution of a drug to be administered by injection, ingestion or inhalation. A common form of diluent in the art is a buffered aqueous solution such as, without limitation, phosphate buffered saline that mimics the composition of human blood.

[0145] As used herein, an “excipient” refers to an inert substance that is added to a pharmaceutical composition to provide, without limitation, bulk, consistency, stability, binding ability, lubrication, disintegrating ability etc., to the composition. A “diluent” is a type of excipient.

[0146] The pharmaceutical compositions described herein can be administered to a human patient per se, or in pharmaceutical compositions where they are mixed with other active ingredients, as in combination therapy, or carriers, diluents, excipients or combinations thereof. Proper formulation is dependent upon the route of administration chosen. Techniques for formulation and administration of the compounds described herein are known to those skilled in the art.

[0147] The pharmaceutical compositions disclosed herein may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or tableting processes. Additionally, the active ingredients are contained in an amount effective to achieve its intended purpose. Many of the compounds used in the pharmaceutical combinations disclosed herein may be provided as salts with pharmaceutically compatible counterions.

[0148] Multiple techniques of administering a compound exist in the art including, but not limited to, oral, rectal, topical, aerosol, injection and parenteral delivery, including intramuscular, subcutaneous, intravenous, intramedullary injections, intrathecal, direct intraventricular, intraperitoneal, intranasal and intraocular injections.

[0149] One may also administer the compound in a local rather than systemic manner, for example, via injection of the compound directly into the infected area, often in a depot or sustained release formulation. Furthermore, one may administer the compound in a targeted drug delivery system, for example, in a liposome coated with a tissue-specific antibody. The liposomes will be targeted to and taken up selectively by the organ.

[0150] The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accompanied with a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration. Such notice, for example, may be the labeling approved by the U.S. Food and Drug Administration for prescription drugs, or the approved product insert. Compositions that can include a compound described herein formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.

[0151] One embodiment disclosed herein relates to a method of treating and/or ameliorating a disease or condition that can include administering to a subject a therapeutically effective amount of one or more compounds described herein, such as a compound of Formula (I) (including compounds of Formula (Iα)), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound described herein.

[0152] Some embodiments disclosed herein relate to a method of ameliorating or treating a neoplastic disease that can include administering to a subject suffering from a neoplastic disease a therapeutically effective amount of one or more compounds described herein (e.g., a compound of Formulae (I) and/or (Iα), or a pharmaceutically acceptable salt thereof), or a pharmaceutical composition that includes a compound described herein). In an embodiment, the neoplastic disease can be cancer. In some embodiments, the neoplastic disease can be a tumor such as a solid tumor. In an embodiment, the neoplastic disease can be leukemia. Exemplary leukemias include, but are not limited to, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and juvenile myelomonocytic leukemia (JMML).

[0153] Some embodiments disclosed herein relate to a method of inhibiting the growth of a tumor that can include administering to a subject having a tumor a therapeutically effective amount of one or more compounds described herein (for example, a compound of Formulae (I) and/or (Iα)), or a pharmaceutical composition that includes one or more compounds described herein.

[0154] Other embodiments disclosed herein relates to a method of ameliorating or treating a viral infection that can include administering to a subject suffering from a viral infection a therapeutically effective amount of one or more compounds described herein (for example, a compound of Formulae (I) and/or (Iα)), or a pharmaceutical composition that includes one or more compounds described herein. In an embodiment, the viral infection can be caused by a virus selected from an adenovirus, an Alphaviridae, an Arbovirus, an Astrovirus, a Bunyaviridae, a Coronaviridae, a Filoviridae, a Flaviviridae, a Hepadnaviridae, a Herpesviridae, an Alphaherpesvirinae, a Betaherpesvirinae, a Gammaherpesvirinae, a Norwalk Virus, an Astroviridae, a Caliciviridae, an Orthomyxoviridae, a Paramyxoviridae, a Paramyxoviruses, a Rubulavirus, a Morbillivirus, a Papovaviridae, a Parvoviridae, a Picornaviridae, an Aphthoviridae, a Cardioviridae, an Enteroviridae, a Coxsackie virus, a Polio Virus, a Rhinoviridae, a Phycodnaviridae, a Poxyiridae, a Reoviridae, a Rotavirus, a Retroviridae, an A-Type Retrovirus, an Immunodeficiency Virus, a Leukemia Viruses, an Avian Sarcoma Viruses, a Rhabdoviruses, a Rubiviridae, a Togaviridae an Arenaviridae and/or a Bornaviridae. In some embodiments, the viral infection can be a hepatitis C viral (HCV) infection. In still other embodiments, the viral infection can be HIV.

[0155] Some embodiments disclosed herein relate to methods of ameliorating and/or treating a viral infection that can include contacting a cell infected with the virus with an effective amount of one or more compounds described herein, or a pharmaceutically acceptable salt of a compound described herein, or a pharmaceutical composition that includes one or more compounds described herein, or a pharmaceutically acceptable salt thereof. Other embodiments described herein relate to using one or more compounds described herein, or a pharmaceutically acceptable salt of a compound described herein, in the manufacture of a medicament for ameliorating and/or treating a viral infection that can include contacting a cell infected with the virus with an effective amount of said compound(s). Still other embodiments described herein relate to one or more compounds described herein, or a pharmaceutically acceptable salt of a compound described herein, that can be used for ameliorating and/or treating a viral infection by contacting a cell infected with the virus with an effective amount of said compound(s). In some embodiments, the compound can be a compound of Formulae (I) and/or (Iα), or a pharmaceutical acceptable salt thereof. In other embodiments, the compound can be a mono-, di- and/or tri-phosphate of a compound of Formulae (I) and/or (Iα), or a pharmaceutically acceptable salt of the foregoing. In some embodiments, the virus can be a HCV virus.

[0156] Some embodiments disclosed herein relate to methods of inhibiting replication of a virus that can include contacting a cell infected with the virus with an effective amount of one or more compounds described herein, or a pharmaceutically acceptable salt of a compound described herein, or a pharmaceutical composition that includes one or more compounds described herein, or a pharmaceutically acceptable salt thereof. Other embodiments described herein relate to using one or more compounds described herein, or a pharmaceutically acceptable salt of a compound described herein, in the manufacture of a medicament for inhibiting replication of a virus that can include contacting a cell infected with the virus with an effective amount of said compound(s). Still other embodiments described herein relate to a compound described herein, or a pharmaceutically acceptable salt of a compound described herein, that can be used for inhibiting replication of a virus by contacting a cell infected with the virus with an effective amount of said compound(s). In some embodiments, the compound can be a compound of Formulae (I) and/or (Iα), or a pharmaceutical acceptable salt thereof. In other embodiments, the compound can be a mono-, di- and/or tri-phosphate of a compound of Formulae (I) and/or (Iα), or a pharmaceutically acceptable salt of the foregoing. In some embodiments, the virus can be a HCV virus.

[0157] HCV is an enveloped positive strand RNA virus in the Flaviviridae family. There are various nonstructural proteins of HCV, such as (NS2, NS3, NS4, NS4A, NS4B, NS5A, and NS5B. NS5B is believed to be an RNA-dependent RNA polymerase involved in the replication of HCV RNA.

[0158] Some embodiments described herein relate to a method of inhibiting NS5B polymerase activity can include contacting a cell (for example, a cell infected with HCV) with an effective amount of a compound of Formulae (I) and/or (Iα), or a pharmaceutical acceptable salt thereof. Some embodiments described herein relate to a method of inhibiting NS5B polymerase activity can include administering a cell (for example, a cell infected with HCV) with an effective amount of a compound of Formulae (I) and/or (Iα), or a pharmaceutical acceptable salt thereof. In some embodiments, a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, can inhibit a RNA dependent RNA polymerase. In some embodiments, a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, can inhibit a HCV polymerase (for example, NS5B polymerase).

[0159] Some embodiments described herein relate to a method of treating HCV infection in a subject suffering from a HCV infection that can include administering to the subject an effective amount of a compound of Formulae (I) and/or (Iα), or a pharmaceutical acceptable salt thereof, or a pharmaceutical composition that includes an effective amount of a compound of Formulae (I) and/or (Iα), or a pharmaceutical acceptable salt thereof. Some embodiments described herein relate to a method of treating a condition selected from liver fibrosis, liver cirrohis, and liver cancer in a subject suffering from one or more of the aforementioned liver conditions that can include administering to the subject an effective amount of a compound or a pharmaceutical composition described herein (for example, a compound of Formulae (I) and/or (Iα), or a pharmaceutical acceptable salt thereof). One cause of the liver fibrosis, liver cirrohis, and/or liver cancer can be a HCV infection. Some embodiments described herein relate to a method of increasing liver function in a subject having a HCV infection that can include administering to the subject an effective amount of a compound or a pharmaceutical composition described herein (for example, a compound of Formulae (I) and/or (Iα), or a pharmaceutical acceptable salt thereof). Also contemplated is a method for reducing or eliminating further virus-caused liver damage in a subject having an HCV infection by administering to the subject an effective amount of a compound or a pharmaceutical composition described herein (for example, a compound of Formulae (I) and/or (Iα), or a pharmaceutical acceptable salt thereof). In one embodiment, this method comprises slowing or halting the progression of liver disease. In another embodiment, the course of the disease is reversed, and stasis or improvement in liver function is contemplated.

[0160] There are a variety of genotypes of HCV, and a variety of subtypes within each genotype. For example, at present it is known that there are eleven (numbered 1 through 11) main genotypes of HCV, although others have classified the genotypes as 6 main genotypes. Each of these genotypes is further subdivided into subtypes (1a-1c; 2a-2c; 3a-3b; 4a-4-e; 5a; 6a; 7a-7b; 8a-8b; 9a; 10a; and 11a). In some embodiments, an effective amount of a compound of Formulae (I) and/or (Iα), or a pharmaceutical acceptable salt thereof, or a pharmaceutical composition that includes an effective amount of a compound of Formulae (I) and/or (Iα), or a pharmaceutical acceptable salt thereof, can be effective to treat at least one genotype of HCV. In some embodiments, a compound described herein (for example, a compound of Formulae (I) and/or (Iα), or a pharmaceutical acceptable salt thereof) can be effective to treat all 11 genotypes of HCV. In some embodiments, a compound described herein (for example, a compound of Formulae (I) and/or (Iα), or a pharmaceutical acceptable salt thereof) can be effective to treat 3 or more, 5 or more, 7 or more of 9 more genotypes of HCV. In some embodiments, a compound of Formula (I) and/or (Iα), or a pharmaceutical acceptable salt thereof is more effective against a larger number of HCV genotypes than the standard of care. In some embodiments, a compound of Formula (I) and/or (Iα), or a pharmaceutical acceptable salt thereof, is more effective against a particular HCV genotype than the standard of care (such as genotype 1, 2, 3, 4, 5 and/or 6).

[0161] Various indicators for determining the effectiveness of a method for treating a HCV infection are known to those skilled in the art. Example of suitable indicators include, but are not limited to, a reduction in viral load, a reduction in viral replication, a reduction in time to seroconversion (virus undetectable in patient serum), an increase in the rate of sustained viral response to therapy, a reduction of morbidity or mortality in clinical outcomes, a reduction in the rate of liver function decrease; stasis in liver function; improvement in liver function; reduction in one or more markers of liver dysfunction, including alanine transaminase, aspartate transaminase, total bilirubin, conjugated bilirubin, gamma glutamyl transpeptidase, and/or other indicator of disease response. Similarly, successful therapy with an effective amount of a compound or a pharmaceutical composition described herein (for example, a compound of Formulae (I) and/or (Iα), or a pharmaceutical acceptable salt thereof) can reduce the incidence of liver cancer in HCV patients.

[0162] In some embodiments, an effective amount of a compound of Formulae (I) and/or (Iα), or a pharmaceutically acceptable salt thereof, is an amount that is effective to reduce viral titers to undetectable levels, for example, to about 1000 to about 5000, to about 500 to about 1000, or to about 100 to about 500 genome copies/mL serum. In some embodiments, an effective amount of a compound of Formula (I) and/or (Iα), or a pharmaceutically acceptable salt thereof, is an amount that is effective to reduce viral load compared to the viral load before administration of the compound of Formula (I) and/or (Iα), or a pharmaceutically acceptable salt thereof. For example, wherein the viral load is measured before administration of the compound of Formula (I) and/or (Iα), or a pharmaceutically acceptable salt thereof, and again after completion of the treatment regime with the compound of Formula (I) and/or (Iα), or a pharmaceutically acceptable salt thereof (for example, 1 month after completion). In some embodiments, an effective amount of a compound of Formula (I) and/or (Iα), or a pharmaceutically acceptable salt thereof, can be an amount that is effective to reduce viral load to lower than about 100 genome copies/mL serum. In some embodiments, an effective amount of a compound of Formula (I) and/or (Iα), or a pharmaceutically acceptable salt thereof, is an amount that is effective to achieve a reduction in viral titer in the serum of the subject in the range of about 1.5-log to about a 2.5-log reduction, about a 3-log to about a 4-log reduction, or a greater than about 5-log reduction compared to the viral load before administration of the compound of Formula (I) and/or (Iα), or a pharmaceutically acceptable salt thereof. For example, the viral load can be measured before administration of the compound of Formula (I) and/or (Iα), or a pharmaceutically acceptable salt thereof, and again after completion of the treatment regime with the compound of Formula (I) and/or (Iα), or a pharmaceutically acceptable salt thereof (for example, 1 month after completion).

[0163] In some embodiments, a compound of Formula (I) and/or (Iα), or a pharmaceutically acceptable salt thereof, can result in at least a 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, 75,100-fold or more reduction in the replication of HCV relative to pre-treatment levels in a subject, as determined after completion of the treatment regime (for example 1 month after completion). In some embodiments, a compound of Formula (I) and/or (Iα), or a pharmaceutically acceptable salt thereof, can result in a reduction of the replication of HCV relative to pre-treatment levels in the range of about 2 to about 5 fold, about 10 to about 20 fold, about 15 to about 40 fold, or about 50 to about 100 fold. In some embodiments, a compound of Formula (I) and/or (Iα), or a pharmaceutically acceptable salt thereof, can result in a reduction of HCV replication in the range of 1 to 1.5 log, 1.5 log to 2 log, 2 log to 2.5 log, 2.5 to 3 log, 3 log to 3.5 log or 3.5 to 4 log more reduction of HCV replication compared to the reduction of HCV reduction achieved by pegylated interferon in combination with ribavirin, administered according to the standard of care, or may achieve the same reduction as that standard of care therapy in a shorter period of time, for example, in one month, two months, or three months, as compared to the reduction achieved after six months of standard of care therapy with ribavirin and pegylated interferon.

[0164] In some embodiments, an effective amount of a compound of Formula (I) and/or (Iα), or a pharmaceutically acceptable salt thereof, is an amount that is effective to achieve a sustained viral response, for example, non-detectable or substantially non-detectable HCV RNA (e.g., less than about 500, less than about 400, less than about 200, or less than about 100 genome copies per milliliter serum) is found in the subject's serum for a period of at least about one month, at least about two months, at least about three months, at least about four months, at least about five months, or at least about six months following cessation of therapy.

[0165] In some embodiments, a therapeutically effective amount of a compound of Formula (I) and/or (Iα), or a pharmaceutically acceptable salt thereof, can reduce a level of a marker of liver fibrosis by at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, or at least about 80%, or more, compared to the level of the marker in an untreated subject, or to a placebo-treated subject. Methods of measuring serum markers are known to those skilled in the art and include immunological-based methods, e.g., enzyme-linked immunosorbent assays (ELISA), radioimmunoassays, and the like, using antibody specific for a given serum marker. A non-limiting list of examples of a markers includes measuring the levels of serum alanine aminotransferase (ALT), asparatate aminotransferacse (AST), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT) and total bilirubin (TBIL) using known methods. In general, an ALT level of less than about 45 IU/L (international units/liter), an AST in the range of 10-34 IU/L, ALP in the range of 44-147 IU/L, GGT in the range of 0-51 IU/L, TBIL in the range of 0.3-1.9 mg/dL is considered normal. In some embodiments, an effective amount of a compound of Formula (I) and/or (Iα) is an amount effective to reduce ALT, AST, ALP, GGT and/or TBIL levels to with what is considered a normal level.

[0166] Subjects who are clinically diagnosed with HCV infection include “naïve” subjects (e.g., subjects not previously treated for HCV, particularly those who have not previously received IFN-alpha-based and/or ribavirin-based therapy) and individuals who have failed prior treatment for HCV (“treatment failure” subjects). Treatment failure subjects include “non-responders” (i.e., subjects in whom the HCV titer was not significantly or sufficiently reduced by a previous treatment for HCV (≦0.5 log IU/mL), for example, a previous IFN-alpha monotherapy, a previous IFN-alpha and ribavirin combination therapy, or a previous pegylated IFN-alpha and ribavirin combination therapy); and “relapsers” (i.e., subjects who were previously treated for HCV, for example, who received a previous IFN-alpha monotherapy, a previous IFN-alpha and ribavirin combination therapy, or a previous pegylated IFN-alpha and ribavirin combination therapy, whose HCV titer decreased, and subsequently increased).

[0167] In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered to a treatment failure subject suffering from HCV. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered to a non-responder subject suffering from HCV. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered to a relapsed subject suffering from HCV.

[0168] After a period of time, infectious agents can develop resistance to one or more therapeutic agents. The term “resistance” as used herein refers to a viral strain displaying a delayed, lessened and/or null response to a therapeutic agent(s). For example, after treatment with an antiviral agent, the viral load of a subject infected with a resistant virus may be reduced to a lesser degree compared to the amount in viral load reduction exhibited by a subject infected with a non-resistant strain. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered to a subject infected with an HCV strain that is resistant to one or more different anti-HCV agents. In some embodiments, development of resistant HCV strains is delayed when patients are treated with a compound of Formula (I), or a pharmaceutically acceptable salt thereof, compared to the development of HCV strains resistant to other HCV drugs.

[0169] In some embodiments, an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered to a subject for whom other anti-HCV medications are contraindicated. For example, administration of pegylated interferon alpha in combination with ribavirin is contraindicated in subjects with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia) and other subjects at risk from the hematologic side effects of current therapy. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be provided to a subject that is hypersensitive to interferon or ribavirin.

[0170] Some subjects being treated for HCV experience a viral load rebound. The term “viral load rebound” as used herein refers to a sustained ≧0.5 log IU/mL increase of viral load above nadir before the end of treatment, where nadir is a ≧0.5 log IU/mL decrease from baseline. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered to a subject experiencing viral load rebound, or can prevent such viral load rebound when used to treat the subject.

[0171] The standard of care for treating HCV has been associated with several side effects (adverse events). In some embodiments, a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, can decrease the number and/or severity of side effects that can be observed in HCV patients being treated with ribavirin and pegylated interferon according to the standard of care. Examples of side effects include, but are not limited to fever, malaise, tachycardia, chills, headache, arthralgias, myalgias, fatigue, apathy, loss of apetite, nausea, vomiting, cognitive changes, asthenia, drowsiness, lack of initiative, irritability, confusion, depression, severe depression, suicidal ideation, anemia, low white blood cell counts, and thinning of hair. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be provided to a subject that discontinued a HCV therapy because of one or more adverse effects or side effects associated with one or more other HCV agents.

[0172] Table 5 provides some embodiments of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, compared to the standard of care. Examples include the following: in some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, results in a percentage of non-responders that is 10% less than the percentage of non-responders receiving the standard of care; in some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, results number of side effects that is in the range of about 10% to about 30% less than compared to the number of side effects experienced by a subject receiving the standard of care; and in some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, results a severity of a side effect (such as one of those described herein) that is 25% less than compared to the severity of the same side effect experienced by a subject receiving the standard of care. Methods of quantifying the severity of a side effect are known to those skilled in the art.

TABLE 5
Percent-			Percent-
age of	Percent-	Percent-	age of	Number	Severity
non-	age of	age of	viral load	of side	of side
responders	relapsers	resistance	rebound	effects	effects
10% less	10% less	10% less	10% less	10% less	10% less
25% less	25% less	25% less	25% less	25% less	25% less
40% less	40% less	40% less	40% less	40% less	40% less
50% less	50% less	50% less	50% less	50% less	50% less
60% less	60% less	60% less	60% less	60% less	60% less
70% less	70% less	70% less	70% less	70% less	70% less
80% less	80% less	80% less	80% less	80% less	80% less
90% less	90% less	90% less	90% less	90% less	90% less
about 10%	about 10%	about 10%	about 10%	about 10%	about 10%
to about	to about	to about	to about	to about	to about
30% less	30% less	30% less	30% less	30% less	30% less
about 20%	about 20%	about 20%	about 20%	about 20%	about 20%
to about	to about	to about	to about	to about	to about
50% less	50% less	50% less	50% less	50% less	50% less
about 30%	about 30%	about 30%	about 30%	about 30%	about 30%
to about	to about	to about	to about	to about	to about
70% less	70% less	70% less	70% less	70% less	70% less
about 20%	about 20%	about 20%	about 20%	about 20%	about 20%
to about	to about	to about	to about	to about	to about
80% less	80% less	80% less	80% less	80% less	80% less

[0173] Yet still other embodiments disclosed herein relates to a method of ameliorating or treating a parasitic disease that can include administering to a subject suffering from a parasitic disease a therapeutically effective amount of one or more compounds described herein (for example, a compound of Formula (I) and/or (Iα)), or a pharmaceutical composition that includes one or more compounds described herein. In an embodiment, the parasite disease can be Chagas' disease.

[0174] As used herein, a “subject” refers to an animal that is the object of treatment, observation or experiment. “Animal” includes cold- and warm-blooded vertebrates and invertebrates such as fish, shellfish, reptiles and, in particular, mammals. “Mammal” includes, without limitation, mice, rats, rabbits, guinea pigs, dogs, cats, sheep, goats, cows, horses, primates, such as monkeys, chimpanzees, and apes, and, in particular, humans. In some embodiments, the subject is human.

[0175] As used herein, the terms “treating,” “treatment,” “therapeutic,” or “therapy” do not necessarily mean total cure or abolition of the disease or condition. Any alleviation of any undesired signs or symptoms of a disease or condition, to any extent can be considered treatment and/or therapy. Furthermore, treatment may include acts that may worsen the patient's overall feeling of well-being or appearance.

[0176] The term “therapeutically effective amount” is used to indicate an amount of an active compound, or pharmaceutical agent, that elicits the biological or medicinal response indicated. For example, a therapeutically effective amount of compound can be the amount needed to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated This response may occur in a tissue, system, animal or human and includes alleviation of the signs or symptoms of the disease being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, in view of the disclosure provided herein. The therapeutically effective amount of the compounds disclosed herein required as a dose will depend on the route of administration, the type of animal, including human, being treated, and the physical characteristics of the specific animal under consideration. The dose can be tailored to achieve a desired effect, but will depend on such factors as weight, diet, concurrent medication and other factors which those skilled in the medical arts will recognize.

[0177] As will be readily apparent to one skilled in the art, the useful in vivo dosage to be administered and the particular mode of administration will vary depending upon the age, weight, the severity of the affliction, and mammalian species treated, the particular compounds employed, and the specific use for which these compounds are employed. The determination of effective dosage levels, that is the dosage levels necessary to achieve the desired result, can be accomplished by one skilled in the art using routine methods, for example, human clinical trials and in vitro studies.

[0178] The dosage may range broadly, depending upon the desired effects and the therapeutic indication. Alternatively dosages may be based and calculated upon the surface area of the patient, as understood by those of skill in the art. Although the exact dosage will be determined on a drug-by-drug basis, in most cases, some generalizations regarding the dosage can be made. The daily dosage regimen for an adult human patient may be, for example, an oral dose of between 0.01 mg and 3000 mg of each active ingredient, preferably between 1 mg and 700 mg, e.g. 5 to 200 mg. The dosage may be a single one or a series of two or more given in the course of one or more days, as is needed by the subject. In some embodiments, the compounds will be administered for a period of continuous therapy, for example for a week or more, or for months or years. In some embodiments, a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, can be administered less frequently compared to the frequency of administration of an agent within the standard of care. In some embodiments, a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, can be administered one time per day. For example, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered one time per day to a subject suffering from a HCV infection. In some embodiments, the total time of the treatment regime with a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, can less compared to the total time of the treatment regime with the standard of care.

[0179] In instances where human dosages for compounds have been established for at least some condition, those same dosages may be used, or dosages that are between about 0.1% and 500%, more preferably between about 25% and 250% of the established human dosage. Where no human dosage is established, as will be the case for newly-discovered pharmaceutical compositions, a suitable human dosage can be inferred from ED₅₀ or ID₅₀ values, or other appropriate values derived from in vitro or in vivo studies, as qualified by toxicity studies and efficacy studies in animals.

[0180] In cases of administration of a pharmaceutically acceptable salt, dosages may be calculated as the free base. As will be understood by those of skill in the art, in certain situations it may be necessary to administer the compounds disclosed herein in amounts that exceed, or even far exceed, the above-stated, preferred dosage range in order to effectively and aggressively treat particularly aggressive diseases or infections.

[0181] Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the modulating effects, or minimal effective concentration (MEC). The MEC will vary for each compound but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations. Dosage intervals can also be determined using MEC value. Compositions should be administered using a regimen which maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90%. In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.

[0182] It should be noted that the attending physician would know how to and when to terminate, interrupt, or adjust administration due to toxicity or organ dysfunctions. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity). The magnitude of an administrated dose in the management of the disorder of interest will vary with the severity of the condition to be treated and to the route of administration. The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose frequency, will also vary according to the age, body weight, and response of the individual patient. A program comparable to that discussed above may be used in veterinary medicine.

[0183] Compounds disclosed herein can be evaluated for efficacy and toxicity using known methods. For example, the toxicology of a particular compound, or of a subset of the compounds, sharing certain chemical moieties, may be established by determining in vitro toxicity towards a cell line, such as a mammalian, and preferably human, cell line. The results of such studies are often predictive of toxicity in animals, such as mammals, or more specifically, humans. Alternatively, the toxicity of particular compounds in an animal model, such as mice, rats, rabbits, or monkeys, may be determined using known methods. The efficacy of a particular compound may be established using several recognized methods, such as in vitro methods, animal models, or human clinical trials. When selecting a model to determine efficacy, the skilled artisan can be guided by the state of the art to choose an appropriate model, dose, route of administration and/or regime.

[0184] In some embodiments, the compounds disclosed herein, such as a compound of Formula (I) (including compounds of Formula (Iα)), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound described herein, can be used in combination with one or more additional agent(s). Examples of additional agents that can be used in combination with a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, include, but are not limited to, agents currently used in a conventional standard of care for treating HCV, HCV protease inhibitors, HCV polymerase inhibitors, NS5A inhibitors, other antiviral compounds, compounds of Formula (AA) (including mono-, di, and/or tri-phosphates of Formula (AA), pharmaceutically acceptable salts and pharmaceutical compositions that can include a compound of Formula (AA), mono-, di- and/or tri-phosphates thereof, or a pharmaceutically acceptable salt of the foregoing), compounds of Formula (BB) (including pharmaceutically acceptable salts and pharmaceutical compositions that can include a compound of Formula (BB), or a pharmaceutically acceptable salt thereof), compounds of Formula (DD) (including pharmaceutically acceptable salts and pharmaceutical compositions that can include a compound of Formula (DD), or a pharmaceutically acceptable salt thereof), and/or combinations thereof. In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be used with one, two, three or more additional agents described herein. A non-limiting list of examples of combinations of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided in Tables A, B, C and D.

[0185] In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be used in combination with an agent(s) currently used in a conventional standard of care therapy. For example, for the treatment of HCV, a compound disclosed herein can be used in combination with Pegylated interferon-alpha-2a (brand name PEGASYS®) and ribavirin, or Pegylated interferon-alpha-2b (brand name PEG-INTRON®) and ribavirin. As another example, a compound disclosed herein can be used in combination with oseltamivir (TAMIFLU®) or zanamivin (RELENZA®) for treating an influenza infection.

[0186] In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be substituted for an agent currently used in a conventional standard of care therapy. For example, for the treatment of HCV, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be used in place of ribavirin.

[0187] In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be used in combination with an interferon, such as a pegylated interferon. Examples of suitable interferons include, but are not limited to, Pegylated interferon-alpha-2a (brand name PEGASYS®), Pegylated interferon-alpha-2b (brand name PEG-INTRON®), interferon alfacon-1 (brand name INFERGEN®), pegylated interferon lambda and/or a combination thereof.

[0188] In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be used in combination with a HCV protease inhibitor. A non-limiting list of example HCV protease inhibitors include the following: VX-950 (TELAPREVIR®), MK-5172, ABT-450, BILN-2061, BI-201335, BMS-650032, SCH 503034 (BOCEPREVIR®), GS-9256, GS-9451, IDX-320, ACH-1625, ACH-2684, TMC-435, ITMN-191 (DANOPREVIR®) and/or a combination thereof. A non-limiting list of example HCV protease inhibitors includes the compounds numbered 1001-1014 in FIG. 2.

[0189] In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be used in combination with a HCV polymerase inhibitor. In some embodiments, the HCV polymerase inhibitor can be a nucleoside inhibitor. In other embodiments, the HCV polymerase inhibitor can be a non-nucleoside inhibitor. Examples of suitable nucleoside inhibitors include, but are not limited to, RG7128, PSI-7851, PSI-7977, INX-184, PSI-352938, PSI-661, 4′-azidouridine (including known prodrugs of 4′-azidouridine), GS-6620, IDX-184, and TMC649128 and/or combinations thereof. A non-limiting list of example nucleoside inhibitors includes compounds numbered 2001-2010 in FIG. 3. Examples of suitable non-nucleoside inhibitors include, but are not limited to, ABT-333, ANA-598, VX-222, HCV-796, BI-207127, GS-9190, PF-00868554 (FILIBUVIR®), VX-497 and/or combinations thereof. A non-limiting list of example non-nucleoside inhibitors includes the compounds numbered 3001-3008 in FIG. 4.

[0190] In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be used in combination with a NS5A inhibitor. A non-limiting list of example NS5A inhibitors include BMS-790052, PPI-461, ACH-2928, GS-5885, BMS-824393 and/or combinations thereof. A non-limiting list of example NS5A inhibitors includes the compounds numbered 4001-4005 in FIG. 5.

[0191] In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be used in combination with other antiviral compounds. Examples of other antiviral compounds include, but are not limited to, Debio-025, MIR-122 and/or combinations thereof. A non-limiting list of example other antiviral compounds includes the compounds numbered 5001-5002 in FIG. 6.

[0192] In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be used in combination with a compound of Formula (AA), mono-, di- and/or tri-phosphate thereof, or a pharmaceutically acceptable salt of the foregoing, or a pharmaceutical composition that includes a compound of Formula (AA), mono-, di- and/or tri-phosphate thereof, or a pharmaceutically acceptable salt of the foregoing (see, U.S. Provisional Application Nos. 61/385,425, filed Sep. 22, 2010, and 61/426,467, filed Dec. 22, 2010, the contents of which are incorporated by reference in its entirety):

wherein B^AA1 can be an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group; R^AA1 can be an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative; R^AA2 can be selected from an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl; R^AA3a and R^AA3b can be independently selected from hydrogen, an optionally substituted C_1-6 alkyl, an optionally substituted C_2-6 alkenyl, an optionally substituted C_2-6 alkynyl, an optionally substituted C_1-6 haloalkyl and aryl(C_1-6 alkyl), provided that at least one of R^AA3a and R^AA3b is not hydrogen; or R^AA3a and R^AA3b can be taken together to form a group selected from an optionally substituted C_3-6 cycloalkyl, an optionally substituted C_3-6 cycloalkenyl, an optionally substituted C_3-6 aryl, and an optionally substituted C_3-6 heteroaryl; R^AA4 can be hydrogen; R^AA5 can be selected from hydrogen, —OR^AA9 and —OC(═O)R^AA10; R^AA6 can be selected from hydrogen, halogen, —OR^AA11 and —OC(═O)R^AAl2; or R^AA5 and R^AA6 can be both oxygen atoms and linked together by a carbonyl group; R^A7 can be selected from hydrogen, halogen, an optionally substituted C_1-6 alkyl, —OR^AA13 and —OC(═O)R^AA14; R^AA8 can be hydrogen or an optionally substituted C_1-6 alkyl; R^AA9, R^AA11 and R^AA13 can be independently selected from hydrogen and an optionally substituted C_1-6 alkyl; and R^AA10, R^AA12 and R^AA14 can be independently selected from an optionally substituted C_1-6 alkyl and an optionally substituted C_3-6 cycloalkyl. A non-limiting list of examples of compounds of Formula (AA), and phosphates thereof, includes the compounds numbered 7000-7077 in FIGS. 8A-8I. In some embodiments, Formula (AA) cannot be compound 7044, 7045, 7046, 7047, 7048, 7049, 7050, 7072, 7073, 7074, 7075, 7076 or 7077.

[0193] In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be used in combination with a compound of Formula (BB), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (BB), or a pharmaceutically acceptable salt thereof (see, U.S. Provisional Application No. 61/426,471, filed Dec. 22, 2010, the contents of which are incorporated by reference in its entirety):

wherein B^BB1 can be an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group; X^BB can be 0 (oxygen) or S (sulfur); R^BB1 can be selected from —Z^BB—R^BB9, an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative; Z^BB can be selected from O (oxygen), S (sulfur) and N(R^BB10); R^BB2 and R^BB3 can be independently selected from hydrogen, an optionally substituted C_1-6 alkyl, an optionally substituted C_2-6 alkenyl, an optionally substituted C_2-6 alkynyl, an optionally substituted C_1-6 haloalkyl and an optionally substituted aryl(C_1-6 alkyl); or R^BB2 and R^BB3 can be taken together to form a group selected from an optionally substituted C_3-6 cycloalkyl, an optionally substituted C_3-6 cycloalkenyl, an optionally substituted C_3-6 aryl and an optionally substituted C_3-6 heteroaryl; R^BB4 can be selected from hydrogen, halogen, azido, cyano, an optionally substituted C_1-6 alkyl, an optionally substituted C_2-6 alkenyl, an optionally substituted C_2-6 alkynyl and an optionally substituted allenyl; R^BB5 can be hydrogen or an optionally substituted C_1-6 alkyl; R^BB6 can be selected from hydrogen, halogen, azido, amino, cyano, an optionally substituted C_1-6 alkyl, —OR^BB11 and —OC(═O)R^BB12; R^BB7 can be selected from hydrogen, halogen, azido, cyano, an optionally substituted C_1-6 alkyl, —OR^BB13 and —OC(═O)R^BB14; R^BB8 can be selected from hydrogen, halogen, azido, cyano, an optionally substituted C_1-6 alkyl, —OR^BB15 and —OC(═O)R^BB16; R^BB9 can be selected from an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted aryl(C_1-6alkyl), an optionally substituted heteroaryl(C_1-6alkyl) and an optionally substituted heterocyclyl(C_1-6alkyl); R^BB10 can be selected from hydrogen, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted aryl(C_1-6alkyl), an optionally substituted heteroaryl(C_1-6alkyl) and an optionally substituted heterocyclyl(C_1-6alkyl); R^BB11, R^BB13 and R^BB15 can be independently hydrogen or an optionally substituted C_1-6 alkyl; and R^BB12, R^BB14 and R^BB16 can be independently an optionally substituted C_1-6 alkyl or an optionally substituted C_3-6 cycloalkyl. In some embodiments, at least one of R^BB2 and R^BB3 is not hydrogen. A non-limiting list of example compounds of Formula (BB) includes the compound numbered 8000-8012 in FIGS. 9A-9B.

[0194] In some embodiments, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be used in combination with a compound of Formula (DD), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (DD), or a pharmaceutically acceptable salt thereof (see, U.S. Publication No. 2010-0249068, filed Mar. 19, 2010, the contents of which are incorporated by reference in its entirety):

wherein each can be independently a double or single bond; A^DD1 can be selected from C (carbon), O (oxygen) and S (sulfur); B^DD1 can be an optionally substituted heterocyclic base or a derivative thereof; D^DD1 can be selected from C═CH₂, CH₂, O (oxygen), S (sulfur), CHF, and CF₂; R^DD1 can be hydrogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted aralkyl, dialkylaminoalkylene, alkyl-C(═O)—, aryl-C(═O)—, alkoxyalkyl-C(═O)—, aryloxyalkyl-C(═O)—, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl,

an —O-linked amino acid, diphosphate, triphosphate or derivatives thereof; R^DD2 and R^DD3 can be each independently selected from hydrogen, an optionally substituted C_1-6 alkyl, an optionally substituted C_2-6 alkenyl, an optionally substituted C_2-6 alkynyl and an optionally substituted C_1-6 haloalkyl, provided that at least one of R^DD2 and R^DD3 cannot be hydrogen; or R^DD2 and R^DD3 are taken together to form a group selected from among C_3-6 cycloalkyl, C_3-6 cycloalkenyl, C_3-6 aryl, and a C_3-6 heteroaryl; R^DD4 and R^DD9 can be independently selected from hydrogen, halogen, —NH₂, —NHR^DDa1, —NR^DDa1R^DDb1, —OR^DDa1, —SR^DDc1, —CN, —NC, —N₃, —NO₂, —N(R^DDc1)—NR^DDa1R^DDb1, —N(R^DDc1)—OR^DDa1, —S—SR^DDa1, C(═O)R^DDa1, —C(═O)OR^DDa1, —C(═O)NR^DDa1R^DDb1, —O—(C═O)R^DDa1, —O—C(═O)OR^DDa1, —O—C(═O)NR^DDa1R^DDa1, —N(R^DDc1)—C(═O)NR^DDa1R^DDb1, —S(═O)R^DDa1, S(═O)₂R^DDa1, —O—S(═O)₂NR^DDa1R^DDb1, —N(R^DDc1—S(═O)₂NR^DDa1R^DDb1 an optionally substituted C_1-6 alkyl, an optionally substituted C_2-6 alkenyl, an optionally substituted C_2-6 alkynyl, an optionally substituted aralkyl and an —O-linked amino acid; R^DD5, R^DD6 and R^DD7 can be independently absent or selected from hydrogen, halogen, —NH₂, —NHR^DDa1, NR^DDa1R^DDb1, —OR^DDa1, —SR^DDa1, —CN, —NC, —N₃, —NO₂, —N(R^DDc1)—NR^DDa1R^DDb1, —N(R^DDc1)—OR^DDa1, —S—SR^DDa1, —C(═O)R^DDa1, —C(═O)OR^DDa1, —C(═O)NR^DDa1R^DDb1, —O—(C═O)R^DDa1, —O—C(═O)OR^DDa1, —O—C(═O)NR^DDa1R^DDb1, —N(R^DDc1)—C(═O)NR^DDa1R^DDb1, —S(═O)R^DDa1, S(═O)₂R^DDa1, —O—S(═O)₂NR^DDa1R^DDb1, —N(R^DDc1—S(═O)₂NR^DDa1R^DDb1 an optionally substituted C_1-6 alkyl, an optionally substituted C_1-6 alkyl, an optionally substituted C_2-6 alkenyl, an optionally substituted C_2-6 alkynyl, an optionally substituted aralkyl and an —O-linked amino acid; or R^DD6 and R^DD7 taken together form —O—C(═O)—O—; R^DD8 can be absent or selected from the group consisting of hydrogen, halogen, —NH₂, —NHR^DDa1, NR^DDa1R^DDb1, —OR^DDa1, —SR^DDa1, —CN, —NC, —N₃, —NO₂, —N(R^DDc1)—NR^DDa1R^DDb1, —N(R^DDc1)—OR^DDa1, —S—SR^DDa1, —C(═O)R^DDa1, —C(═O)OR^DDa1, —C(═O)NR^DDa1R^DDb1, —O—C(═O)OR^DDa1, —O—C(═O)NR^DDa1R^DDb1, —N(R^DDc1)—C(═O)NR^DDa1R^DDb1, —S(═O)R^DDa1, S(═O)₂R^DDa1, —O—S(═O)₂NR^DDa1R^DDb1, —N(R^DDc1—S(═O)₂NR^DDa1R^DDb1, an optionally substituted C_1-6 alkyl, an optionally substituted C_2-6 alkenyl, an optionally substituted C_2-6 alkynyl, an optionally substituted haloalkyl, an optionally substituted hydroxyalkyl and an —O-linked amino acid, or when the bond to R^DD7 indicated by is a double bond, then R^DD7 is a C_2-6 alkylidene and R^DD8 is absent; R^DDa1, R^DDb1 and R^DDc1 can be each independently selected from hydrogen, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aralkyl and an optionally substituted heteroaryl(C_1-6 alkyl); R^DD10 can be selected from O⁻, —OH, an optionally substituted aryloxy or aryl-O—,

alkyl-C(═O)—O—CH₂—O—, alkyl-C(═O)—S—CH₂CH₂—O— and an —N-linked amino acid: R^DD11 can be selected from O⁻, —OH, an optionally substituted aryloxy or aryl-O—,

alkyl-C(═O)—O—CH₂—O—, alkyl-C(═O)—S—CH₂CH₂—O— and an —N-linked amino acid; each R^DD12 and each R^DD13 can be independently —C≡N or an optionally substituted substituent selected from C_1-8 organylcarbonyl, C_1-8 alkoxycarbonyl and C_1-8 organylaminocarbonyl; each R^DD14 can be hydrogen or an optionally substituted C_1-6-alkyl; each m^DD can be independently 1 or 2, and if both R^DD10 and R^DD11 are

each R^DD12, each R^DD13, each R^DD14 and each m^DD can be the same or different. In some embodiments, R^DD8 can be halogen, —OR^DDa1, an optionally substituted C_1-6 alkyl, an optionally substituted C_2-6 alkenyl, an optionally substituted C_2-6 alkynyl and an optionally substituted C_1-6 haloalkyl.

[0195] Some embodiments described herein relate to a method of ameliorating or treating a viral infection that can include contacting a cell infected with the viral infection with a therapeutically effective amount of a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, in combination with one or more agents selected from an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an antiviral compound, a compound of Formula (AA), a mono-, di, and/or tri-phosphate thereof, a compound of Formula (BB), and a compound of Formula (DD), or a pharmaceutically acceptable salt of any of the aforementioned compounds.

[0196] Some embodiments described herein relate to a method of ameliorating or treating a viral infection that can include administering to a subject suffering from the viral infection a therapeutically effective amount of a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, in combination with one or more agents selected from an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an antiviral compound, a compound of Formula (AA), a mono-, di, and/or tri-phosphate thereof, a compound of Formula (BB), and a compound of Formula (DD), or a pharmaceutically acceptable salt of any of the aforementioned compounds.

[0197] Some embodiments described herein relate to a method of inhibiting viral replication of a virus that can include contacting a cell infected with the virus with an effective amount of a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, in combination with one or more agents selected from an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an antiviral compound, a compound of Formula (AA), a mono-, di, and/or tri-phosphate thereof, a compound of Formula (BB), and a compound of Formula (DD), or a pharmaceutically acceptable salt of any of the aforementioned compounds.

[0198] Some embodiments described herein relate to a method of ameliorating or treating a viral infection that can include contacting a cell infected with the viral infection with a therapeutically effective amount of a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, in combination with one or more agents selected from an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an antiviral compound, a compound of Formula (AA), a compound of Formula (BB), and a compound of Formula (DD), or a pharmaceutically acceptable salt of any of the aforementioned compounds.

[0199] Some embodiments described herein relate to a method of ameliorating or treating a viral infection that can include administering to a subject suffering from the viral infection a therapeutically effective amount of a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, in combination with one or more agents selected from an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an antiviral compound, a compound of Formula (AA), a compound of Formula (BB), and a compound of Formula (DD), or a pharmaceutically acceptable salt of any of the aforementioned compounds.

[0200] Some embodiments described herein relate to a method of inhibiting viral replication of a virus that can include contacting a cell infected with the virus with an effective amount of a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, in combination with one or more agents selected from an interferon, ribavirin, a HCV protease inhibitor, a HCV polymerase inhibitor, a NS5A inhibitor, an antiviral compound, a compound of Formula (AA), a compound of Formula (BB), and a compound of Formula (DD), or a pharmaceutically acceptable salt of any of the aforementioned compounds.

[0201] In some embodiments, a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, can be administered with one or more additional agent(s) together in a single pharmaceutical composition. In some embodiments, a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt the thereof, can be administered with one or more additional agent(s) as two or more separate pharmaceutical compositions. For example, a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, can be administered in one pharmaceutical composition, and at least one of the additional agents can be administered in a second pharmaceutical composition. If there are at least two additional agents, one or more of the additional agents can be in a first pharmaceutical composition that includes a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, and at least one of the other additional agent(s) can be in a second pharmaceutical composition.

[0202] The dosing amount(s) and dosing schedule(s) when using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and one or more additional agents are within the knowledge of those skilled in the art. For example, when performing a conventional standard of care therapy using art-recognized dosing amounts and dosing schedules, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, can be administered in addition to that therapy, or in place of one of the agents of a combination therapy, using effective amounts and dosing protocols as described herein.

[0203] The order of administration of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, with one or more additional agent(s) can vary. In some embodiments, a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, can be administered prior to all additional agents. In other embodiments, a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, can be administered prior to at least one additional agent. In still other embodiments, a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, can be administered concomitantly with one or more additional agent(s). In yet still other embodiments, a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, can be administered subsequent to the administration of at least one additional agent. In some embodiments, a compound of Formula (I) (including a compound of Formula (Iα)), or a pharmaceutically acceptable salt thereof, can be administered subsequent to the administration of all additional agents.

[0204] In some embodiments, the combination of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more additional agent(s) in FIGS. 2-6 and 8-10 (including pharmaceutically acceptable salts and prodrugs thereof) can result in an additive effect. In some embodiments, the combination of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more additional agent(s) in FIGS. 2-6 and 8-10 (including pharmaceutically acceptable salts and prodrugs thereof) can result in a synergistic effect. In some embodiments, the combination of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more additional agent(s) in FIGS. 2-6 and 8-10 (including pharmaceutically acceptable salts and prodrugs thereof) can result in a strongly synergistic effect. In some embodiments, the combination of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more additional agent(s) in FIGS. 2-6 and 8-10 (including pharmaceutically acceptable salts and prodrugs thereof) is not antagonistic.

[0205] As used herein, the term “antagonistic” means that the activity of the combination of compounds is less compared to the sum of the activities of the compounds in combination when the activity of each compound is determined individually (i.e. as a single compound). As used herein, the term “synergistic effect” means that the activity of the combination of compounds is greater than the sum of the individual activities of the compounds in the combination when the activity of each compound is determined individually. As used herein, the term “additive effect” means that the activity of the combination of compounds is about equal to the sum of the individual activities of the compound in the combination when the activity of each compound is determined individually.

[0206] A potential advantage of utilizing a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more additional agent(s) in FIGS. 2-6 and 8-10 (including pharmaceutically acceptable salts and prodrugs thereof) may be a reduction in the required amount(s) of one or more compounds of FIGS. 2-6 and 8-10 (including pharmaceutically acceptable salts and prodrugs thereof) that is effective in treating a disease condition disclosed herein (for example, HCV), as compared to the amount required to achieve same therapeutic result when one or more compounds of FIGS. 2-6 and 8-10 (including pharmaceutically acceptable salts and prodrugs thereof) are administered without a compound of Formula (I), or a pharmaceutically acceptable salt thereof. For example, the amount of a compound in FIGS. 2-6 and 8-10 (including a pharmaceutically acceptable salt and prodrug thereof), can be less compared to the amount of the compound in FIGS. 2-6 and 8-10 (including a pharmaceutically acceptable salt and prodrug thereof), needed to achieve the same viral load reduction when administered as a monotherapy. Another potential advantage of utilizing a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more additional agent(s) in FIGS. 2-6 and 8-10 (including pharmaceutically acceptable salts and prodrugs thereof) is that the use of two or more compounds having different mechanism of actions can create a higher barrier to the development of resistant viral strains compared to the barrier when a compound is administered as monotherapy.

[0207] Additional advantages of utilizing a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more additional agent(s) in FIGS. 2-6 and 8-10 (including pharmaceutically acceptable salts and prodrugs thereof) may include little to no cross resistance between a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and one or more additional agent(s) in FIGS. 2-6 and 8-10 (including pharmaceutically acceptable salts and prodrugs thereof) thereof; different routes for elimination of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and one or more additional agent(s) in FIGS. 2-6 and 8-10 (including pharmaceutically acceptable salts and prodrugs thereof); little to no overlapping toxicities between a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and one or more additional agent(s) in FIGS. 2-6 and 8-10 (including pharmaceutically acceptable salts and prodrugs thereof); little to no significant effects on cytochrome P450; and/or little to no pharmacokinetic interactions between a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and one or more additional agent(s) in FIGS. 2-6 and 8-10 (including pharmaceutically acceptable salts and prodrugs thereof).

[0208] A non-limiting list of example combination of compounds of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition that includes a compound described herein, with one or more additional agent(s) are provided in Tables A, B, C and D. Each numbered X and Y compound in Tables A, B, C and D has a corresponding name and/or structure provided in FIGS. 2 to 10. The numbered compounds in Tables A, B, C and D includes pharmaceutically acceptable salts of the compounds and pharmaceutical compositions containing the compounds or a pharmaceutically acceptable salt thereof. For example, 1001 includes the compound corresponding to 1001, pharmaceutically acceptable salts thereof, and pharmaceutical compositions that include compound 1001 and/or a pharmaceutically acceptable salt thereof. The combinations exemplified in Tables A, B, C and

[0209] D are designated by the formula X:Y, which represents a combination of a compound X with a compound Y. For example, the combination designated as 1001:6001 in Table A represents a combination of compound 1001 with compound 6001, including pharmaceutically acceptable salts of compound 1001 and/or 6001, and pharmaceutical compositions including compound 1001 and 6001 (including pharmaceutical compositions that include pharmaceutically acceptable salts of compound 1001 and/or compound 6001). Thus, the combination designated as 1001:6001 in Table A represents the combination of Telaprevir (compound 1001, as shown in FIG. 2) and

(compound 6001, as shown in FIG. 7A), including pharmaceutically acceptable salts of compound 1001 and/or 6001, and pharmaceutical compositions including compound 1001 and 6001 (including pharmaceutical compositions that include pharmaceutically acceptable salts of compound 1001 and/or compound 6001). Each of the combinations provided in Tables A, B, C and D can be used with one, two, three or more additional agents described herein. In some embodiments, embodiments described herein, the combination of agents can be used to treat, amerliorate and/or inhibit a virus and/or a viral infection, wherein the virus can be HCV and the viral infection can be an HCV viral infection.

TABLE A
Example combinations of a compound X with a compound Y.
X:Y
1001:6000
1002:6000
1003:6000
1004:6000
1005:6000
1006:6000
1007:6000
1008:6000
1009:6000
1010:6000
1011:6000
1012:6000
1013:6000
1014:6000
2001:6000
2002:6000
2003:6000
2004:6000
2005:6000
2006:6000
2007:6000
2008:6000
2009:6000
2010:6000
3001:6000
3002:6000
3003:6000
3004:6000
3005:6000
3006:6000
3007:6000
3008:6000
4001:6000
4002:6000
4003:6000
4004:6000
4005:6000
5001:6000
5002:6000
1001:6001
1002:6001
1003:6001
1004:6001
1005:6001
1006:6001
1007:6001
1008:6001
1009:6001
1010:6001
1011:6001
1012:6001
1013:6001
1014:6001
2001:6001
2002:6001
2003:6001
2004:6001
2005:6001
2006:6001
2007:6001
2008:6001
2009:6001
2010:6001
3001:6001
3002:6001
3003:6001
3004:6001
3005:6001
3006:6001
3007:6001
3008:6001
4001:6001
4002:6001
4003:6001
4004:6001
4005:6001
5001:6001
5002:6001
1001:6002
1002:6002
1003:6002
1004:6002
1005:6002
1006:6002
1007:6002
1008:6002
1009:6002
1010:6002
1011:6002
1012:6002
1013:6002
1014:6002
2001:6002
2002:6002
2003:6002
2004:6002
2005:6002
2006:6002
2007:6002
2008:6002
2009:6002
2010:6002
3001:6002
3002:6002
3003:6002
3004:6002
3005:6002
3006:6002
3007:6002
3008:6002
4001:6002
4002:6002
4003:6002
4004:6002
4005:6002
5001:6002
5002:6002
1001:6003
1002:6003
1003:6003
1004:6003
1005:6003
1006:6003
1007:6003
1008:6003
1009:6003
1010:6003
1011:6003
1012:6003
1013:6003
1014:6003
2001:6003
2002:6003
2003:6003
2004:6003
2005:6003
2006:6003
2007:6003
2008:6003
2009:6003
2010:6003
3001:6003
3002:6003
3003:6003
3004:6003
3005:6003
3006:6003
3007:6003
3008:6003
4001:6003
4002:6003
4003:6003
4004:6003
4005:6003
5001:6003
5002:6003
1001:6004
1002:6004
1003:6004
1004:6004
1005:6004
1006:6004
1007:6004
1008:6004
1009:6004
1010:6004
1011:6004
1012:6004
1013:6004
1014:6004
2001:6004
2002:6004
2003:6004
2004:6004
2005:6004
2006:6004
2007:6004
2008:6004
2009:6004
2010:6004
3001:6004
3002:6004
3003:6004
3004:6004
3005:6004
3006:6004
3007:6004
3008:6004
4001:6004
4002:6004
4003:6004
4004:6004
4005:6004
5001:6004
5002:6004
1001:6005
1002:6005
1003:6005
1004:6005
1005:6005
1006:6005
1007:6005
1008:6005
1009:6005
1010:6005
1011:6005
1012:6005
1013:6005
1014:6005
2001:6005
2002:6005
2003:6005
2004:6005
2005:6005
2006:6005
2007:6005
2008:6005
2009:6005
2010:6005
3001:6005
3002:6005
3003:6005
3004:6005
3005:6005
3006:6005
3007:6005
3008:6005
4001:6005
4002:6005
4003:6005
4004:6005
4005:6005
5001:6005
5002:6005
1001:6006
1002:6006
1003:6006
1004:6006
1005:6006
1006:6006
1007:6006
1008:6006
1009:6006
1010:6006
1011:6006
1012:6006
1013:6006
1014:6006
2001:6006
2002:6006
2003:6006
2004:6006
2005:6006
2006:6006
2007:6006
2008:6006
2009:6006
2010:6006
3001:6006
3002:6006
3003:6006
3004:6006
3005:6006
3006:6006
3007:6006
3008:6006
4001:6006
4002:6006
4003:6006
4004:6006
4005:6006
5001:6006
5002:6006
1001:6007
1002:6007
1003:6007
1004:6007
1005:6007
1006:6007
1007:6007
1008:6007
1009:6007
1010:6007
1011:6007
1012:6007
1013:6007
1014:6007
2001:6007
2002:6007
2003:6007
2004:6007
2005:6007
2006:6007
2007:6007
2008:6007
2009:6007
2010:6007
3001:6007
3002:6007
3003:6007
3004:6007
3005:6007
3006:6007
3007:6007
3008:6007
4001:6007
4002:6007
4003:6007
4004:6007
4005:6007
5001:6007
5002:6007
1001:6008
1002:6008
1003:6008
1004:6008
1005:6008
1006:6008
1007:6008
1008:6008
1009:6008
1010:6008
1011:6008
1012:6008
1013:6008
1014:6008
2001:6008
2002:6008
2003:6008
2004:6008
2005:6008
2006:6008
2007:6008
2008:6008
2009:6008
2010:6008
3001:6008
3002:6008
3003:6008
3004:6008
3005:6008
3006:6008
3007:6008
3008:6008
4001:6008
4002:6008
4003:6008
4004:6008
4005:6008
5001:6008
5002:6008
1001:6009
1002:6009
1003:6009
1004:6009
1005:6009
1006:6009
1007:6009
1008:6009
1009:6009
1010:6009
1011:6009
1012:6009
1013:6009
1014:6009
2001:6009
2002:6009
2003:6009
2004:6009
2005:6009
2006:6009
2007:6009
2008:6009
2009:6009
2010:6009
3001:6009
3002:6009
3003:6009
3004:6009
3005:6009
3006:6009
3007:6009
3008:6009
4001:6009
4002:6009
4003:6009
4004:6009
4005:6009
5001:6009
5002:6009
1001:6010
1002:6010
1003:6010
1004:6010
1005:6010
1006:6010
1007:6010
1008:6010
1009:6010
1010:6010
1011:6010
1012:6010
1013:6010
1014:6010
2001:6010
2002:6010
2003:6010
2004:6010
2005:6010
2006:6010
2007:6010
2008:6010
2009:6010
2010:6010
3001:6010
3002:6010
3003:6010
3004:6010
3005:6010
3006:6010
3007:6010
3008:6010
4001:6010
4002:6010
4003:6010
4004:6010
4005:6010
5001:6010
5002:6010
1001:6011
1002:6011
1003:6011
1004:6011
1005:6011
1006:6011
1007:6011
1008:6011
1009:6011
1010:6011
1011:6011
1012:6011
1013:6011
1014:6011
2001:6011
2002:6011
2003:6011
2004:6011
2005:6011
2006:6011
2007:6011
2008:6011
2009:6011
2010:6011
3001:6011
3002:6011
3003:6011
3004:6011
3005:6011
3006:6011
3007:6011
3008:6011
4001:6011
4002:6011
4003:6011
4004:6011
4005:6011
5001:6011
5002:6011
1001:6012
1002:6012
1003:6012
1004:6012
1005:6012
1006:6012
1007:6012
1008:6012
1009:6012
1010:6012
1011:6012
1012:6012
1013:6012
1014:6012
2001:6012
2002:6012
2003:6012
2004:6012
2005:6012
2006:6012
2007:6012
2008:6012
2009:6012
2010:6012
3001:6012
3002:6012
3003:6012
3004:6012
3005:6012
3006:6012
3007:6012
3008:6012
4001:6012
4002:6012
4003:6012
4004:6012
4005:6012
5001:6012
5002:6012
1001:6013
1002:6013
1003:6013
1004:6013
1005:6013
1006:6013
1007:6013
1008:6013
1009:6013
1010:6013
1011:6013
1012:6013
1013:6013
1014:6013
2001:6013
2002:6013
2003:6013
2004:6013
2005:6013
2006:6013
2007:6013
2008:6013
2009:6013
2010:6013
3001:6013
3002:6013
3003:6013
3004:6013
3005:6013
3006:6013
3007:6013
3008:6013
4001:6013
4002:6013
4003:6013
4004:6013
4005:6013
5001:6013
5002:6013
1001:6014
1002:6014
1003:6014
1004:6014
1005:6014
1006:6014
1007:6014
1008:6014
1009:6014
1010:6014
1011:6014
1012:6014
1013:6014
1014:6014
2001:6014
2002:6014
2003:6014
2004:6014
2005:6014
2006:6014
2007:6014
2008:6014
2009:6014
2010:6014
3001:6014
3002:6014
3003:6014
3004:6014
3005:6014
3006:6014
3007:6014
3008:6014
4001:6014
4002:6014
4003:6014
4004:6014
4005:6014
5001:6014
5002:6014
1001:6015
1002:6015
1003:6015
1004:6015
1005:6015
1006:6015
1007:6015
1008:6015
1009:6015
1010:6015
1011:6015
1012:6015
1013:6015
1014:6015
2001:6015
2002:6015
2003:6015
2004:6015
2005:6015
2006:6015
2007:6015
2008:6015
2009:6015
2010:6015
3001:6015
3002:6015
3003:6015
3004:6015
3005:6015
3006:6015
3007:6015
3008:6015
4001:6015
4002:6015
4003:6015
4004:6015
4005:6015
5001:6015
5002:6015
1001:6016
1002:6016
1003:6016
1004:6016
1005:6016
1006:6016
1007:6016
1008:6016
1009:6016
1010:6016
1011:6016
1012:6016
1013:6016
1014:6016
2001:6016
2002:6016
2003:6016
2004:6016
2005:6016
2006:6016
2007:6016
2008:6016
2009:6016
2010:6016
3001:6016
3002:6016
3003:6016
3004:6016
3005:6016
3006:6016
3007:6016
3008:6016
4001:6016
4002:6016
4003:6016
4004:6016
4005:6016
5001:6016
5002:6016
1001:6017
1002:6017
1003:6017
1004:6017
1005:6017
1006:6017
1007:6017
1008:6017
1009:6017
1010:6017
1011:6017
1012:6017
1013:6017
1014:6017
2001:6017
2002:6017
2003:6017
2004:6017
2005:6017
2006:6017
2007:6017
2008:6017
2009:6017
2010:6017
3001:6017
3002:6017
3003:6017
3004:6017
3005:6017
3006:6017
3007:6017
3008:6017
4001:6017
4002:6017
4003:6017
4004:6017
4005:6017
5001:6017
5002:6017
1001:6018
1002:6018
1003:6018
1004:6018
1005:6018
1006:6018
1007:6018
1008:6018
1009:6018
1010:6018
1011:6018
1012:6018
1013:6018
1014:6018
2001:6018
2002:6018
2003:6018
2004:6018
2005:6018
2006:6018
2007:6018
2008:6018
2009:6018
2010:6018
3001:6018
3002:6018
3003:6018
3004:6018
3005:6018
3006:6018
3007:6018
3008:6018
4001:6018
4002:6018
4003:6018
4004:6018
4005:6018
5001:6018
5002:6018
1001:6019
1002:6019
1003:6019
1004:6019
1005:6019
1006:6019
1007:6019
1008:6019
1009:6019
1010:6019
1011:6019
1012:6019
1013:6019
1014:6019
2001:6019
2002:6019
2003:6019
2004:6019
2005:6019
2006:6019
2007:6019
2008:6019
2009:6019
2010:6019
3001:6019
3002:6019
3003:6019
3004:6019
3005:6019
3006:6019
3007:6019
3008:6019
4001:6019
4002:6019
4003:6019
4004:6019
4005:6019
5001:6019
5002:6019
1001:6020
1002:6020
1003:6020
1004:6020
1005:6020
1006:6020
1007:6020
1008:6020
1009:6020
1010:6020
1011:6020
1012:6020
1013:6020
1014:6020
2001:6020
2002:6020
2003:6020
2004:6020
2005:6020
2006:6020
2007:6020
2008:6020
2009:6020
2010:6020
3001:6020
3002:6020
3003:6020
3004:6020
3005:6020
3006:6020
3007:6020
3008:6020
4001:6020
4002:6020
4003:6020
4004:6020
4005:6020
5001:6020
5002:6020
1001:6021
1002:6021
1003:6021
1004:6021
1005:6021
1006:6021
1007:6021
1008:6021
1009:6021
1010:6021
1011:6021
1012:6021
1013:6021
1014:6021
2001:6021
2002:6021
2003:6021
2004:6021
2005:6021
2006:6021
2007:6021
2008:6021
2009:6021
2010:6021
3001:6021
3002:6021
3003:6021
3004:6021
3005:6021
3006:6021
3007:6021
3008:6021
4001:6021
4002:6021
4003:6021
4004:6021
4005:6021
5001:6021
5002:6021
1001:6022
1002:6022
1003:6022
1004:6022
1005:6022
1006:6022
1007:6022
1008:6022
1009:6022
1010:6022
1011:6022
1012:6022
1013:6022
1014:6022
2001:6022
2002:6022
2003:6022
2004:6022
2005:6022
2006:6022
2007:6022
2008:6022
2009:6022
2010:6022
3001:6022
3002:6022
3003:6022
3004:6022
3005:6022
3006:6022
3007:6022
3008:6022
4001:6022
4002:6022
4003:6022
4004:6022
4005:6022
5001:6022
5002:6022
1001:6023
1002:6023
1003:6023
1004:6023
1005:6023
1006:6023
1007:6023
1008:6023
1009:6023
1010:6023
1011:6023
1012:6023
1013:6023
1014:6023
2001:6023
2002:6023
2003:6023
2004:6023
2005:6023
2006:6023
2007:6023
2008:6023
2009:6023
2010:6023
3001:6023
3002:6023
3003:6023
3004:6023
3005:6023
3006:6023
3007:6023
3008:6023
4001:6023
4002:6023
4003:6023
4004:6023
4005:6023
5001:6023
5002:6023
1001:6024
1002:6024
1003:6024
1004:6024
1005:6024
1006:6024
1007:6024
1008:6024
1009:6024
1010:6024
1011:6024
1012:6024
1013:6024
1014:6024
2001:6024
2002:6024
2003:6024
2004:6024
2005:6024
2006:6024
2007:6024
2008:6024
2009:6024
2010:6024
3001:6024
3002:6024
3003:6024
3004:6024
3005:6024
3006:6024
3007:6024
3008:6024
4001:6024
4002:6024
4003:6024
4004:6024
4005:6024
5001:6024
5002:6024
1001:6025
1002:6025
1003:6025
1004:6025
1005:6025
1006:6025
1007:6025
1008:6025
1009:6025
1010:6025
1011:6025
1012:6025
1013:6025
1014:6025
2001:6025
2002:6025
2003:6025
2004:6025
2005:6025
2006:6025
2007:6025
2008:6025
2009:6025
2010:6025
3001:6025
3002:6025
3003:6025
3004:6025
3005:6025
3006:6025
3007:6025
3008:6025
4001:6025
4002:6025
4003:6025
4004:6025
4005:6025
5001:6025
5002:6025
1001:6026
1002:6026
1003:6026
1004:6026
1005:6026
1006:6026
1007:6026
1008:6026
1009:6026
1010:6026
1011:6026
1012:6026
1013:6026
1014:6026
2001:6026
2002:6026
2003:6026
2004:6026
2005:6026
2006:6026
2007:6026
2008:6026
2009:6026
2010:6026
3001:6026
3002:6026
3003:6026
3004:6026
3005:6026
3006:6026
3007:6026
3008:6026
4001:6026
4002:6026
4003:6026
4004:6026
4005:6026
5001:6026
5002:6026
1001:6027
1002:6027
1003:6027
1004:6027
1005:6027
1006:6027
1007:6027
1008:6027
1009:6027
1010:6027
1011:6027
1012:6027
1013:6027
1014:6027
2001:6027
2002:6027
2003:6027
2004:6027
2005:6027
2006:6027
2007:6027
2008:6027
2009:6027
2010:6027
3001:6027
3002:6027
3003:6027
3004:6027
3005:6027
3006:6027
3007:6027
3008:6027
4001:6027
4002:6027
4003:6027
4004:6027
4005:6027
5001:6027
5002:6027
1001:6028
1002:6028
1003:6028
1004:6028
1005:6028
1006:6028
1007:6028
1008:6028
1009:6028
1010:6028
1011:6028
1012:6028
1013:6028
1014:6028
2001:6028
2002:6028
2003:6028
2004:6028
2005:6028
2006:6028
2007:6028
2008:6028
2009:6028
2010:6028
3001:6028
3002:6028
3003:6028
3004:6028
3005:6028
3006:6028
3007:6028
3008:6028
4001:6028
4002:6028
4003:6028
4004:6028
4005:6028
5001:6028
5002:6028
1001:6029
1002:6029
1003:6029
1004:6029
1005:6029
1006:6029
1007:6029
1008:6029
1009:6029
1010:6029
1011:6029
1012:6029
1013:6029
1014:6029
2001:6029
2002:6029
2003:6029
2004:6029
2005:6029
2006:6029
2007:6029
2008:6029
2009:6029
2010:6029
3001:6029
3002:6029
3003:6029
3004:6029
3005:6029
3006:6029
3007:6029
3008:6029
4001:6029
4002:6029
4003:6029
4004:6029
4005:6029
5001:6029
5002:6029
1001:6030
1002:6030
1003:6030
1004:6030
1005:6030
1006:6030
1007:6030
1008:6030
1009:6030
1010:6030
1011:6030
1012:6030
1013:6030
1014:6030
2001:6030
2002:6030
2003:6030
2004:6030
2005:6030
2006:6030
2007:6030
2008:6030
2009:6030
2010:6030
3001:6030
3002:6030
3003:6030
3004:6030
3005:6030
3006:6030
3007:6030
3008:6030
4001:6030
4002:6030
4003:6030
4004:6030
4005:6030
5001:6030
5002:6030
1001:6031
1002:6031
1003:6031
1004:6031
1005:6031
1006:6031
1007:6031
1008:6031
1009:6031
1010:6031
1011:6031
1012:6031
1013:6031
1014:6031
2001:6031
2002:6031
2003:6031
2004:6031
2005:6031
2006:6031
2007:6031
2008:6031
2009:6031
2010:6031
3001:6031
3002:6031
3003:6031
3004:6031
3005:6031
3006:6031
3007:6031
3008:6031
4001:6031
4002:6031
4003:6031
4004:6031
4005:6031
5001:6031
5002:6031
1001:6032
1002:6032
1003:6032
1004:6032
1005:6032
1006:6032
1007:6032
1008:6032
1009:6032
1010:6032
1011:6032
1012:6032
1013:6032
1014:6032
2001:6032
2002:6032
2003:6032
2004:6032
2005:6032
2006:6032
2007:6032
2008:6032
2009:6032
2010:6032
3001:6032
3002:6032
3003:6032
3004:6032
3005:6032
3006:6032
3007:6032
3008:6032
4001:6032
4002:6032
4003:6032
4004:6032
4005:6032
5001:6032
5002:6032
1001:6033
1002:6033
1003:6033
1004:6033
1005:6033
1006:6033
1007:6033
1008:6033
1009:6033
1010:6033
1011:6033
1012:6033
1013:6033
1014:6033
2001:6033
2002:6033
2003:6033
2004:6033
2005:6033
2006:6033
2007:6033
2008:6033
2009:6033
2010:6033
3001:6033
3002:6033
3003:6033
3004:6033
3005:6033
3006:6033
3007:6033
3008:6033
4001:6033
4002:6033
4003:6033
4004:6033
4005:6033
5001:6033
5002:6033
1001:6034
1002:6034
1003:6034
1004:6034
1005:6034
1006:6034
1007:6034
1008:6034
1009:6034
1010:6034
1011:6034
1012:6034
1013:6034
1014:6034
2001:6034
2002:6034
2003:6034
2004:6034
2005:6034
2006:6034
2007:6034
2008:6034
2009:6034
2010:6034
3001:6034
3002:6034
3003:6034
3004:6034
3005:6034
3006:6034
3007:6034
3008:6034
4001:6034
4002:6034
4003:6034
4004:6034
4005:6034
5001:6034
5002:6034
1001:6035
1002:6035
1003:6035
1004:6035
1005:6035
1006:6035
1007:6035
1008:6035
1009:6035
1010:6035
1011:6035
1012:6035
1013:6035
1014:6035
2001:6035
2002:6035
2003:6035
2004:6035
2005:6035
2006:6035
2007:6035
2008:6035
2009:6035
2010:6035
3001:6035
3002:6035
3003:6035
3004:6035
3005:6035
3006:6035
3007:6035
3008:6035
4001:6035
4002:6035
4003:6035
4004:6035
4005:6035
5001:6035
5002:6035
1001:6036
1002:6036
1003:6036
1004:6036
1005:6036
1006:6036
1007:6036
1008:6036
1009:6036
1010:6036
1011:6036
1012:6036
1013:6036
1014:6036
2001:6036
2002:6036
2003:6036
2004:6036
2005:6036
2006:6036
2007:6036
2008:6036
2009:6036
2010:6036
3001:6036
3002:6036
3003:6036
3004:6036
3005:6036
3006:6036
3007:6036
3008:6036
4001:6036
4002:6036
4003:6036
4004:6036
4005:6036
5001:6036
5002:6036
1001:6037
1002:6037
1003:6037
1004:6037
1005:6037
1006:6037
1007:6037
1008:6037
1009:6037
1010:6037
1011:6037
1012:6037
1013:6037
1014:6037
2001:6037
2002:6037
2003:6037
2004:6037
2005:6037
2006:6037
2007:6037
2008:6037
2009:6037
2010:6037
3001:6037
3002:6037
3003:6037
3004:6037
3005:6037
3006:6037
3007:6037
3008:6037
4001:6037
4002:6037
4003:6037
4004:6037
4005:6037
5001:6037
5002:6037
1001:6038
1002:6038
1003:6038
1004:6038
1005:6038
1006:6038
1007:6038
1008:6038
1009:6038
1010:6038
1011:6038
1012:6038
1013:6038
1014:6038
2001:6038
2002:6038
2003:6038
2004:6038
2005:6038
2006:6038
2007:6038
2008:6038
2009:6038
2010:6038
3001:6038
3002:6038
3003:6038
3004:6038
3005:6038
3006:6038
3007:6038
3008:6038
4001:6038
4002:6038
4003:6038
4004:6038
4005:6038
5001:6038
5002:6038
1001:6039
1002:6039
1003:6039
1004:6039
1005:6039
1006:6039
1007:6039
1008:6039
1009:6039
1010:6039
1011:6039
1012:6039
1013:6039
1014:6039
2001:6039
2002:6039
2003:6039
2004:6039
2005:6039
2006:6039
2007:6039
2008:6039
2009:6039
2010:6039
3001:6039
3002:6039
3003:6039
3004:6039
3005:6039
3006:6039
3007:6039
3008:6039
4001:6039
4002:6039
4003:6039
4004:6039
4005:6039
5001:6039
5002:6039
1001:6040
1002:6040
1003:6040
1004:6040
1005:6040
1006:6040
1007:6040
1008:6040
1009:6040
1010:6040
1011:6040
1012:6040
1013:6040
1014:6040
2001:6040
2002:6040
2003:6040
2004:6040
2005:6040
2006:6040
2007:6040
2008:6040
2009:6040
2010:6040
3001:6040
3002:6040
3003:6040
3004:6040
3005:6040
3006:6040
3007:6040
3008:6040
4001:6040
4002:6040
4003:6040
4004:6040
4005:6040
5001:6040
5002:6040
1001:6041
1002:6041
1003:6041
1004:6041
1005:6041
1006:6041
1007:6041
1008:6041
1009:6041
1010:6041
1011:6041
1012:6041
1013:6041
1014:6041
2001:6041
2002:6041
2003:6041
2004:6041
2005:6041
2006:6041
2007:6041
2008:6041
2009:6041
2010:6041
3001:6041
3002:6041
3003:6041
3004:6041
3005:6041
3006:6041
3007:6041
3008:6041
4001:6041
4002:6041
4003:6041
4004:6041
4005:6041
5001:6041
5002:6041
1001:6042
1002:6042
1003:6042
1004:6042
1005:6042
1006:6042
1007:6042
1008:6042
1009:6042
1010:6042
1011:6042
1012:6042
1013:6042
1014:6042
2001:6042
2002:6042
2003:6042
2004:6042
2005:6042
2006:6042
2007:6042
2008:6042
2009:6042
2010:6042
3001:6042
3002:6042
3003:6042
3004:6042
3005:6042
3006:6042
3007:6042
3008:6042
4001:6042
4002:6042
4003:6042
4004:6042
4005:6042
5001:6042
5002:6042
1001:6043
1002:6043
1003:6043
1004:6043
1005:6043
1006:6043
1007:6043
1008:6043
1009:6043
1010:6043
1011:6043
1012:6043
1013:6043
1014:6043
2001:6043
2002:6043
2003:6043
2004:6043
2005:6043
2006:6043
2007:6043
2008:6043
2009:6043
2010:6043
3001:6043
3002:6043
3003:6043
3004:6043
3005:6043
3006:6043
3007:6043
3008:6043
4001:6043
4002:6043
4003:6043
4004:6043
4005:6043
5001:6043
5002:6043
1001:6044
1002:6044
1003:6044
1004:6044
1005:6044
1006:6044
1007:6044
1008:6044
1009:6044
1010:6044
1011:6044
1012:6044
1013:6044
1014:6044
2001:6044
2002:6044
2003:6044
2004:6044
2005:6044
2006:6044
2007:6044
2008:6044
2009:6044
2010:6044
3001:6044
3002:6044
3003:6044
3004:6044
3005:6044
3006:6044
3007:6044
3008:6044
4001:6044
4002:6044
4003:6044
4004:6044
4005:6044
5001:6044
5002:6044
1001:6045
1002:6045
1003:6045
1004:6045
1005:6045
1006:6045
1007:6045
1008:6045
1009:6045
1010:6045
1011:6045
1012:6045
1013:6045
1014:6045
2001:6045
2002:6045
2003:6045
2004:6045
2005:6045
2006:6045
2007:6045
2008:6045
2009:6045
2010:6045
3001:6045
3002:6045
3003:6045
3004:6045
3005:6045
3006:6045
3007:6045
3008:6045
4001:6045
4002:6045
4003:6045
4004:6045
4005:6045
5001:6045
5002:6045
1001:6046
1002:6046
1003:6046
1004:6046
1005:6046
1006:6046
1007:6046
1008:6046
1009:6046
1010:6046
1011:6046
1012:6046
1013:6046
1014:6046
2001:6046
2002:6046
2003:6046
2004:6046
2005:6046
2006:6046
2007:6046
2008:6046
2009:6046
2010:6046
3001:6046
3002:6046
3003:6046
3004:6046
3005:6046
3006:6046
3007:6046
3008:6046
4001:6046
4002:6046
4003:6046
4004:6046
4005:6046
5001:6046
5002:6046
1001:6047
1002:6047
1003:6047
1004:6047
1005:6047
1006:6047
1007:6047
1008:6047
1009:6047
1010:6047
1011:6047
1012:6047
1013:6047
1014:6047
2001:6047
2002:6047
2003:6047
2004:6047
2005:6047
2006:6047
2007:6047
2008:6047
2009:6047
2010:6047
3001:6047
3002:6047
3003:6047
3004:6047
3005:6047
3006:6047
3007:6047
3008:6047
4001:6047
4002:6047
4003:6047
4004:6047
4005:6047
5001:6047
5002:6047
1001:6048
1002:6048
1003:6048
1004:6048
1005:6048
1006:6048
1007:6048
1008:6048
1009:6048
1010:6048
1011:6048
1012:6048
1013:6048
1014:6048
2001:6048
2002:6048
2003:6048
2004:6048
2005:6048
2006:6048
2007:6048
2008:6048
2009:6048
2010:6048
3001:6048
3002:6048
3003:6048
3004:6048
3005:6048
3006:6048
3007:6048
3008:6048
4001:6048
4002:6048
4003:6048
4004:6048
4005:6048
5001:6048
5002:6048
1001:6049
1002:6049
1003:6049
1004:6049
1005:6049
1006:6049
1007:6049
1008:6049
1009:6049
1010:6049
1011:6049
1012:6049
1013:6049
1014:6049
2001:6049
2002:6049
2003:6049
2004:6049
2005:6049
2006:6049
2007:6049
2008:6049
2009:6049
2010:6049
3001:6049
3002:6049
3003:6049
3004:6049
3005:6049
3006:6049
3007:6049
3008:6049
4001:6049
4002:6049
4003:6049
4004:6049
4005:6049
5001:6049
5002:6049
1001:6050
1002:6050
1003:6050
1004:6050
1005:6050
1006:6050
1007:6050
1008:6050
1009:6050
1010:6050
1011:6050
1012:6050
1013:6050
1014:6050
2001:6050
2002:6050
2003:6050
2004:6050
2005:6050
2006:6050
2007:6050
2008:6050
2009:6050
2010:6050
3001:6050
3002:6050
3003:6050
3004:6050
3005:6050
3006:6050
3007:6050
3008:6050
4001:6050
4002:6050
4003:6050
4004:6050
4005:6050
5001:6050
5002:6050
1001:6051
1002:6051
1003:6051
1004:6051
1005:6051
1006:6051
1007:6051
1008:6051
1009:6051
1010:6051
1011:6051
1012:6051
1013:6051
1014:6051
2001:6051
2002:6051
2003:6051
2004:6051
2005:6051
2006:6051
2007:6051
2008:6051
2009:6051
2010:6051
3001:6051
3002:6051
3003:6051
3004:6051
3005:6051
3006:6051
3007:6051
3008:6051
4001:6051
4002:6051
4003:6051
4004:6051
4005:6051
5001:6051
5002:6051
1001:6052
1002:6052
1003:6052
1004:6052
1005:6052
1006:6052
1007:6052
1008:6052
1009:6052
1010:6052
1011:6052
1012:6052
1013:6052
1014:6052
2001:6052
2002:6052
2003:6052
2004:6052
2005:6052
2006:6052
2007:6052
2008:6052
2009:6052
2010:6052
3001:6052
3002:6052
3003:6052
3004:6052
3005:6052
3006:6052
3007:6052
3008:6052
4001:6052
4002:6052
4003:6052
4004:6052
4005:6052
5001:6052
5002:6052
1001:6053
1002:6053
1003:6053
1004:6053
1005:6053
1006:6053
1007:6053
1008:6053
1009:6053
1010:6053
1011:6053
1012:6053
1013:6053
1014:6053
2001:6053
2002:6053
2003:6053
2004:6053
2005:6053
2006:6053
2007:6053
2008:6053
2009:6053
2010:6053
3001:6053
3002:6053
3003:6053
3004:6053
3005:6053
3006:6053
3007:6053
3008:6053
4001:6053
4002:6053
4003:6053
4004:6053
4005:6053
5001:6053
5002:6053
1001:6054
1002:6054
1003:6054
1004:6054
1005:6054
1006:6054
1007:6054
1008:6054
1009:6054
1010:6054
1011:6054
1012:6054
1013:6054
1014:6054
2001:6054
2002:6054
2003:6054
2004:6054
2005:6054
2006:6054
2007:6054
2008:6054
2009:6054
2010:6054
3001:6054
3002:6054
3003:6054
3004:6054
3005:6054
3006:6054
3007:6054
3008:6054
4001:6054
4002:6054
4003:6054
4004:6054
4005:6054
5001:6054
5002:6054
1001:6055
1002:6055
1003:6055
1004:6055
1005:6055
1006:6055
1007:6055
1008:6055
1009:6055
1010:6055
1011:6055
1012:6055
1013:6055
1014:6055
2001:6055
2002:6055
2003:6055
2004:6055
2005:6055
2006:6055
2007:6055
2008:6055
2009:6055
2010:6055
3001:6055
3002:6055
3003:6055
3004:6055
3005:6055
3006:6055
3007:6055
3008:6055
4001:6055
4002:6055
4003:6055
4004:6055
4005:6055
5001:6055
5002:6055
1001:6056
1002:6056
1003:6056
1004:6056
1005:6056
1006:6056
1007:6056
1008:6056
1009:6056
1010:6056
1011:6056
1012:6056
1013:6056
1014:6056
2001:6056
2002:6056
2003:6056
2004:6056
2005:6056
2006:6056
2007:6056
2008:6056
2009:6056
2010:6056
3001:6056
3002:6056
3003:6056
3004:6056
3005:6056
3006:6056
3007:6056
3008:6056
4001:6056
4002:6056
4003:6056
4004:6056
4005:6056
5001:6056
5002:6056
1001:6057
1002:6057
1003:6057
1004:6057
1005:6057
1006:6057
1007:6057
1008:6057
1009:6057
1010:6057
1011:6057
1012:6057
1013:6057
1014:6057
2001:6057
2002:6057
2003:6057
2004:6057
2005:6057
2006:6057
2007:6057
2008:6057
2009:6057
2010:6057
3001:6057
3002:6057
3003:6057
3004:6057
3005:6057
3006:6057
3007:6057
3008:6057
4001:6057
4002:6057
4003:6057
4004:6057
4005:6057
5001:6057
5002:6057
1001:6058
1002:6058
1003:6058
1004:6058
1005:6058
1006:6058
1007:6058
1008:6058
1009:6058
1010:6058
1011:6058
1012:6058
1013:6058
1014:6058
2001:6058
2002:6058
2003:6058
2004:6058
2005:6058
2006:6058
2007:6058
2008:6058
2009:6058
2010:6058
3001:6058
3002:6058
3003:6058
3004:6058
3005:6058
3006:6058
3007:6058
3008:6058
4001:6058
4002:6058
4003:6058
4004:6058
4005:6058
5001:6058
5002:6058
1001:6059
1002:6059
1003:6059
1004:6059
1005:6059
1006:6059
1007:6059
1008:6059
1009:6059
1010:6059
1011:6059
1012:6059
1013:6059
1014:6059
2001:6059
2002:6059
2003:6059
2004:6059
2005:6059
2006:6059
2007:6059
2008:6059
2009:6059
2010:6059
3001:6059
3002:6059
3003:6059
3004:6059
3005:6059
3006:6059
3007:6059
3008:6059
4001:6059
4002:6059
4003:6059
4004:6059
4005:6059
5001:6059
5002:6059
1001:6060
1002:6060
1003:6060
1004:6060
1005:6060
1006:6060
1007:6060
1008:6060
1009:6060
1010:6060
1011:6060
1012:6060
1013:6060
1014:6060
2001:6060
2002:6060
2003:6060
2004:6060
2005:6060
2006:6060
2007:6060
2008:6060
2009:6060
2010:6060
3001:6060
3002:6060
3003:6060
3004:6060
3005:6060
3006:6060
3007:6060
3008:6060
4001:6060
4002:6060
4003:6060
4004:6060
4005:6060
5001:6060
5002:6060
1001:6061
1002:6061
1003:6061
1004:6061
1005:6061
1006:6061
1007:6061
1008:6061
1009:6061
1010:6061
1011:6061
1012:6061
1013:6061
1014:6061
2001:6061
2002:6061
2003:6061
2004:6061
2005:6061
2006:6061
2007:6061
2008:6061
2009:6061
2010:6061
3001:6061
3002:6061
3003:6061
3004:6061
3005:6061
3006:6061
3007:6061
3008:6061
4001:6061
4002:6061
4003:6061
4004:6061
4005:6061
5001:6061
5002:6061
1001:6062
1002:6062
1003:6062
1004:6062
1005:6062
1006:6062
1007:6062
1008:6062
1009:6062
1010:6062
1011:6062
1012:6062
1013:6062
1014:6062
2001:6062
2002:6062
2003:6062
2004:6062
2005:6062
2006:6062
2007:6062
2008:6062
2009:6062
2010:6062
3001:6062
3002:6062
3003:6062
3004:6062
3005:6062
3006:6062
3007:6062
3008:6062
4001:6062
4002:6062
4003:6062
4004:6062
4005:6062
5001:6062
5002:6062
1001:6063
1002:6063
1003:6063
1004:6063
1005:6063
1006:6063
1007:6063
1008:6063
1009:6063
1010:6063
1011:6063
1012:6063
1013:6063
1014:6063
2001:6063
2002:6063
2003:6063
2004:6063
2005:6063
2006:6063
2007:6063
2008:6063
2009:6063
2010:6063
3001:6063
3002:6063
3003:6063
3004:6063
3005:6063
3006:6063
3007:6063
3008:6063
4001:6063
4002:6063
4003:6063
4004:6063
4005:6063
5001:6063
5002:6063
1001:6064
1002:6064
1003:6064
1004:6064
1005:6064
1006:6064
1007:6064
1008:6064
1009:6064
1010:6064
1011:6064
1012:6064
1013:6064
1014:6064
2001:6064
2002:6064
2003:6064
2004:6064
2005:6064
2006:6064
2007:6064
2008:6064
2009:6064
2010:6064
3001:6064
3002:6064
3003:6064
3004:6064
3005:6064
3006:6064
3007:6064
3008:6064
4001:6064
4002:6064
4003:6064
4004:6064
4005:6064
5001:6064
5002:6064
1001:6065
1002:6065
1003:6065
1004:6065
1005:6065
1006:6065
1007:6065
1008:6065
1009:6065
1010:6065
1011:6065
1012:6065
1013:6065
1014:6065
2001:6065
2002:6065
2003:6065
2004:6065
2005:6065
2006:6065
2007:6065
2008:6065
2009:6065
2010:6065
3001:6065
3002:6065
3003:6065
3004:6065
3005:6065
3006:6065
3007:6065
3008:6065
4001:6065
4002:6065
4003:6065
4004:6065
4005:6065
5001:6065
5002:6065
1001:6066
1002:6066
1003:6066
1004:6066
1005:6066
1006:6066
1007:6066
1008:6066
1009:6066
1010:6066
1011:6066
1012:6066
1013:6066
1014:6066
2001:6066
2002:6066
2003:6066
2004:6066
2005:6066
2006:6066
2007:6066
2008:6066
2009:6066
2010:6066
3001:6066
3002:6066
3003:6066
3004:6066
3005:6066
3006:6066
3007:6066
3008:6066
4001:6066
4002:6066
4003:6066
4004:6066
4005:6066
5001:6066
5002:6066
1001:6067
1002:6067
1003:6067
1004:6067
1005:6067
1006:6067
1007:6067
1008:6067
1009:6067
1010:6067
1011:6067
1012:6067
1013:6067
1014:6067
2001:6067
2002:6067
2003:6067
2004:6067
2005:6067
2006:6067
2007:6067
2008:6067
2009:6067
2010:6067
3001:6067
3002:6067
3003:6067
3004:6067
3005:6067
3006:6067
3007:6067
3008:6067
4001:6067
4002:6067
4003:6067
4004:6067
4005:6067
5001:6067
5002:6067
1001:6068
1002:6068
1003:6068
1004:6068
1005:6068
1006:6068
1007:6068
1008:6068
1009:6068
1010:6068
1011:6068
1012:6068
1013:6068
1014:6068
2001:6068
2002:6068
2003:6068
2004:6068
2005:6068
2006:6068
2007:6068
2008:6068
2009:6068
2010:6068
3001:6068
3002:6068
3003:6068
3004:6068
3005:6068
3006:6068
3007:6068
3008:6068
4001:6068
4002:6068
4003:6068
4004:6068
4005:6068
5001:6068
5002:6068
1001:6069
1002:6069
1003:6069
1004:6069
1005:6069
1006:6069
1007:6069
1008:6069
1009:6069
1010:6069
1011:6069
1012:6069
1013:6069
1014:6069
2001:6069
2002:6069
2003:6069
2004:6069
2005:6069
2006:6069
2007:6069
2008:6069
2009:6069
2010:6069
3001:6069
3002:6069
3003:6069
3004:6069
3005:6069
3006:6069
3007:6069
3008:6069
4001:6069
4002:6069
4003:6069
4004:6069
4005:6069
5001:6069
5002:6069
1001:6070
1002:6070
1003:6070
1004:6070
1005:6070
1006:6070
1007:6070
1008:6070
1009:6070
1010:6070
1011:6070
1012:6070
1013:6070
1014:6070
2001:6070
2002:6070
2003:6070
2004:6070
2005:6070
2006:6070
2007:6070
2008:6070
2009:6070
2010:6070
3001:6070
3002:6070
3003:6070
3004:6070
3005:6070
3006:6070
3007:6070
3008:6070
4001:6070
4002:6070
4003:6070
4004:6070
4005:6070
5001:6070
5002:6070
1001:6071
1002:6071
1003:6071
1004:6071
1005:6071
1006:6071
1007:6071
1008:6071
1009:6071
1010:6071
1011:6071
1012:6071
1013:6071
1014:6071
2001:6071
2002:6071
2003:6071
2004:6071
2005:6071
2006:6071
2007:6071
2008:6071
2009:6071
2010:6071
3001:6071
3002:6071
3003:6071
3004:6071
3005:6071
3006:6071
3007:6071
3008:6071
4001:6071
4002:6071
4003:6071
4004:6071
4005:6071
5001:6071
5002:6071
1001:6072
1002:6072
1003:6072
1004:6072
1005:6072
1006:6072
1007:6072
1008:6072
1009:6072
1010:6072
1011:6072
1012:6072
1013:6072
1014:6072
2001:6072
2002:6072
2003:6072
2004:6072
2005:6072
2006:6072
2007:6072
2008:6072
2009:6072
2010:6072
3001:6072
3002:6072
3003:6072
3004:6072
3005:6072
3006:6072
3007:6072
3008:6072
4001:6072
4002:6072
4003:6072
4004:6072
4005:6072
5001:6072
5002:6072
1001:6073
1002:6073
1003:6073
1004:6073
1005:6073
1006:6073
1007:6073
1008:6073
1009:6073
1010:6073
1011:6073
1012:6073
1013:6073
1014:6073
2001:6073
2002:6073
2003:6073
2004:6073
2005:6073
2006:6073
2007:6073
2008:6073
2009:6073
2010:6073
3001:6073
3002:6073
3003:6073
3004:6073
3005:6073
3006:6073
3007:6073
3008:6073
4001:6073
4002:6073
4003:6073
4004:6073
4005:6073
5001:6073
5002:6073
1001:6074
1002:6074
1003:6074
1004:6074
1005:6074
1006:6074
1007:6074
1008:6074
1009:6074
1010:6074
1011:6074
1012:6074
1013:6074
1014:6074
2001:6074
2002:6074
2003:6074
2004:6074
2005:6074
2006:6074
2007:6074
2008:6074
2009:6074
2010:6074
3001:6074
3002:6074
3003:6074
3004:6074
3005:6074
3006:6074
3007:6074
3008:6074
4001:6074
4002:6074
4003:6074
4004:6074
4005:6074
5001:6074
5002:6074
1001:6075
1002:6075
1003:6075
1004:6075
1005:6075
1006:6075
1007:6075
1008:6075
1009:6075
1010:6075
1011:6075
1012:6075
1013:6075
1014:6075
2001:6075
2002:6075
2003:6075
2004:6075
2005:6075
2006:6075
2007:6075
2008:6075
2009:6075
2010:6075
3001:6075
3002:6075
3003:6075
3004:6075
3005:6075
3006:6075
3007:6075
3008:6075
4001:6075
4002:6075
4003:6075
4004:6075
4005:6075
5001:6075
5002:6075
1001:6076
1002:6076
1003:6076
1004:6076
1005:6076
1006:6076
1007:6076
1008:6076
1009:6076
1010:6076
1011:6076
1012:6076
1013:6076
1014:6076
2001:6076
2002:6076
2003:6076
2004:6076
2005:6076
2006:6076
2007:6076
2008:6076
2009:6076
2010:6076
3001:6076
3002:6076
3003:6076
3004:6076
3005:6076
3006:6076
3007:6076
3008:6076
4001:6076
4002:6076
4003:6076
4004:6076
4005:6076
5001:6076
5002:6076
1001:6077
1002:6077
1003:6077
1004:6077
1005:6077
1006:6077
1007:6077
1008:6077
1009:6077
1010:6077
1011:6077
1012:6077
1013:6077
1014:6077
2001:6077
2002:6077
2003:6077
2004:6077
2005:6077
2006:6077
2007:6077
2008:6077
2009:6077
2010:6077
3001:6077
3002:6077
3003:6077
3004:6077
3005:6077
3006:6077
3007:6077
3008:6077
4001:6077
4002:6077
4003:6077
4004:6077
4005:6077
5001:6077
5002:6077
1001:6078
1002:6078
1003:6078
1004:6078
1005:6078
1006:6078
1007:6078
1008:6078
1009:6078
1010:6078
1011:6078
1012:6078
1013:6078
1014:6078
2001:6078
2002:6078
2003:6078
2004:6078
2005:6078
2006:6078
2007:6078
2008:6078
2009:6078
2010:6078
3001:6078
3002:6078
3003:6078
3004:6078
3005:6078
3006:6078
3007:6078
3008:6078
4001:6078
4002:6078
4003:6078
4004:6078
4005:6078
5001:6078
5002:6078
—